Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2020

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)
www.gastro.org

* Information contained in this report is current as of April 22, 2020.
AGA Oral Presentations
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
234. . . . PATIENTS WITH NON-
ALCOHOLIC STEATOHEPATITIS (NASH)
HAVE... (5*)

235. . . . LARGE EFFECTS OF SGLT2
INHIBITORS/GLP1 RECEPTOR... (5*)

236. . . . INFliximab, Adalimumab
AND VEDOLIZUMAB LEVELS ARE...
(6*)|(4)

237. . . . BASELINE DRUG CLEARANCE
OF INFliximab PREDICTS... (5*)

238. . . . VEDOLIZUMAB
CONCENTRATIONS IN COLONIC
MUCOSAL TISSUE... (5*)

239. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES... (4*)

240. . . . REAL-WORLD APPLICATION OF
AN ADAPTIVE DOSING...
(4*)|(Prometheus Ran the drug levels)

241. . . . COMBINATION OF SERUM
ENDOSCOPIC HEALING INDEX...
(3*)|(7)|(Prometheus Biosciences, San
Diego, CA)

242. . . . BASELINE DRUG CLEARANCE
OF INFliximab PREDICTS...
(5*)

243. . . . COMPUTER-AIDED DETECTION
OF ADVANCED NEOPLASIA IN...
(7*)|(4)

244. . . . IMPAIRMENT OF THE
EMBRYONIC MACROPHAGE
COMPARTMENT...

245. . . . EMBRYONIC MACROPHAGE
MACROPHAGES PROMOTE VASCULAR
IMPAIRMENT OF THE...

246. . . . A NOVEL TNFSF13 VARIANT IN
POLY (ADP-RIbose)
POLYMERASE 1 (PARP1) PROMOTES...

247. . . . THE INCIDENCE OF
PNEUMONIA AND IMPACT...
(3*)|(Janssen R&D)

248. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES...
(4*)

249. . . . REAL-WORLD APPLICATION OF
AN ADAPTIVE DOSING...
(4*)|(Prometheus Biosciences, San
Diego, CA)

250. . . . BASELINE DRUG CLEARANCE
OF INFliximab PREDICTS...
(5*)

251. . . . A NOVEL TNFSF13 VARIANT IN
VERY...
(4*)

252. . . . NEW STRATEGIES FOR...

253. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES...
(4*)

254. . . . IMPAIRMENT OF THE
EMBRYONIC MACROPHAGE
COMPARTMENT...

255. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES...
(4*)

256. . . . COMPUTER-AIDED DETECTION
OF ADVANCED NEOPLASIA IN...
(7*)|(4)

257. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES...
(4*)

258. . . . IMPAIRMENT OF THE
EMBRYONIC MACROPHAGE
COMPARTMENT...

259. . . . COMPUTER-AIDED DETECTION
OF ADVANCED NEOPLASIA IN...
(7*)|(4)

260. . . . NEONATAL INTESTINAL
MACROPHAGES PROMOTE VASCULAR
TUBE-LIKE...
(2*)

261. . . . TARGETED DELETION OF THE
CDC42/RAC NUCLEOTIDE...
(2*)

262. . . . SHORT-TERM WESTERN DIET
DRIVES MICROVILLI ALTERATIONS...
(2*)

263. . . . PREVALENCE AND IMPACT OF
FUNCTIONAL DYSPESIA...
(3*)|(Ironwood, Shire, Allergan, Takeda,
Takeda-israel)

264. . . . 4D CINE-MRI-ASSESS
GASTRIC FUNCTION IS MODULATED...
(2*)

265. . . . THE EFFECT OF CANNABIS
LEGALIZATION ON...
(4*)

266. . . . FRAILTY IS ASSOCIATED
WITH AN INCREASED...
(6*)

267. . . . EFFECTIVENESS OF
RECOMBINANT ZOSTER VACCINE
(Shingrix)...
(5*)

268. . . . EARLY LAPAROSCOPIC
ILEOCECAL RESECTION DECREASES
NEED...
(5*)

269. . . . GASTRIC FUNCTION IS MODULATED...
(2*)

270. . . . COMBINATION OF SERUM
ENDOSCOPIC HEALING INDEX...
(3*)|(7)|(Prometheus Biosciences, San
Diego, CA)

271. . . . NON-INVASIVE BREATH TEST
SCREENING FOR BARRETT'S...
(2*)

272. . . . VEDOLIZUMAB
CONCENTRATIONS IN COLONIC
MUCOSAL TISSUE...

273. . . . THE EARLY APPEARANCE OF
ANTI-DRUG ANTIBODIES...
(4*)

274. . . . COMPUTER-AIDED DETECTION
OF ADVANCED NEOPLASIA IN...
(7*)|(4)

275. . . . THE IMPACT OF NIGHT-TIME
EMERGENCY DEPARTMENT...
(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds   (5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CFPA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
373. . . . DEVELOPING SURVEILLANCE STRATEGY FOR PANCREATIC CANCER... (1)
374. . . . A SYSTEMATIC EVALUATION OF CELL LINEAGE... (5)
375. . . . NONSTEROIDAL ANTI-INFLAMMATORY DRUGS REDUCE THE RISK... (2)
388. . . . ASSOCIATION OF ASPIRIN USE AND GASTROINTESTINAL... (5) (2)
389. . . . ASPIRIN REDUCES PGE2 BIOSYNTHESIS TO LEVELS... (2) (6)
390. . . . THIOGUANINE INHIBITS COLORECTAL TUMORIGENESIS VIA β-CATENIN... (2)
391. . . . ASPIRIN USE IS ASSOCIATED WITH REDUCED... (2)
392. . . . A NOVEL PH-SENSITIVE OPIOID ANALGESIC THAT... (6)
393. . . . CANNABINOIDS AND OPIOIDS SYNERGISTICALLY INHIBIT MOUSE... (4)
394. . . . RESOLVIN D2 REVERSES VISCERAL HYPERSENSITIVITY IN... (4)
395. . . . INCREASE IN FETAL CORTICOSTEROID DURING MATERNAL... (2)
396. . . . INVOLVEMENT OF PIEZO2 IN COLONIC MECHANICAL... (2) (4)
397. . . . MICROBIOME GENOMICS REVEALS NOVEL BACTERIAL STRAINS... (3) (Biomica LTD.)
398. . . . THE GEM PROJECT: IDENTIFICATION OF A... (2) (6)
399. . . . PROTEOMIC AND TRANSCRIPTOMIC ANALYSIS OF VERY... (6)
400. . . . GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF... (4)
401. . . . NORMALIZATION OF FECAL CALPROTECTIN WITHIN 12... (5)
402. . . . RECTAL CANCER INCIDENCE IS LOW FOLLOWING... (4)
403. . . . THE IMPACT OF CHOLECYSTECTOMY ON LONG-TERM... (2)
404. . . . RISK OF POST-COLONOSCOPY IRRITABLE BOWEL SYNDROME... (2)
405. . . . ROME IV AND ROME III IRRITABLE... (3) (4) (Ironwood, Shire, Allergan, Takeda, Takeda-Israel)
406. . . . BAROSTAT ASSISTED SENSORY ADAPTATION TRAINING FOR... (2)
408. . . . A BRIEF EDUCATIONAL INTERVENTION FOR IBS... (4) (1)
409. . . . RANDOMISED TRIAL OF MULTI-DISCIPLINARY VERSUS STANDARD... (1)
410. . . . LES MUSCLE OF PATIENTS WITH ACHALASIA... (4)
411. . . . IDENTIFICATION OF ESOPHAGEAL MICROBIOME SIGNATURES IN... (2)
412. . . . PHARMACOLOGIC PROVOCATION WITH AMYL NITRITE &... (4)
413. . . . DISTENSION CONTRACTION PLOTS OF ESOPHAGEAL PERISTALSIS... (2)
414. . . . UPPER ESOPHAGEAL SPHINCTER ABNORMALITIES ARE ASSOCIATED... (5)
415. . . . UPPER ESOPHAGEAL SPHINCTER DYSFUNCTION IS AN... (5)
416. . . . CLONAL ARCHITECTURE OF EPITHELIAL STEM CELL... (2)
417. . . . ANKRD22 AS A PROMISING THERAPEUTIC TARGET... (2)
418. . . . PROLYL HYDROXYLASE 2 SILENCING ENHANCES THE... (5)
419. . . . ZERO-SUM EPIGENETIC PATTERNING DEFINES STEM... (2)
420. . . . INTEGRATING HPSC-DERIVED 3D ORGANOIDS AND MOUSE... (2) (6)
421. . . . LRIG3 RESTRICTS THE SIZE OF THE... (4) (2)
422. . . . A DORMANT BLOOD MICROBIOME MAY UNDERLIE... (4)
423. . . . DYNAMICS OF INTESTINAL INFLAMMATION AND MICROBIAL... (5)
424. . . . THE COMBINATION OF ALTERED MICROBIAL BIOGEOGRAPHY... (2) (7) (PFIZER ASPIRE GRANT)
425. . . . SUBSETS OF HUMAN RESIDENT BACTERIAL SPECIES... (2)
426. . . . FURTHER EVIDENCE THAT PROTEUS MIRABILIS IS... (6)
427. . . . F.PRAUSNITZI PROTECT THE MICE FROM DEXTRAN-SULFATE... (2)
428. . . . LIRAGLUTIDE ESCALATED TO 3 MG REDUCES... (2)
429. . . . A NOVEL TARGET IN THE TREATMENT... (2)
430. . . . STROMAL DLK1 PROMOTES EPITHELIAL PROLIFERATION AND... (2)
431. . . . GATA4 IS REQUIRED TO MAINTAIN GASTRIC... (6) (2)
432. . . . IDENTIFICATION AND DEVELOPMENT OF GENE SIGNATURE... (5)
433. . . . THE POTENTIAL OF PERSONALIZED SURVEILLANCE INTERVALS... (6) (2)
434. . . . MULTIOMIC CHARACTERIZATION OF BARRET'S ESOPHAGUS REVEALS... (6)
435. . . . ALTERATION OF KRAS, TP53 AND RB1... (4)
436. . . . PHYSICAL ACTIVITY IS ASSOCIATED WITH A... (2)
437. . . . INHIBITION OF HUR ASSOCIATION WITH CX43... (2)
438. . . . LOSS OF INTESTINAL AXIN 1 PROMOTES... (2)
439. . . . GUT MICROBIOTA REGULATES ROSETONE INDUCED DISRUPTIONS... (5)
440. . . . TTCT7A DIRECTS APICAL LUMEN FORMATION IN... (2)
441. . . . PROBIOTIC ENHANCEMENT OF INTESTINAL EPITHELIAL BARRIER... (2)
442. . . . BACTERIAL METABOLITES SHORT CHAIN FATTY ACIDS... (2)
443. . . . CORRELATION OF FLUORESCENCE IN SITU HYBRIDIZATION... (5)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds     (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)     (3) = Industry or Commercial Entity     (4) = Institutional Funds

(5) = No Study Funding     (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)     (7) = Professional Organization (e.g. AGA, AASLD, etc.)
563. . . . INTESTINE-SPECIFIC DELETION OF RNA-BINDING MOTIF PROTEIN... (2*)

564. . . . AN INFLAMMATORY DIET AND RISK OF... (2*)

565. . . . TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF A... (6*)[3](Taekda Pharmaceuticals)

566. . . . LARGE META GENOME WIDE ASSOCIATION STUDY... (4*)[2](Helmskey Charitable Trust)

567. . . . TL1A OVEREXPRESSION IN CD PATIENTS AND... (2*)

568. . . . FAMILIAL SMALL INTESTINAL (MIDGUT) NEUROENDOCRINE TUMOR... (2*)

569. . . . INVESTIGATION OF THE INTEGRIN SIGNALLING PATHWAY... (4*)

570. . . . PREVALENCE OF LYMPH NODE/DISTANT METASTASIS... (5*)

571. . . . NOVEL DIGITAL SPATIAL PROFILING OF GASTROENTEROPANCREATIC... (2*)

572. . . . ASSOCIATION BETWEEN SOMATOSTATIN ANALOGUE TREATMENT AND... (5*)

573. . . . EGF-INDUCED NUCLEAR EXPORT OF MENIN STIMULATES... (2*)

574. . . . RECENT TRENDS IN COLORECTAL CANCER SCREENING... (3*)[Exact Sciences]

575. . . . A HIGHLY SENSITIVE AND QUANTITATIVE MULTIMODAL... (3*)[CellMax Life]

576. . . . EARLY COLORECTAL CANCER SCREENING IN AFRICAN... (5*)

577. . . . EFFECT OF ORGANIZED MAILED FECAL IMMUNOCHEMICAL... (2*)[4]

578. . . . DELAY TO DIAGNOSTIC COLONOSCOPY AFTER ABNORMAL... (2*)

579. . . . PREVALENCE AND CHARACTERISTICS OF POST-COLONOSCOPY COLORECTAL... (2*)

580. . . . RACE, ETHNICITY, AND SOCIOECONOMIC STATUS PREDICT... (5*)

581. . . . DECREASED EXPRESSION AND FUNCTION OF INTESTINAL... (2*)

582. . . . TEDUGLUTIDE INHIBITS SODIUM CAPRATE-INDUCED CLATHRIN-MEDIATED LPS... (2*)[3](Shire/Takeda Pharmaceuticals)

583. . . . NPC1L1-DEPENDENT TRANSPORT OF 27-ALKYNE CHOLESTEROL TO... (2*)

584. . . . DYNAMIC INTERACTIONS AMONG CFTR, NHERF4 (NF4)... (2*)

585. . . . UNIQUE REGULATION OF CHLORIDE BICARBONATE EXCHANGERS... (2*)

586. . . . ER LUMINAL ERAD AS A NOVEL... (4*)[2]

587. . . . INFLAMMATION CAN BE RE-INDUCTED IN ORGANOID... (2*)

588. . . . GIL3 HUMAN NOROVIRUS REQUIRES BILE ACID... (2*)

589. . . . PEDIATRIC CROHN'S DISEASE PATIENT DERIVED ORGANOIDS... (4*)

590. . . . AN ORGANOID-IMMUNE CELL CO-CULTURE PREDICTIVE MODEL... (2*)[4]

591. . . . HUMAN BIOPSY-DERIVED COLONIOIDS ARE USEFUL TO... (3*[Merck ISP 53472]

592. . . . HUMAN INTESTINAL STEM CELL (ISC)-DERIVED ENTEROIDS/OLONOIIDS... (2*)

593. . . . CONFOCAL LASER ENDOMICROSCOPY FOR DETECTION OF... (2*)

594. . . . CLINICAL SIGNIFICANCE OF SURVEILLANCE-DETECTED DUCTAL ABNORMALITIES... (2*)[6]

595. . . . SYNCHRONOUS OCCURRENCE OF PRENEOPLASTIC LESIONS IN... (5*)

596. . . . SURVEILLANCE BIOPSY SHOUL BE DONE ON... (5*)

598. . . . POST-COLONOSCOPY COLORECTAL CANCER IN LYNCH SYNDROME... (5*)

601. . . . EFFICACY OF ENDOSCOPIC SURVEILLANCE AND FAMILY... (5*)

602. . . . OUTCOMES OF ENDOSCOPIC SURVEILLANCE AND FAMILY... (5*)

603. . . . RESULTS OF THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[Mitsubishi-Tanabe Pharma]

604. . . . THE IMPACT OF SCREENING LOWER ENDOSCOPY... (2*)[4]

605. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)[Mitsubishi-Tanabe Pharma]

606. . . . RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL... (6*)[2]

607. . . . DIRECT ACTING ANTI-VIRAL PROPHYLAXIS TO PREVENT... (4*)[3][Gilead provided DAA for some patients.]

608. . . . UNRAVELLING THE MOLECULAR MECHANISM RESPONSIBLE FOR... (2*)[6]

609. . . . TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES... (2*)[4]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
638. COLONIC SPROUTY2 EXPRESSION IS DYSREGULATED IN... (2*)[[6]](NIH IR10DK119694 (Frey); Crohn's and Colitis Foundation CDA (Schumacher))

639. NEUROTENSIN (NT) SIGNALING-ASSOCIATED LONG NON-CODING RNA... (6*)

640. CIRCULAR RNA HIPK3 PROMOTES INTESTINAL EPITHELIAL... (2*)

641. DISRUPTION OF INTESTINAL EPITHELIUM DUE TO... (2*)

642. HIGH-THROUGHPUT SCREENING IDENTIFIED LORATArine AND GENISTEIN... (2*)[[3]](MERCK)

643. HOST-DIRECTED DRUG CANDIDATES TO CLOT... CLOSTRIDIODES... (2*)[[4]]

644. IDENTIFICATION OF NOVEL CHANGES IN MICOBially-DERIVED... (2*)[[4]]

645. CLOSTRIDIODES DIFFICILE WHOLE GENOME SEQUENCING DIFFERENTIAT... (5*)

646. COLONIC MUCOSAL COLONIZATION OF CLOSTRIDIODES DIFFICILE... (4*)

647. FECAL MICRORNAs ARE ASSOCIATED WITH TGF-BETA... (2*)

648. BRAIN-DERIVED NEUROTROPHIC FACTOR PLAYS A CRITICAL... (2*)

649. DE NOVO ENTERIC NEUROGENESIS IN POST-EMBRYONIC... (2*)[[4]]

650. ENTERIC GLIAL ACTIVATION IS A PATHWAY-SPECIFIC... (2*)[[4]]

652. ENTERIC GLIAL MHC II EXPRESSION MODULATES... (2*)

653. MIR-10B-5P RESCUES AND PREVENTS DIABETIC GASTROPARESIS... (2*)

654. EFFECTS OF SCFA ON HISTONE ACETYLATION... (2*)

655. DIETARY MONOSODIUM GLUTAMATE EXACERBATES VISCERAL HYPERSENSITIVITY... (2*)

656. EPIGENETIC MECHANISMS IN THE AMYGDALA UNDERLYING... (2*)

657. PGE2 PRODUCED BY MAST CELLS IS... (2*)

658. GUT DYSBIOSIS PROMOTES COLONIC M1 MACROPHAGE... (2*)

659. ENDOPLASMIC RETICULUM STRESS DRIVES INTESTINAL HYPERPERMEABILITY... (5*)

660. INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN... (3*)[[Pitzer Inc]]

697. VIRTUAL REALITY MINDFULNESS THERAPY VS. VIRTUAL... (5*)

698. TRANSLUMBOSACRAL NEUROMODULATION THERAPY (TNT): A NOVEL... (5*)

699. CHANGES IN AGED ENS INDUCES A... (2*)

700. CELL THERAPY USING ADULT NEURAL-PROGENITOR CELLS... (4*)

702. MACHINE LEARNING MODELS IN THE PREDICTION... (4*)

703. IS HELICOBACTER PYLORI CURE A LONG-LIFE... (5*)

705. TAILORED ANTIBIOTIC SUSCEPTIBILITY-GUIDED THERAPY VIA GASTRIC... (5*)

706. TREATMENT OF H PYLORI IS NOT... (2*)

707. COMPREHENSIVE PROFILING OF THE ANTIBIOTIC RESISTANCE... (4*)

708. IMMUNOGLOBULIN A COATING OF INTESTINAL MICROBIOTA... (4*)[[EB is supported by the Alexandre Suerman program for MD and PhD candidates of the University Medical Centre Utrecht, Netherlands.]]

709. PAIRED IMMUNOGLOBULIN-LIKE RECEPTOR B REGULATES INFLAMMATION... (2*)

711. BLOCKADE OF ALPHA E BETA 7... (2*)[[6]]

712. METABOLIC MODULATION OF CD4+ T CELLS... (4*)[[2]]

713. NON-INVASIVE ELECTRICAL SPLenic NERVE STIMULATION AMELIORATES... (3*)[[Galvani Bioelectronics]]

714. CONSISTENT ALTERATIONS OF SPECIFIC GUT MICROBIAL... (2*)

715. SACCHAROMYCES BOULARDII CNCM I-745 IMPROVES GUT-BRAIN... (3*)[[Biocodex – Gentilly – France]]

716. INCREASED RISK OF DEPRESSIVE DISORDER AFTR... (2*)

717. NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH... (2*)

718. EFFECT OF EXCLUSION DIETS ON SYMPTOM... (5*)

719. HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (2*)[[4]]

736. MUTANT EPCAM MODEL OF CONGENITAL TUFTING... (2*)

737. MICROPHYSIOLOGICAL ENGINEERING OF INTESTINAL MORPHOGENESIS BY... (2*)[[4]]

750. DIFFERENCES IN THE RISK OF PERSISTENT... (5*)

751. A FIVE BIOMARKER PANEL OUTPERFORMS EXISTING... (2*)

752. THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (2*)

753. NOTCH INHIBITION PROMOTES PanCREATIC KRT5+ CELLS... (4*)

754. VARIABLE CELL-SPECIFIC SPNKi EXPRESSION IN THE... (2*)[[4]]

755. AN INDIVIDUAL-HOUSING BASED SOCIOECONOMIC STATUS MEASURE... (5*)

756. ASSOCIATION BETWEEN NEIGHBORHOOD INCOME AND PERSISTENT... (5*)

757. WHO’S OUT? RESULTS OF A SCREENING... (4*)

758. CHILDHOOD GROWTH IN SCREEN-DETECTED CELIAC DISEASE... (2*)

759. IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE... (2*)[[7]]

760. A NOVEL ORDINAL SEVERITY SCALE ALLOWS... (3*)[[This study was funded by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Steve Banner of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.]]

761. INCREASED RISK OF DEPRESSIVE DISORDER AFTER... (2*)

762. NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH... (2*)

763. EFFECT OF EXCLUSION DIETS ON SYMPTOM... (5*)

764. HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (2*)[[4]]

765. AN INDIVIDUAL-HOUSING BASED SOCIOECONOMIC STATUS MEASURE... (5*)

766. ASSOCIATION BETWEEN NEIGHBORHOOD INCOME AND PERSISTENT... (5*)

767. WHO’S OUT? RESULTS OF A SCREENING... (4*)

768. CHILDHOOD GROWTH IN SCREEN-DETECTED CELIAC DISEASE... (2*)

769. IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE... (2*)[[7]]

770. A NOVEL ORDINAL SEVERITY SCALE ALLOWS... (3*)[[This study was funded by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Steve Banner of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.]]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
761. . . MEGA-ANALYSIS REVEALS NOVEL GENETIC ASSOCIATIONS WITH...[2*][6]
762. . . INCREASED RISK OF SMALL BOWEL CANCER...[4*]
763. . . PREVALENCE AND EFFECT OF GENETIC RISK...[4*][2][Helmsey Charitable Trust]
764. . . MACHINE LEARNING IDENTIFIES NOVEL BLOOD PROTEOMIC...[2*][6]
765. . . RISK OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER...[5*]
766. . . SCATTERED INTESTINAL EPITHELIAL APOPTOSIS INDUCES MOUSE...[2*]
767. . . ACTIVATION OF FXR SUPPRESSES TNFA AND...[3*][Metacrine]
768. . . THE ORIGIN AND FUNCTION OF CANCER-ASSOCIATED...[2*]
769. . . DIETARY PROTEIN DEFICIENCY RECAPITULATES KEY HISTOLOGIC...[4*]
770. . . GENERATION OF A GASTRIC ADENOCARCINOMA AND...[2*]
771. . . LSYPHOSPHATIDIC ACID TREATMENT IMPROVES BRUSH BORDER...[2*]
814. . . PLACEBO WITHOUT DECEPTION IS EFFECTIVE IN...[2*][6]
815. . . IMPACT OF PARENTAL ILLNESS AND INJURY...[2*]
816. . . OESOPHAGEAL MUCOSAL INTEGRITY AND INNERVATION IN...[4*]
817. . . THE HUMAN GUT VIROME IS GEOGRAPHY...[2*][4]
818. . . IMBALANCE OF THE INTESTINAL VIROME CAUSED...[2*][4]
825. . . ONCOGENIC POTENTIAL OF DYSPLASTIC STEM CELLS...[2*][4]
826. . . THE ROLE OF THE HIPPO PATHWAY...[2*][7]
827. . . STROMAL CELLS STIMULATE BM11-DEPENDENT SMALL INTESTINAL...[2*]
828. . . SLC26A9 PROTECTS GASTRIC EPITHELIAL CELLS AGAINST...[2*]
829. . . CONFIRMATION OF CHIEF CELLS AS THE...[2*][4]
830. . . TYPE II INNATE LYMPHOID CELLS (ILC2S)...[2*]
831. . . CB1 MEDIATES THE ENERGY EFFECTS OF...[4*]
832. . . EFFECT OF MODERATE ALCOHOL CONSUMPTION ON...[2*]
833. . . DIETS HIGH IN OMEGA AND...[2*]
834. . . EFFECT OF MATERNAL OBESITY INDUCED BY...[4*]
835. . . LACTATED RINGER'S SOLUTION VERSUS NORMAL SALINE...[5*]
836. . . EFFECT OF SYMBIOTICS IN REDUCING THE...[4*]
837. . . RADIOMIC FEATURES DISTINGUISH PANCREATIC CANCER FROM...[2*]
838. . . DISORDERING OF ACINAR CELL CHOLESTEROL HOMEOSTASIS...[2*]
840. . . TOWARDS THE BIOCHEMICAL DIAGNOSIS OF BILE...[2*][3][Sigma-tau Rare Disease Ltd. provided chenodeoxycholic acid (Xenbilox®) without restrictions as an independent grant.]
841. . . EFFECT OF AMOXICILLIN-CLAVULANATE VERSUS METRONIDAZOLE AND...[2*]
842. . . VALIDATION OF PERIPHERAL EOSINOPENIA AS A...[5*]
844. . . MEDICATION USE AND MICROSCOPIC COLITIS: A...[5*]
845. . . CAN WE RELIABLY REPLACE THE SEHCAT...[3*]
846. . . ANTIBIOTIC USE AND THE DEVELOPMENT OF...[6*][2]
847. . . DIETARY GLUTEN INTAKE AND RISK OF...[2*][4]
848. . . ASSOCIATION BETWEEN STATIN USE AND RISK...[4*][6]
849. . . CHOLECYSTECTOMY CONTRIBUTES TO FUNCTIONAL ABDOMINAL SYMPTOMS...[2*]
850. . . ASSOCIATION OF LYMPHOMA WITH AGE AT...[6*]
851. . . SQUALENE EPOXIDASE (SQLE) PROMOTES CRC VIA...[2*]
852. . . BILOPHILA WADSWORTHIA SUPPLEMENTATION REDUCES ADENOMA BURDEN...[4*][2]
853. . . CIGARETTE SMOKE PROMOTES COLORECTAL CANCER THROUGH...[2*]
854. . . EPITHELIAL TLR4-SHAPED MICROBIOTA INCREASES SUSCEPTIBILITY TO...[2*][6]
855. . . INVASIVE E. COLI SUPPRESS EPITHELIAL AUTOPHagy...[2*]
856. . . SPATIAL MICROBIAL SIGNATURES IN COLORECTAL NEOPLASIA...[1*][4]
857. . . RATES AND TIME COURSE OF EXCESS SERIOUS...[5*]
858. . . HOT OR COLD? PERSISTENCE OF HOT...[5*]
859. . . COMPUTER-AIDED-DETECTION EMBEDDED COLONOSCOPY VERSUS ROUTINE COLONOSCOPY...[5*]
860. . . DIGITAL NAVIGATION IMPROVES NO-SHOW RATES AND...[4*]
861. . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN):...[3*][This study was supported by Pendopharm, division of Pharmascience Inc.]
862. . . MULTICOMPONENT INTERVENTION IMPROVES UPTAKE OF SURVEILLANCE...[4*]
863. . . THE IL-33 RECEPTOR ST2 IS HIGHLY...[4*][2]
864. . . BARRIER DYSFUNCTION IN EOSINOPHILIC ESOPHAGITIS IS...[6*][2]
865. . . EOSINOPHILIC ESOPHAGITIS MAY FOSTER ESOPHAGEAL BASAL...[2*]
866. . . CD252 (OX40L)+ ANTIGEN PRESENTING CELLS ARE...[4*]
867. . . EGD BIOPSIIES HAVE FUNCTIONALLY DISTINCT AND...[3*][Allakos, Inc.]
868. . . HEPATOCELLULAR CARCINOMA INCIDENCE DECLINES AFTER WIDESPREAD...[2*]
869. . . TELE-MEDICINE HCV TREATMENT IN DEPARTMENT OF...[5*]
870. . . RANDOMIZED CONTROLLED TRIAL OF IN-REACH WITH... [2*](3)[(This study was conducted with support from CPRIT PP180091 and FOCUS.)
871. . . IMMUNOMODULATION OF AUTOIMMUNE HEPATITIS WITH A... (5*)
872. . . AUTOIMMUNE HEPATITIS PATIENTS ARE LESS LIKELY... (5*)
873. . . INCREASED RISK OF POST-TRANSPLANT MORTALITY IN... (5*)
911. . . LINACLOTIDE SAFETY AND EFFICACY IN CHILDREN... (3*)[(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc. Writing assistance by Complete HealthVizion, funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)
913. . . QUANTITATIVE ANALYSIS OF TUG SIGN: AN... (1*)
914. . . NOVEL SUBTYPING OF EOSINOPHILIC ESOPHAGITIS BASED... (5*)
928. . . AN ELECTRONIC HEALTH RECORD-BASED MACHINE LEARNING... (2*)
929. . . INTERLEUKIN13-MEDIATED DISRUPTION OF MITochondrial BIOLOGY CONTRIBUTES... (2*)[(4)
930. . . HELICOBACTER PYLORI PROMOTES THE DIFFERENTIATION OF... (2*)
931. . . INCIDENCE OF NONCARDIA GASTRIC ADENOCARCINOMA AFTER... (1*)
932. . . HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE... (3*)[(2)](Allakos, Inc.)
933. . . INTERLEUKIN-23 RECEPTOR SIGNALING MODULATES THE STABILITY... (2*)[(4)
934. . . STROMAL TNF RECEPTOR 1 (TNFR1) PRESERVES... (2*)
935. . . PRE-TREATMENT MUCOSAL INFLAMMATORY AND WOUND HEALING... (6*)
936. . . CADHERIN-11 IS UPREGULATED IN INFLAMMATORY BOWEL... (3*)[(Pliant Therapeutics)
937. . . A POSITIVE FEEDBACK LOOP BETWEEN CREEPING... (4*)
938. . . ADIPOSE DERIVED MENenchymal STEM CELLS ACELLULAR... (4*)[(5)](MSC2018003 New Strategy to Improve MSC Based GVHD Therapy, Biological Industries USA (Li, PRINCIPAL INVESTIGATOR)
939. . . TRADIPITANT TREATMENT CAUSED CLINICALLY MEANINGFUL AND... (3*)[(Vanda Pharmaceuticals, Inc)
940. . . GLOBAL KNOCKOUT OF MIR-10B IN MICE... (2*)
941. . . EPGENETIC ALTERATIONS IN THE PERIPHERAL CIRCULATION... (2*)
942. . . SYSTEMIC EPGENETIC ALTERATIONS ARE ASSOCIATED WITH... (2*)
943. . . ASSESSMENT OF SMALL BOWEL MOTILITY IN... (4*)
944. . . MOLECULAR MECHANISM OF CINNAMALDEHYDE AND CURCUMIN... (2*)
945. . . HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS... (3*)[(AbbVie Inc.)
946. . . DEEP REMISSION AT 1 YEAR IS... (5*)
947. . . TOP-DOWN INFILXIMAB SUPERIOR TO STEP-UP IN... (1*)[(3)](Pfizer)
948. . . A NOVEL SUBCUTANEOUS INFILXIMAB (CT-P13) IN... (3*)[(Celltrion, Inc.)
949. . . EFFICACY AND SAFETY OF 2 VEDOLIZUMAB... (3*)[(Takeda)
950. . . THE VISIBLE 2 PHASE 3 STUDY... (3*)[(Takeda)
951. . . DEXAMETHASONE PROPHYLAXIS OF POSTEMBOLIZATION SYNDROME AFTER... (5*)
952. . . INSUFFICIENT RADIOFREQUENCY ABLATION PROMOTES THE METASTASIS... (2*)
953. . . IN SITU VACCINE IMMUNOTHERAPY FOR GASTROINTESTINAL... (5*)
954. . . THE INFLUENCE OF IMMUNE HETEROGENEITY ON... (2*)
955. . . INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES... (6*)
956. . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL... (5*)
992. . . VEGETARIAN DIET REDUCES HUMAN GUT MICROBIAL... (2*)
993. . . NEURAL NETWORK PREDICTS DROP IN HEMOGLOBIN... (2*)
994. . . ASSOCIATION OF METEOROLOGICAL PARAMETERS WITH INCIDENCES... (4*)
995. . . PHASE 3 STUDY EVALUATING THE EFFICACY... (3*)[(Funded by Takeda Development Center Asia Pte Ltd, Singapore.)
996. . . OUTCOMES IN PATIENTS ADMITTED WITH ACUTE... (5*)
997. . . SUPPRESSION OF LPS-INDUCED IL-6 PRODUCTION IN... (2*)[(6]
998. . . LOCAL AND SYSTEMIC IMMUNE SIGNATURE DIFFERENCES... (2*)
999. . . FECAL MICROBIOTA TRANSPLANTATION AMELIORATES EXPERIMENTALLY INDUCED... (2*)
1000. . . TWO TYPES OF HUMAN PANCREATIC ACINAR... (4*)[(2)
1007. . . DIETARY FIBER INTAKE, THE GUT MICROBIOME,... (2*)[(4]
1008. . . A RANDOMIZED CONTROLLED-FeEDING STUDY OF... (2*)
1009. . . ALTERED DIURNAL FEEDING PATTERNS LINKED WITH... (6*)
1010. . . MATERNAL EMULSIFIER EXPOSURE EXACERBATES THE SUSCEPTIBILITY... (2*)
1011. . . IMPAIRED THERMOGENESIS IN BROWN ADIPOSE TISSUE... (2*)
1012. . . DIET AND FEEDING PATTERN AFFECT THE... (2*)[(7]
1013. . . SINGLE CELL (SC) RNA SEQ OF... (2*)[(4]
1014. . . EXPLORING THE CANCER GENOME ATLAS (TCGA)... (5*)
1015. . . INTEGRATIVE MOLECULAR MARKER ANALYSES OF EARLY-ONSET... (2*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Abstract Funding Source Key | 1016. LOSS OF TGFB2 IN DIFFUSE TYPE... | 1017. GENOMIC LANDSCAPE AND IMMUNE CHARACTERISTICS OF... | 1018. IDENTIFICATION OF THE CANCER-SUPPRESSING CANCER-ASSOCIATED FIBROBLASTS... | 1019. VITAMIN D RECEPTOR PROTECTS INTESTINAL BARRIERS... | 1020. DEOXYCHOLATE ACID INDUCED-GUT DYSBIOSIS DISRUPTS BILE... | 1021. NFAT5 POSITIVELY CONTROLS GLYCOSLYSIS IN INTESTINAL... | 1022. LOSS OF OLFATORY G PROTEIN-COUPLED RECEPTOR... | 1023. VITAMIN D RECEPTOR REGULATES EPITHELIAL-MESENCHYMAL TRANSITION... | 1024. FUSOBACTERIUM NUCLEATUM SECRETES OUTER MEMBRANE Vesicles... | 1025. EFFECTS OF ACUPUNCTURE ON SYMPTOMS, MICROBIOTA,... | 1026. LOW DOSE INTERLEUKIN-2 FOR THE TREATMENT... | 1027. SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A... | 1028. IUSTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS... | 1029. GASTRIC SLEEVE SURGERY WITH DUODENAL SWITCH... | 1030. A PHASE 2, OPEN-LABEL, MULTICENTER, 2X2... | 1031. A DISTINCT BRAIN-GUT MICROBIOME PROFILE EXISTS... | 1032. PLASMA METABOLIC IN A TARGETED PANEL... | 1033. UTILITY OF COMBINING ENDOSCOPIC ULTRASOUND WITH... | 1034. SEX DIFFERENCES IN PEDIATRIC ACUTE RECURRENT... | 1035. A PROSPECTIVE ENDOSCOPIC AND HISTOLOGIC STUDY... | 1036. RECURRENT NEOPLASIA AFTER ENDOSCOPIC TREATMENT FOR... | 1037. INDEPENDENT VALIDATION OF AN ACCURATE METHYLATED... | 1038. INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT... | 1039. EPITHELIAL-DERIVED SELENOPROTEIN P ATTENUATES OXIDATIVE STRESS... | 1040. SPERMIDINE PROTECTS FROM COLITIS AND COLITIS-ASSOCIATED... | 1041. ROLE OF MYELOID CELLS IN THE... | 1042. COLONIC EPITHELIAL CELL- DERIVED AFTIPHILIN (AFTPH) REGULATES... | 1043. NEUROTENSIN DEFICIENCY IMPROVES BILE ACID HOMEOSTASIS... | 1044. THE ROLE OF SMOOTH MUSCLE CELL... | 1045. ELEVATED HEXOKINASE 1 IMPAIRS INTESTINAL ENTEROCYTE... | 1046. COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE... |

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
TRANSITION...(2*)[(National Natural Science Foundation of China,81871947) research was supported by AMED (grant number JP18k0108077), and JSPS KAKENHI (grant number JP18K16183). This research was also supported by grants from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Uehara Memorial Foun]

1137. . . . OPIOID-RELATED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS... (2*)

1138. . . . HIGH-DOSE DAILY OPIOID USE AMONG VETERANS... (2*)

1139. . . . HIGH-VOLUME OPIOID PRESCRIBERS ACCOUNT FOR A... (4*)

1140. . . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE... (5*)

1141. . . . TRENDS AND SOCIOECONOMIC HEALTH OUTCOMES OF... (5*)

1142. . . . MICROBIAL DEGRADATION OF ILEAL MUCUS PROMOTES... (2*][0])

1143. . . . URINE 3-INDOXYL SULFATE, A GUT MICROBIOME-DERIVED... (2*)

1144. . . . FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT... (2*)][3)]

1145. . . . AN EFFECTIVE METHOD OF ERADICATING HELICOBACTER... (2*)

1147. . . . DETECTION OF SEASONAL INFLUENZA RNA IN... (2*)][3)](This research was supported by AMED (grant number JP18k0108077), and JSPS KAKENHI (grant number JP18K16183). This research was also supported by grants from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Uehara Memorial Foun)

1148. . . . JAK INHIBITORS SUPPRESS COLON CANCER CACHEXIA-ASSOCIATED... (7*)][4)]

1149. . . . THE DIETARY-SHAPED GUT MICROBIOME ACCELERATES THE... (4*)

1150. . . . HIGH FAT DIET PROMOTES COLORECTAL TUMORIGENESIS... (2*)

1151. . . . THE SULFUR MICROBIAL DIET SCORE AND... (2*)][6)]

1152. . . . AUTOPHAGY INHIBITS COLORECTAL CARCINOGENESIS INDUCED BY... (4*)][2)]

1153. . . . TRANSCRIPTIONAL SIGNATURES OF WESTERN-STYLE DIET IN... (4*)

1154. . . . RNF125 CONTROL OF THE HISTONE DEACETYLASE... (2*)

1155. . . . CO-TARGETING MAPK SIGNALING AND ASPARAGINE... (2*)

1156. . . . ALDH1A3 PROMOTES PANCREATIC CANCER METASTASIS VIA... (2*)

1157. . . . CIRCULATING IL-10R2+ MYELOID CELLS IN PERIPHERAL... (5*)

1159. . . . CLINICOPATHOLOGICAL FEATURES OF THE FLAT... (5*)

1160. . . . REAL-WORLD PEDIATRIC INFlixIMAB PHARMACOKINETIC MODEL VERIFIES... (2*)][6)]

1161. . . . CLINICAL AND HOST BIOLOGICAL FACTORS CAN... (2*)

1162. . . . BASELINE ILEAL LUMINAL NARROWING IS ASSOCIATED... (2*)][6)](NIH Funding P30DK078392, CCFA funding)

1163. . . . STEP-CD STUDY: USTEKINUMAB USE IN PAEDIATRIC... (5*)

1164. . . . EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN... (3*)][This study was funded by Janssen Research and Development, LLC)

1165. . . . CLINICAL HYMNOSIS IN PEDIATRIC CROHN’S DISEASE:... (4*)][6)
AGA Poster Presentations
Sa1000. . . . PUBLICATION TRENDS IN GASTROENTEROLOGY AND HEPATOLOGY... (5*)
Sa1001. . . . ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR... (5*)
Sa1002. . . . PREVALENCE OF ACHALASIA IN THE MEDICARE... (2*)
Sa1003. . . . ACCURACY OF FIBROSCAN CONTINUOUS ATTENUATION PARAMETER... (4*)
Sa1004. . . . PREVALENCE OF COMPLICATIONS RELATED TO CHRONIC... (5*)
Sa1005. . . . PREVALENCE OF GASTROINTESTINAL DISEASE IN AN... (2*)
Sa1006. . . . TRENDS AND CHARACTERISTICS OF ACUTE CARE... (5*)
Sa1007. . . . PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE... (5*)
Sa1008. . . . INCIDENCE OF CLOSTRIIDOIDS DIFFICILE INFECTION FROM... (4*)
Sa1009. . . . POOR RATES OF RETESTING FOR ERADICATION... (2*)
Sa1010. . . . HEYDE SYNDROME: EPIDEMIOLOGY OF ANGIODYPLASIA IN... (5*)
Sa1011. . . . HYPERBILIRUBINEMIA IN HOSPITALIZED PATIENTS: ETIOLOGY AND... (4*)
Sa1012. . . . EFFECTS OF SYSTEMIC LUPUS ERYTHEMATOSUS ON... (5*)
Sa1013. . . . EPIDEMIOLOGY AND PREVALENCE OF PSYCHIATRIC DISEASES... (5*)
Sa1014. . . . WHAT IF IT’S STILL THERE? ANALYSIS... (5*)
Sa1015. . . . NATIONAL HEALTH BURDEN OF ASPIRATION PNEUMONIA... (3*) [(Aspisafe Solutions Inc.)]
Sa1016. . . . CLOSTRIIDOIDS DIFFICILE INFECTION: NOT AN EQUAL... (5*)
Sa1017. . . . A COMPARISON OF LYMPHOCYTIC COLITIS AND... (5*)
Sa1018. . . . THE EPIDEMIOLOGY OF ANNULAR PANCREAS IN... (5*)
Sa1019. . . . CHRONIC MESENTERIC ISCHEMIA, A HORSE INSTEAD... (5*)
Sa1020. . . . EFFECT OF HELICOBACTER PYLORI ERADICATION ON... (5*)
Sa1021. . . . CAN FECAL CALPROTECTIN LEVELS BE USED... (5*)
Sa1022. . . . EPIDEMIOLOGY OF DEPRESSIVE DISORDERS IN PATIENTS... (5*)
Sa1023. . . . AN INDIAN NATIONAL SURVEY OF THERAPEUTIC... (5*)
Sa1024. . . . HIGH COMPLEXITY AND CONFLICTING RECOMMENDATIONS ARE... (5*)
Sa1025. . . . CHARACTERISTICS OF OPIOID PRESCRIPTIONS TO VETERANS... (2*)
Sa1026. . . . EVALUATION OF SOCIOECONOMIC AND HEALTHCARE DISPARITIES... (5*)
Sa1027. . . . GENDER DISPARITIES IN PREVALENCE AND CONFLICTS... (5*)
Sa1028. . . . INVESTIGATION OF REPEAT GASTROINTESTINAL BLEEDING AMONG... (5*)
Sa1029. . . . THE OVERALL QUALITY OF EVIDENCE SURROUNDING... (5*)
Sa1030. . . . DEVELOPMENT OF A PRELIMINARY QUESTION PROMPT... (5*)
Sa1031. . . . ENHANCED E-CONSULTS AT A FEDARALLY QUALIFIED... (5*)
Sa1032. . . . FROM ABSTRACT TO PUBLICATION SUCCESS: A... (5*)
Sa1033. . . . IDENTIFYING PATIENTS WITH ACUTE GASTROINTESTINAL BLEEDING... (5*)
Sa1034. . . . HARD TO SWALLOW RESULTS: ASSESSMENT OF... (5*)
Sa1035. . . . WHAT TYPES OF QUESTIONS CAN BE... (5*)
Sa1036. . . . DEVELOPMENT OF QUALITY INDICATORS FOR THE... (5*)
Sa1037. . . . TIME AND EFFORT SPENT AFTER WORK... (5*)
Sa1038. . . . PATIENT AND PROCESS-DRIVEN BARRIERS TO GASTROENTEROLOGY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1060. . . COMPARING THE CONTRIBUTION OF INTERNATIONAL MEDICAL... (5*)
Sa1061. . . CHARACTERIZATION OF ENGAGEMENT AND CONTENT ANALYSIS... (5*)
Sa1062. . . CHANGHAI ADVANCED ENDOSCOPY COURSES FOR ERCP... (5*)
Sa1063. . . ARE PARENTAL LEAVE POLICIES HELPING OUR... (5*)
Sa1064. . . SURVEYING GASTROENTEROLOGY CONTENT AND METHODS OF... (5*)
Sa1065. . . TEACHING GASTROENTEROLOGY TO FIRST YEAR MEDICAL... (5*)
Sa1066. . . ADVANCED ENDOSCOPY TRAINING IN PEDIATRICS: THE... (5*)
Sa1067. . . IMPLEMENTATION OF A FIRST-YEAR GASTROENTEROLOGY FELLOWS... (4*)
Sa1068. . . GI TALK: A COMMUNICATION SKILLS TRAINING... (5*)
Sa1069. . . GENDER DISPARITIES IN GASTROENTEROLOGY FELLOWS ACROSS... (5*)
Sa1070. . . IMPACT OF A VIRTUAL REALITY SIMULATION... (5*)
Sa1071. . . EVALUATING THE IMPACT OF ADVANCED ENDOSCOPY... (5*)
Sa1072. . . IMPACT OF PARENTHOOD ON GASTROENTEROLOGY TRAINING... (5*)
Sa1073. . . IMPACT OF TRAINEE PARTICIPATION ON ADENOMA... (5*)
Sa1074. . . SIGNIFICANT IMPROVEMENT OF PRIMARY CARE DOCTORS' ENGAGEMENT... (3*) (Xian Janssen Pharmaceutical Ltd)
Sa1075. . . HONOKIOL, A NOVEL AGENT THAT PROMOTES... (2*)
Sa1076. . . A NOVEL RAT MODEL OF HEARTBURN... (2*) (4)
Sa1077. . . P2X7 RECEPTOR ANTAGONIST RECOVERS MYENTERIC NEURONS... (4*)
Sa1078. . . CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT... (3*) (2) (Arena Pharmaceuticals)
Sa1079. . . ESTABLISHING AN INTESTINAL EPITHELIAL-NEURONAL CO-CULTURE SYSTEM... (4*) (2)
Sa1080. . . THE DEUBIQUITINATING ENZYME USP10 REGULATES NA+/H+... (2*)
Sa1081. . . UNIQUE MECHANISMS OF REGULATION OF L-TYPE... (2*)
Sa1082. . . MOLECULAR MECHANISM OF STIMULATION OF NA-K-ATPASE... (2*)
Sa1083. . . GASTRIC AND PANCREATIC-DERIVED DOPAMINE STIMULATES... (2*)
Sa1084. . . MUSCARINIC AND NICOTINIC SIGNALING SYNERGISTICALLY REGULATE... (2*)
Sa1085. . . REGULATION OF ELECTROLYTE AND NUTRIENT TRANSPORTERS... (2*)
Sa1086. . . AUTOPHAGY REGULATES PUTATIVE ANION TRANSPORTER 1... (2*)
Sa1087. . . DEFICIENT ACTIVITY OF A GOBLET CELL-SPECIFIC... (2*) (6)
Sa1088. . . GLUCOSE-STIMULATED ANION CHANNEL ACTIVITY DECREASED NET... (3*)
Sa1089. . . SLCP2643 (DRA) IS STIMULATED BY BOTH... (2*)
Sa1090. . . PROTEIN KINASE A-ALPHA REGULATES PGE2 MEDIATED... (2*)
Sa1091. . . POLARIZED RESPONSES TO EXTRACELLULAR CYCLIC DINUCLEOTIDES... (2*)
Sa1092. . . APICAL BK CHANNELS IN INTESTINAL EPITHELIA... (6*)
Sa1093. . . CONTRIBUTION OF EPITHELIAL HYPERPROLIFERATION TO INCREASED... (6*)
Sa1094. . . EVIDENCE OF DUODENAL EPITHELIAL BARRIER IMPAIRMENT... (4*) (2)
Sa1095. . . PAR6B REGULATES INTESTINAL BARRIER FUNCTION IN... (2*)
Sa1096. . . SELECTIVE INHIBITION OF COX-1, BUT NOT... (2*)
Sa1097. . . EXPLORING THE MECHANISMS OF LARAZOTIDE IN... (3*) (4*) (Innovate Biopharmaceuticals Inc., Raleigh, NC, USA)
Sa1098. . . OLEOYLETHANOLAMIDE AMELIORATES DEXTRAN SULFATE SODIUM-INDUCED COLITIS... (4*)
Sa1099. . . LACTOBACILLUS RHAMNOSUS GG (LGG) #NAME? ENTERIC... (2*)
Sa1100. . . INGESTED MICROPLASTICS POSE A POTENTIALLY SERIOUS... (4*)
Sa1102. . . PROTECTIVE EFFECT OF ALISMATIS RHIZOMA ON... (2*)
Sa1103. . . ANTI-INFLAMMATORY EFFECT OF TEGOPRAZAN(CJ-12420), A NOVEL... (5*)
Sa1104. . . RELATIONSHIP BETWEEN ANTIMICROBIAL REG IIIγ EXPRESSION... (5*)
Sa1105. . . EFFECT OF ANTIMICROBIAL REG IIIγ EXPRESSION... (5*)
Sa1106. . . THE IMPACT OF BILE SALT SEQUESTRANTS... (3*)
Sa1107. . . EFFECTS OF QIZHI WEITONG GRANULES ON... (5*)
Sa1108. . . SERUM AMYLLOID A PROMOTES INFLAMMATION-ASSOCIATED DAMAGE... (2*) (6)
Sa1109. . . CRONKHITE-CANADA SYNDROME: A PRELIMINARY STUDY TO... (2*)
Sa1110. . . ENDOSCOPIC AND HISTOLOGIC INFLAMMATION IN THE... (5*)
Sa1111. . . DOWN-REGULATION OF OLFM4 CONTRIBUTES TO METASTASIS... (5*)
Sa1112. . . TARGETED DELETION OF CIRCULAR RNA CDR1AS... (2*)
Sa1113. . . LYCIUM BARBARUM POLYSACCHARIDES ATTENUATES-Colonic Inflammation... (4*) (5)
Sa1114. . . MODELING CONTEXT-DEPENDENT BUBR1 KINASE SIGNALING USING... (2*) (6)
Sa1115. . . CIRCADIAN MISALIGNMENT BY ENVIRONMENTAL LIGHT: DARK SHIFTING... (5*)
Sa1116. . . BISMUTH SUBSALICYLATE ALTERS THE EFFECTS OF... (3*) (5) (P & G grant IISP opportunity)
Sa1117. . . . THE EFFECTS OF
SULGLYCOTIDE ON THE... (3*)[(Samil
pharmaceutical company)

Sa1118. . . . AUTOPHAGY IS REQUIRED
FOR THE BENEFICIAL... (4*)

Sa1119. . . . TRISTETRAPROLIN
EXPRESSION IN THE INTESTINAL
EPITHELIUM... (5*)

Sa1120. . . . DEPLETION OF DELTA-LIKE
LIGAND 4 (DLL4)... (2*)

Sa1121. . . . COMPOUND
HETEROZYGOTE TRIM22 VARIANTS
ARE A... (6*)

Sa1122. . . . TARGETED DRUG
DELIVERY FOR INFLAMMATORY
BOWEL... (2*)

Sa1123. . . . REGULATORS OF THE
GUANYLYL CYCLASE PATHWAY... (2*)

Sa1124. . . . SINGLE CELL
TRANSCRIPTOMIC APPROACH TO
UNDERSTANDING... (2*)[(U01DK112194
(Baylor), U01DK073983[HU],
U01DK112193 [Braden Kuo],
U01DK073975 [Temple], U01DK074035
(UTU), U01DK074007 (Louisville – Abell),
U01DK073974 (Wake Forest – Koch),
U01DK074008)]

Sa1125. . . . GENE EXPRESSION (GE)
VALUES IN A... (3*)[(NCT02589665 and
this subsidiary analysis were designed,
and conducted by Eli Lilly and
Company.)

Sa1126. . . . IMMUNE IMPAIRMENTS IN
BOWEL OBSTRUCTION: ROLE... (2*)

Sa1127. . . . THE KETOGENIC ENZYME,
HMGCS2, PROTECTS INTESTINAL... (2*)

Sa1128. . . . LUBIPROSTONE
INCREASED EXPRESSION OF CLAUDIN-
1 AND... (4*)

Sa1129. . . . WATER AVOIDANCE
STRESS DECREASES INNATE
LYMPHOID... (4*)

Sa1130. . . . THE EFFECT OF
PHENOXIN-14 ON... (4*)

Sa1131. . . . EXOSOMES FROM HUMAN
MESENCHYMAL STEM CELLS... (2*)

Sa1132. . . . CHARACTERIZATION OF
IL10 GENE-DEFICIENT MOUSE
INTESTINAL... (2*)[(National
Natural Science Foundation of China,
81670477, 81600418, 81600412, 81600419; Sun Yat-Sen University
Clinical Research 5010 Program (2014008))

Sa1133. . . . THE ROLE OF INTERFERON-
α AND PLASMACYTOID... (4*)

Sa1134. . . . THE GUT-SKIN AXIS IN
SAMP1/YITFCC MICE... (2*)

Sa1135. . . . CYSTATHIONINE-γ-LYASE
(CSE) DERIVED HYDROGEN SULFIDE
(H2S)... (2*)

Sa1136. . . . EFFECT OF
TETRAHYDROCANNABINOL ON THE
CANONICAL... (4*)

Sa1137. . . . AN ADHESIONIC ROLE OF
THBS4 IN... (2*)

Sa1138. . . . MURINE INTRARECTAL
INSTILURATION OF PURIFIED
RECOMBINANT... (2*)[(4)

Sa1139. . . . NEW THERAPEUTIC
STRATEGY FOR AMINO ACID... (2*)

Sa1140. . . . MMP-9 DISRUPTION OF
INTESTINAL EPITHELIAL TIGHT... (6*)[(4)

Sa1141. . . . CSN6 PROMOTES
COLORECTAL CANCER BY
Supporting... (2*)

Sa1142. . . . THE ROLE FOR LONG NON-
CODING RNA... (4*)

Sa1143. . . . CONCORDANCE BETWEEN
SOMATIC AND GERMLINE MUTATION... (5*)

Sa1145. . . . NOVEL LINCRNA HERES
REGULATES WNT SIGNALING... (2*)

Sa1146. . . . CANCER-RELATED GENETIC
VARIANTS OF HELICOBACTER
PYLORI... (2*)[(This study was funded by the
Ministry of Science and Information and
Communication Technologies (ICT)
(grant numbers 2017MSA9084539, 2017IA2B4006316, and
2018IA2B2003782))

Sa1147. . . . GENETIC COMPARISON OF
YOUNG-ONSET AND LATE-ONSET... (2*)

Sa1148. . . . GENERATION AND
CHARACTERIZATION OF HUMAN
PANCREATIC... (2*)

Sa1149. . . . NEW THERAPEUTIC
STRATEGY FOR AMINO ACID... (2*)

Sa1150. . . . THE ROLE FOR LONG NON-
CODED RNA... (2*)[(5)

Sa1151. . . . POST-TRAUMATIC STRESS
DISORDER IN NEUROENDOCRINE
TUMOR... (5*)

Sa1152. . . . TUMOR RESPONSE TO
PEPTIDE RECEPTOR RADIONUCLIDE... (5*)

Sa1153. . . . RACIAL DIFFERENCES IN
GASTROENTEROPANCREATIC
NEUROENDOCRINE TUMOR... (6*)

Sa1154. . . . ORGANOID-BASED
PRECLINICAL MODELS RECAPITULATE
RENALASE SIGNALING... (2*)

Sa1155. . . . BILE ACIDS AND THE
MICROBIOTA PLAY... (2*)[(6)

Sa1156. . . . ROLE OF WNT NON-
CANONICAL PATHWAY IN... (4*)

Sa1157. . . . MURINE INTRARECTAL
DISRUPTION OF
INTESTINAL TIGHT... (6*)[(4)

Sa1158. . . . THE EFFECT OF
THBS4 IN... (2*)

Sa1159. . . . MURINE INTRARECTAL
DISRUPTION OF
INTESTINAL TIGHT... (6*)[(4)

Sa1160. . . . THE ROLE FOR P21 IN CD4+ T...
(4*)

Sa1161. . . . INFLAMMATORY IMMUNE
RESPONSES ASSOCIATED WITH ORAL...
(4*)

Sa1162. . . . COLORECTAL CANCER
PROLIFERATION AND SURVIVAL ARE...
(2*)[(5)

Sa1163. . . . PATIENTS WITH IBD ARE
AT AN... (5*)

Sa1164. . . . PREOPERATIVE
INTRAVENOUS IRON THERAPY AND
SURVIVAL... (2*)

Sa1165. . . . THE DNA MISMATCH
REPAIR (MMR) PROTEIN... (2*)[(4)

Sa1166. . . . SYSTEMIC LUPUS
ERYTHEMATOUS AND COLORECTAL
CANCER:... (5*)

Sa1167. . . . ADRENALINE-DEPENDENT
IMMUNOLOGIC REPROGRAMMING IN
ENDOTHELIAL CELLS... (2*)

Sa1168. . . . RHEUMATOID ARTHRITIS
AND COLORECTAL CANCER: THE... (5*)

Sa1169. . . . ACHIEVING HISTOLOGIC
NORMALIZATION IN LONG-STANDING
ULCERATIVE... (5*)

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1332. GASTRIC CORPUS MUCOSAL HYPERPLASIA AND NEOENDOCRINE... (4*)
Sa1333. BILE ACIDS PROMOTE GASTRIC INTESTINAL METAPLASIA... (2*)
Sa1334. CLINICOPATHOLOGICAL FEATURES AND TREATMENTS EFFECTS ON... (5*)
Sa1335. NEOPLASIA RISK AND RESECTION COMPLICATIONS... (5*)
Sa1336. HYPERGASTRINEMIA IS ASSOCIATED WITH PROXIMAL AND... (2*) (7)
Sa1337. DIFFERENTIAL EXPRESSION OF CIRCULATING MICRONAS IN... (4*) (6)
Sa1338. NATURAL HISTORY OF AUTOIMMUNE GASTRITIS: PROSPECTIVE... (5*)
Sa1339. INTEROBSERVER CONSISTENCY ON THE HISTOLOGICAL ASSESSMENT... (5*)
Sa1340. IMPACT OF OBESITY ON RATES AND... (2*)
Sa1341. HELICOBACTER PYLORI INFECTION IS ASSOCIATED WITH... (5*)
Sa1342. GASTRIC CANCER OCCURRENCE DESPITE PRIOR ENDOSCOPY;... (5*)
Sa1343. CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON... (5*)
Sa1344. STAT3 SIGNALING ACTIVATES CDX2 VIA INDUCTION... (5*)
Sa1345. THE GASTRIC PRECANCEROUS CONDITIONS STUDY (GAPS)... (4*) (6)
Sa1346. HYPERGASTRINEMIA DUE TO P-CAB (AN... (5*)
Sa1347. MTHFR C677T GENETIC POLYMORPHISM INVOLVED IN... (2*)
Sa1348. CORRELATION BETWEEN SERUM GASTRIC BIOMARKERS AND... (5*)
Sa1349. A NON-INVASIVE TEST IN THE MANAGEMENT... (5*)
Sa1351. COMPARISON BETWEEN PROACTIVE VERSUS STANDARD PERCUTANEOUS... (5*)
Sa1352. MOLECULAR PHENOTYPING OF INFECTED PANCREATIC NECROSIS... (6*)
Sa1353. MORTALITY IN PATIENTS WITH ACUTE PANCREATITIS... (5*)
Sa1354. THE VALIDATION OF PANCREATITIS ACTIVITY SCORING... (5*)
Sa1355. CAN ARTIFICIAL INTELLIGENCE (AI) PREDICT... (5*)
Sa1356. NEED FOR INTERVENTION IN NECROTIZING PANCREATITIS... (5*)
Sa1357. BILIARY INTERVENTIONS IN PATIENTS WITH STERILE... (5*)
Sa1358. VALUE OF MEASUREMENT OF WHOLE BODY... (5*)
Sa1359. LONGITUDINAL ASSESSMENT OF HBA1C LEVELS IN... (3*) (4*) (AbbVie)
Sa1360. IMMUNE CHECKPOINT-INHIBITOR INDUCED ACUTE PANCREATITIS: A... (5*)
Sa1361. PATIENT-CONTROLLED ANALGESIA LEADS TO INCREASED HOSPITAL... (5*)
Sa1362. INCREASED FLUID RATE HASTENS RECOVERY OF... (5*)
Sa1363. USE OF ACOUSTIC RADIATION FORCE IMPULSE... (5*)
Sa1364. PANCREATIC CANCER IN ACUTE PANCREATITIS: A... (5*)
Sa1365. PRACTICE PATTERNS IN THE NUTRITIONAL SUPPORT... (5*)
Sa1366. PREDICTORS OF EMERGENCY DEPARTMENT OPIATE USE... (5*)
Sa1367. PROGRESSION FROM ACUTE PANCREATITIS WITH SYSTEMIC... (2*)
Sa1368. ASSOCIATION OF INCREASED SERUM TRIGLYCERIDE LEVELS... (5*)
Sa1369. DIAGNOSIS AND TREATMENT OF Pancreatic Duct... (5*)
Sa1370. EPIDEMIOLOGY AND RISK OF ANXIETY AND... (5*)
Sa1371. SPLANCHNIC VEIN THROMBOSIS IN ACUTE PANCREATITIS... (5*)
Sa1372. ISCHEMIC PANCREATITIS IS A RARE BUT... (5*)
Sa1373. PREOPERATIVE ERCP HAS NO IMPACT ON... (2*)
Sa1374. SINGLE OPERATOR PANCREATOSCOPY WITH INTRADUCTAL LITHOTRIPSY... (5*)
Sa1375. FOLATE AND VITAMIN B12 DEFICIENCY INCREASES... (2*)
Sa1376. PANCREAS CANCER ASSOCIATED MORTALITY IS LOW... (7*) (2)
Sa1377. LIFETIME SMOKING IN PERSONS WITH CHRONIC... (2*)
Sa1378. CHRONIC PanCREATITIS (CP) HAS A PROFOUND... (2*)
Sa1379. WHAT IS A BENEFIT OF ISLET... (5*)
Sa1380. SEVERE PAIN IN CHRONIC PanCREATITIS IS... (2*)
Sa1381. PREDICTIVE FACTORS OF RELAPSE IN AUTOIMMUNE... (5*)
Sa1382. CLASSIFICATION OF EARLY-ONSET AND LATE-ONSET IDIOPATHIC... (5*)
Sa1383. A COMPARISON OF UROLOGIST VS. GASTROENTEROLGIST-DIRECTED... (5*)
Sa1384. FRAGMENTED INPATIENT CARE IS PREVALENT AMONG... (5*)
Sa1385. CHRONIC PanCREATITIS IS ASSOCIATED WITH INCREASED... (5*)
Sa1386. ISLET AUTOTRANSPLANTATION IMPROVES GLYCEMIC CONTROL IN... (5*)
Sa1387. NATIONWIDE EPIDEMIOLOGICAL SURVEY OF AUTOIMMUNE PanCREATITIS... (7*) (2)
Sa1388. LOOKING FOR A SUBROGATE BIOMARKER OF... (5*)
Sa1389. THE RISK OF VITAMIN D DEFICIENCY,... (5*)
Sa1390. MANAGEMENT AND SURVEILLANCE OF EXOCRINE PanCREATITIS... (5*)
Sa1391. ANTIoxidANT DECREASES THE FREQUENCY OF PAIN... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1392. . . . NATIONWIDE EPIDEMIOLOGICAL SURVEY OF CHRONIC... (5*)
Sa1393. . . . LIFESTYLE MODIFICATIONS IN CHRONIC PANCREATITIS ... (5*)
Sa1394. . . . OPIATEDEPENDENCE IS A SIGNIFICANT RISK... (5*)
Sa1550. . . . HEAVY ALCOHOL USE AND LIVER DISEASE... (5*)
Sa1551. . . . TEMPORAL TRENDS OF MORTALITY AND HEALTHCARE... (5*)
Sa1552. . . . CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ALCOHOLIC... (5*)
Sa1553. . . . PROTON PUMP INHIBITOR THERAPY REDUCES FERRITIN... (5*)
Sa1554. . . . NATIONAL TRENDS AND OUTCOMES OF GENETICALLY... (5*)
Sa1555. . . . POLYCYTHEMIA AND ANEMIA IN HEREDITARY HEMOCROMATOSIS... (5*)
Sa1556. . . . IMPAIRED INTESTINAL CHYLOMICRON SECRETION DISSOCIATES REVERSAL... (2*)
Sa1557. . . . PRAGMATIC USE OF NON-INVASIVE DIAGNOSTIC METHODS... (4*)
Sa1558. . . . THE ROLE OF IAA IN NON-ALCOHOLIC... (2*)
Sa1559. . . . ELEVATED LIVER ENZYMES NOT CORRELATED WITH... (5*)
Sa1560. . . . PROTEIN TRUNCATING SPICE VARIANT (RS72613567) IN... (4*)
Sa1561. . . . CANNABIS IS ASSOCIATED WITH REDUCED IN-PATIENT... (5*)
Sa1562. . . . NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID... (3*)
Sa1563. . . . FIB-4 INDEX CORRELATES WITH MEASURES OF... (4*)
Sa1564. . . . CHARACTERISTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
Sa1565. . . . CHILD-TURCOTTE-PUGH CLASS AT TRANSPLANTATION PREDICTS POST-TRANSPLANTATION... (5*)
Sa1566. . . . LIVER SURFACE NODULARITY AS AN ESTIMATE... (5*)
Sa1567. . . . MRI INTENSITY PATTERNS IN PATIENTS WITH... (5*)
Sa1568. . . . EUS-GUIDED SAMPLING AND PROFILING OF PORTAL... (5*)
Sa1569. . . . TIMELY DIAGNOSIS AND STAGING OF NAFLD... (5*)
Sa1615. . . . GASTRIC DYSMOTILITY NEGATIVELY IMPACTS BOTH GASTROINTESTINAL... (2*)
Sa1616. . . . SACRAL NERVE STIMULATION LEADS TO LONG-TERM... (5*)
Sa1617. . . . OVERLAPPING SYMPTOMS OF GASTROESOPHAGEAL REFUX AND... (4*)
Sa1618. . . . A RETROSPECTIVE REVIEW OF LINACLOTIDE TREATMENT... (5*)
Sa1619. . . . IS CELIAC DISEASE TESTING NECESSARY IN... (5*)
Sa1620. . . . POLYETHYLENE GLYCOL 3350 CHANGES STOOL CONSISTENCY... (4*)
Sa1621. . . . EFFECT OF MIRTAZAPINE IN CHILDREN WITH... (5*)
Sa1622. . . . SLEEP DISTURBANCES IN SCHOOL-AGE CHILDREN WITH... (2*)
Sa1623. . . . URINARY EXOSOMES ISOLATED FROM PEDIATRIC PATIENTS... (4*)
Sa1624. . . . PYRIDOSTIGMINE FOR TREATMENT OF CHILDREN WITH... (5*)
Sa1625. . . . NON-GASTROINTESTINAL PAIN SYMPTOMS IN CHILDREN WITH... (2*)
Sa1626. . . . HYPNOSIS TO REDUCE DISTRESS IN CHILDREN... (1*)
Sa1627. . . . THE NOT SO RARE ABSENT RAIR... (5*)
Sa1628. . . . UTILIZATION AND COST FOR PEDIATRIC IRRITABLE... (5*)
Sa1629. . . . COMPARISON OF THE BRISTOL STOOL FORM... (5*)
Sa1630. . . . APREPIANT FOR ACUTE TREATMENT OF SEVERE... (5*)
Sa1631. . . . INTRAPYLORIC BOTULINUM INJECTIONS IMPROVE FEEDING OUTCOMES... (2*)
Sa1632. . . . COMPARING VULNERABILITIES AND TRIGGERS IN PEDIATRIC... (5*)
Sa1633. . . . COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN... (1*)
Sa1634. . . . ALLERGY-RELATED DISEASES DURING CHILDHOOD AND RISK... (6*)(2)
Sa1635. . . . CINE-MRI VERSUS COLONIC MANOMETRY IN THE... (5*)
Sa1636. . . . PEDIATRIC ROME IV CRITERIA HAS SUBSTANTIAL... (5*)
Sa1637. . . . IBS MOTHERS IN JAPAN WHO HAVE... (2*)
Sa1638. . . . STANDARDIZING LONG-TERM GASTROINTESTINAL MOTILITY RECORDINGS IN... (5*)
Sa1639. . . . AZITHROMYCIN IS EQUALLY ABLE TO INDUCE... (4*)
Sa1640. . . . NONINVASIVE MEASUREMENT OF SMALL BOWEL SLOW... (4*)
Sa1641. . . . THE EFFECTS OF DIABETES MELLITUS ON... (5*)
Sa1642. . . . THE EFFECTS OF VENOUS THROMBOEMBOLISM IN... (5*)
Sa1643. . . . RISK FACTORS AND INCIDENCE OF 90-DAY... (5*)
Sa1644. . . . TRENDS IN MANAGEMENT OF ACUTE COLONIC... (5*)
Sa1645. . . . DIVERTICULAR DISEASE WITH AND WITHOUT BLEEDING... (5*)
Sa1646. . . . VIRTUAL REALITY AS AN ALTERNATIVE TO... (4*)
Sa1647. . . . COMPARISON OF SECOND FORWARD VIEW EXAMINATION... (5*)
Sa1649. . . . HOT AVULSION VS COLD AVULSION IN... (5*)
Sa1650. . . . INCIDENCE OF INVASIVE COLORECTAL CANCER AFTER... (5*)
Sa1651. . . . PLASMA BASED CELL-FREE CIRCULATING TUMOR DNA... (3*)([Guardant Health]
Sa1652. . . . ARTIFICIAL INTELLIGENCE-AUGMENTED VISUALIZATION WITH REAL TIME... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1717. . . . THE EFFECT OF ELOBIXIBAT ON GUT... (5*)

Sa1718. . . . PELVIC FLOOR BIOFEEDBACK IS EFFECTIVE TREATMENT... (5*)

Sa1719. . . . EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS... (3*) [(This study was funded by Shire LLC, a Takeda company. Medical writing support was provided by Laura Knapp of PharmaGenesis London, London, UK with funding from Shire Human Genetic Therapies, Inc., a Takeda company.)]

Sa1720. . . . PLECANATIDE FOR PATIENTS WITH CHRONIC IDIOPATHIC... (3*) (Salix Pharmaceuticals)

Sa1721. . . . DISORDERED DEFECATION ASSOCIATED WITH POOR BOWEL... (5*)

Sa1722. . . . OPIOID RELATED DISORDERS IN PATIENTS WITH... (5*)

Sa1723. . . . COSTLY WASTE: EMERGENCY DEPARTMENT VISITS AND... (5*)

Sa1724. . . . PLECANATIDE FOR PATIENTS WITH CHRONIC IDIOPATHIC... (3*) (Salix Pharmaceuticals)

Sa1725. . . . CONCENTRATION OF SEROTONIN AND ITS METABOLITES... (4*)

Sa1726. . . . ATTRITION OF METHYLALTREXONE TREATMENT-EMERGENT ADVERSE EVENTS... (3*) (This analysis was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Ferring Pharmaceuticals, Inc, New York, NY, USA.)

Sa1727. . . . CUMULATIVE LAXATION RESPONSE WITH METHYLALTREXONE: IMPLICATIONS... (3*) (Source of financial support for this project: This study was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Ferring Pharmaceuticals, Inc.)

Sa1728. . . . HOW USEFUL IS CONSTIPATION STOOL APP... (5*)

Sa1729. . . . EFFICACY OF PRUCALOPRIDE IN PATIENTS WITH... (5*)

Sa1730. . . . CLINICAL CHARACTERISTICS AND ANORECTAL PHYSIOLOGY IN... (5*)

Sa1731. . . . EXPANDING CRITERIA FOR DIAGNOSING SLOW TRANSIT... (5*)

Sa1732. . . . PATTERN OF METHANE LEVELS WITH LACTULOSE... (5*)

Sa1733. . . . RIGHT-SIDEDS COLONIC DIVERTICULA ARE NEGATIVELY ASSOCIATED... (5*)

Sa1734. . . . CONSTIPATIN IS ASSOCIATED WITH INCREASED ODDS... (5*)

Sa1735. . . . SAFETY AND EFFICACY OF A NEW... (2*)

Sa1736. . . . PSEUDOMELANOSIS COLI CAUSES DISTURBED COLONIC MOTILITY... (4*)

Sa1737. . . . FAILURE OF PRESCRIBING BOWEL REGIMENS TO... (5*)

Sa1738. . . . LACTULOSE INCREASES SMALL BOWEL BUT NOT... (4*)

Sa1739. . . . DIFFERENCES IN EFFICACY AND SAFETY OF... (5*)

Sa1740. . . . FACTORS ASSOCIATED WITH THE IMPORTANCE OF... (5*)

Sa1741. . . . A REAL-WORLD COMPARISON OF THE EFFECTIVENESS... (3*) (Takeda Pharmaceuticals Company Ltd)

Sa1742. . . . THIOGUANINE AND LOW DOSE THIOPURINES AND... (1*)

Sa1743. . . . ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY... (5*)

Sa1744. . . . IMPACT OF LINE OF THERAPY, THERAPEUTIC... (5*)

Sa1745. . . . IMPACT OF A PATIENT SUPPORT PROGRAM... (3*) (Financial support for this study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors contributed to the development of the publication and maintained control over the final content)

Sa1746. . . . VEDOLIZUMAB DOSE ESCALATION IN PATIENTS WITH... (3*) (This study was sponsored by Takeda Pharmaceuticals International)

Sa1747. . . . A MULTICENTER, OPEN-LABEL, CONTROLLED, RANDOMIZED STUDY... (3*) (Ferring Pharmaceuticals)

Sa1748. . . . CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE... (3*) (Takeda Pharmaceuticals Company Ltd)

Sa1749. . . . PATIENTS WITH CROHN’S DISEASE TREATED WITH... (3*) (Takeda Pharmaceuticals U.S.A, Inc.)

Sa1750. . . . WOULD K50* BY ANY OTHER NAME... (6*)

Sa1751. . . . COMPARATIVE EFFECTIVENESS OF HIGH-DOSE INFlixIMAB VS... (5*)

Sa1752. . . . POSTOPERATIVE CROHN'S DISEASE RECURRENCE BASED ON... (5*)

Sa1753. . . . STEROID-SPARING THERAPY USE AND PREVENTION OF... (2*) (6)

Sa1754. . . . THE EFFECT OF IMMUNOMODULATORS AND OTHER... (5*)

Sa1755. . . . EFFECTIVENESS AND SAFETY OF ABP501, AN... (5*)

Sa1756. . . . PRIMARY BIOLOGIC-COMBINATION THERAPY IS SUPERIOR COMPARED... (5*)

Sa1757. . . . THE IBD URGENT CARE TOOLKIT: WHICH... (6*)

Sa1758. . . . TARGETED HOUSESTAFF INTERVENTION REDUCES INAPPROPRIATE OPIOID... (5*)

Sa1759. . . . IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE CARE... (6*)

Sa1760. . . . INCREASING PREVALENCE OF VENOUS THROMBOEMBOLISM IN... (5*)

Sa1761. . . . AN INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY... (4*) (2)

Sa1762. . . . IBD MEDICATION COVERAGE DENIALS AND FORCED... (6*) (3) (CCF and Takeda)

Sa1764. . . . PERCEPTION OF REMISSION AND PREFERENCE FOR... (3*) (This study was funded by Shire, a...
Sa1819. . . . DEVELOPMENT OF AN INFLAMMATORY BOWEL DISEASE... [2*]
Sa1820. . . . THE URGENCY NUMERIC RATING SCALE (NRS)... [5*]
Sa1821. . . . THE FOOD-RELATED QUALITY OF LIFE... [2*](4)
Sa1822. . . . WORK LIMITATION AMONG ADULTS WITH INFLAMMATORY... [5*]
Sa1823. . . . DO ESTROGEN CONTRACEPTIVES WORSEN DISEASE SEVERITY... [2*]
Sa1824. . . . A PROSPECTIVE COHORT STUDY OF ADHERENCE... [2*]
Sa1825. . . . ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM... [3*](Takeda)
Sa1826. . . . CHRONIC OPIOID USE IN INFLAMMATORY BOWEL... [5*]
Sa1827. . . . PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS,... [3*](This study was supported by Janssen Research and Development, LLC and Janssen Biologics B.V.)
Sa1828. . . . INCIDENCE AND PREDICTORS OF FLARE IN... [5*]
Sa1829. . . . CHARACTERISTICS AND LONG-TERM OUTCOMES OF PREGNANCY-ONSET... [5*]
Sa1830. . . . FRAILTY IS INDEPENDENTLY ASSOCIATED WITH INCREASED... [6*]
Sa1831. . . . VEDOLIZUMAB LEVELS IN BREAST MILK: RESULTS... [3*](Takeda)
Sa1832. . . . DIFFERENCE IN OUTCOMES OF HOSPITALIZATION ACROSS... [5*]
Sa1833. . . . FECAL BIOMARKERS MAY NOT ACCURATELY DETECT... [3*](4)(TechLab, Inc)
Sa1834. . . . RACE INFLUENCES CLINICAL OUTCOMES OF PATIENTS... [4*]
Sa1835. . . . THE IMPACT OF OBESITY ON OUTCOMES... [5*]
Sa1836. . . . FRAILTY AS A RISK FACTOR FOR... [5*]
Sa1837. . . . INFLAMMATORY BOWEL DISEASE READMISSIONS IN THE... [5*]
Sa1838. . . . SAFETY AND EFFICACY OF CONTRACEPTIVE USE... [5*]
Sa1839. . . . TRENDS IN COMMON LABORATORY MARKERS DURING... [5*]
Sa1840. . . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE DISCONTINUE... [5*]
Sa1841. . . . USTEKINUMAB IS SAFE IN ELDERLY CROHN’S... [5*]
Sa1842. . . . COMPARISON OF MODES OF DELIVERY AND... [1*]
Sa1843. . . . TRENDS AND RISK FACTORS OF ELDERLY-ONSET... [5*]
Sa1844. . . . ELEVATED FECAL CALPROTECTIN IN EARLY PREGNANCY... [5*]
Sa1845. . . . THE RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... [5*]
Sa1846. . . . EXCLUSIVE ENTERAL NUTRITION(EEN) IS EFFECTIVE FOR... [5*]
Sa1847. . . . DIETARY PRACTICES AND BELIEFS OF PATIENTS... [3*](Takeda: Investigator Initiated Sponsored Research Grant)
Sa1848. . . . DIETARY PRACTICES AND BELIEFS OF BRITISH... [3*](Takeda: Investigator Initiated Sponsored Research Grant)
Sa1849. . . . LOW PREVALENCE OF NONALCOHOLIC FATTY LIVER... [4*]
Sa1850. . . . COLITIS PATIENTS WITH PSC MAY... [4*]
Sa1851. . . . LOW PREVALENCE OF NONALCOHOLIC FATTY LIVER... [4*]
Sa1852. . . . VEDOLIZUMAB DRUG LEVELS IN MATERNAL AND... [1*]
Sa1853. . . . DISPARITIES IN IBD-RELATED INPATIENT COMPLICATIONS BETWEEN... [2*](Oriana Damas supported by NIDDK: 1K23DK117054-01A1)
Sa1854. . . . WOMEN WITH IMMUNE MEDIATED INFLAMMATORY DISEASES... [5*]
Sa1855. . . . PREGNANCY COMPLICATIONS IN WOMEN WITH INFLAMMATORY... [5*]
Sa1856. . . . FRAILTY ESTIMATED BY GERIATRIC NUTRITIONAL RISK... [2*]
Sa1857. . . . EARLY DISCONTINUATION OF ADAлимумAB THERAPY IN... [5*]
Sa1858. . . . DISPARITIES IN SOCIOECONOMIC STATUS AND HOUSEHOLD... [2*]
Sa1859. . . . SEXUAL FUNCTION AND CONTRACEPTION USE IN... [5*]
Sa1860. . . . DOES RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... [5*]
Sa1861. . . . SHARED DECISION MAKING IN PREGNANCY IN... [2*](3)(MSD Grant)
Sa1862. . . . FERTILITY RATE IN WOMEN WITH INFLAMMATORY... [5*]
Sa1863. . . . SNAPSHOT OF INFLAMMATORY BOWEL DISEASE AMONG... [5*]
Sa1864. . . . PROSPECTIVE STUDY OF PHARMACOKINETICS OF INFliximab... [3*](Research grant obtained for Mundipharma)
Sa1865. . . . ASSOCIATION BETWEEN VEDOLIZUMAB LEVELS, ANTI-VEDOLIZUMAB LEVELS... [5*]
Sa1866. . . . LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY... [3*](7)(Biosciences, San Diego, CA)
Sa1867. . . . LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL... [3*](Supported by an unrestricted educational grant from Takeda)
Sa1868. . . . AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP... [3*](Takeda)
Sa1869. . . . COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX... [3*](7)(Prometheus Biosciences, San Diego, CA)
Sa1870. . . . USTEKINUMAB LEVELS DIFFERENTIATE PATIENTS WITH ENDOSCOPICALLY... [3*](Prometheus Laboratories)
Sa1871. . . . USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE... [3*](Testing provided by Prometheus)
Sa1872. . . . IMMUNOGENICITY OF TUMOR NECROSIS FACTOR ANTAGONISTS... [5*]
Sa1873. . . . OBJECTIVE DISEASE ACTIVITY ASSESSMENT AND THERAPEUTIC... [3*](TARGET PharmaSolutions, Inc. is the sponsor of TARGET-IBD.)
Sa1874. . . . INFLIXIMAB DE-
ESCALATION IN PATIENTS WITH 
CROHN’S... (5*)

Sa1875. . . . THERAPEUTIC 
THRESHOLDS FOR GOLIMUMAB 
SERUM CONCENTRATIONS... (3*)[GO-
LEVEL was an investigator initiated study 
funded by a grant from MSD)

Sa1876. . . . LOW FECAL CALPROTECTIN 
LEVEL PREDICTS HISTOLOGICAL... (5*)

Sa1877. . . . EFFECTIVENESS, SAFETY 
AND IMMUNOGENICITY OF 
SWITCHING... (5*)

Sa1878. . . . POST HOC EXAMINATION 
OF VISIBLE 1... (3*)[Takeda 
Pharmaceuticals U.S.A, Inc.)

Sa1879. . . . EFFICACY AND SAFETY OF 
VEDOLIZUMAB REINITIATION... 
(3*)[Takeda Pharmaceuticals U.S.A, Inc.)

Sa1880. . . . DOSE ESCALATION OF 
SUBCUTANEOUS VEDOLIZUMAB IN... 
(3*)[Takeda Pharmaceuticals U.S.A, Inc.)

Sa1881. . . . A COMPARISON OF EARLY 
RESPONSE PARAMETERS... (3*)[Takeda 
Pharmaceuticals U.S.A, Inc.)

Sa1882. . . . SWITCHING INFLIXIMAB 
BIOSIMILAR: NO ADVERSE IMPACT... 
(5*)

Sa1883. . . . ADA LIMUMAB DRUG 
LEVELS AT SECONDARY LOSS... (5*)

Sa1884. . . . ASSOCIATION OF 
USTEKINUMAB SERUM 
CONCENTRATIONS AND... (3*)[Jansen 
Canada Inc.)

Sa1885. . . . PERIPHERAL BLOOD 
EOSINOPHILIA PREDICTS EARLIER 
ANTI-TNF... (2*)

Sa1886. . . . EARLY VEDOLIZUMAB 
TROUGH LEVELS PREDICT CLINICAL... 
(3*)[4](Takeda Pharmaceuticals IISR-
2017-101926)

Sa1887. . . . PROACTIVE DRUG 
MONITORING IS ASSOCIATED WITH... 
(4*)[2]

Sa1888. . . . CHRONOTHERAPY OF 6-
MERCAPTOPURINE (6-MP) 
METABOLITES IN... (4*)

Sa1889. . . . PATIENTS WITH CROHN’S 
DISEASE AT RISK... (3*)[UBG, Inc.)

Sa1890. . . . DECREASING PATTERNS OF 
INFLIXIMAB TROUGH LEVELS... (5*)

Sa1891. . . . HIGHER INFLIXIMAB AND 
adalimumab TROUGH LEVELS... (5*)

Sa1892. . . . REVISED THERAPEUTIC 
DRUG MONITORING VALUES 
DIRECTLY... (5*)

Sa1893. . . . PRIOR IMMUNOGENICITY 
TO ANTI-TNF BIOLOGICS IS... (5*)

Sa1894. . . . IN FAILURE OF NON-
OPTIMIZED ADA LIMUMAB (ADA)... (4*)

Sa1895. . . . VALIDATION OF THE 
LEMANN INDEX IN... (5*)

Sa1896. . . . A SERIES OF GENES AS 
CANDIDATES... (2*)

Sa1897. . . . DEVELOPMENT AND 
VALIDATION OF DRIED BLOOD... (6*)

Sa1898. . . . DEVELOPMENT AND 
eVALUATION OF I-TRACKER 
ADA LIMUMAB... (3*)[Theradiag]

Sa1899. . . . CLINICAL IMPLICATIONS 
OF INFLIXIMAB AND ADA LIMUMAB... 
(2*)

Sa1900. . . . BIOMARKERS RESPONSE 
tO ANTITNF TREATMENT IN... (5*)

Sa1901. . . . THE NATURAL CLINICAL 
COURSE AFTER PER-ORAL... (4*)[Borsa 
di studio Gerry Scotti 2017]

Sa1902. . . . B. OVATUS THERAPY 
UPREGULATES IL-22-MEDIATED 
SUPPRESSION... (2*)

Sa1903. . . . A RATIONALLY SELECTED, 
ORALLY ADMINISTERED, LIVE... 
(3*)[Assembly Biosciences Allergan]

Sa1904. . . . EFFICACY OF ANTI-
PARASITIC TREATMENT FOR 
BLASTOCYSTIS... (5*)

Sa1905. . . . IN-VIVO SAFETY OF 
INTERNALLY APPLIED ULTRAVIOLET-
A... (6*)

Sa1906. . . . HUMAN-DERIVED 
CLOSTRIDIUM VE202 STRAINS REDUCE 
ENTEROBACTERIAEAE... 
(2*)[6][Jansen Research & 
Development]

Sa1907. . . . TIME OF COLLECTION IS 
CRITICAL TO... (2*)[7]

Sa1908. . . . BERBERINE RESTORES 
MICROGLIA ACTIVATION INDUCED 
BY... (2*)

Sa1909. . . . THE THERAPEUTIC EFFECT 
AND RELATED... (2*)

Sa1910. . . . GUT ARCHAEOME 
COMPOSITIONAL AND ECOLOGICAL 
SHIFTS... (2*)

Sa1911. . . . DISTINCT BRAIN-GUT 
MICROBIOME ALTERATIONS IN 
FEMALE... (2*)[4]

Sa1912. . . . METHANOGEN 
ABUNDANCE THRESHOLDS 
DIFFERENTIATE METHANE AND... (4*)

Sa1913. . . . CONSENSUS GUIDELINES 
FOR THE REGULATION, PRODUCTION...
(4*)

Sa1914. . . . THE FUNGUS 
FILOBASIDIUM AS POSSIBLE 
pREDICTIVE... (2*)

Sa1915. . . . POPULATION-LEVEL 
CONFIGURATIONS OF GUT 
MYCOBIOME ACROSS... (2*)

Sa1916. . . . DEVELOPMENT OF A 
TARGETED 7 α-DEHYDRATASE... (2*)

Sa1917. . . . GUT MICROBIOTA ALONG 
HUMAN GASTROINTESTINAL TRACTS... 
(5*)

Sa1918. . . . CHANGES OF THE HUMAN 
GUT MICROBIOTA... (5*)

Sa1919. . . . AFFECTING INTESTINAL 
BIOFILM FORMATION AND 
COLONIZATION... (7*)[2]

Sa1920. . . . FECAL MICROBIOTA 
TRANSFER IN PATIENTS WITH... 
(5*)[4]

Sa1921. . . . FECAL MICROBIOTA 
TRANSPLANTATION FOR METABOLIC 
SYNDROME... (5*)

Sa1922. . . . IDENTIFICATION OF NEW 
ASSOCIATIONS BETWEEN PSORIATIC... 
(6*)[4]

Sa1923. . . . COMPOSITIONAL AND 
FUNCTIONAL CHANGES OF GUT... (2*)

Sa1924. . . . THERE ARE MAJOR 
DIFFERENCES BETWEEN LUMINAL... 
(6*)

Sa1925. . . . NO DISTINCTION OF FECAL 
MICROBIOTA BETWEEN... (4*)

Sa1926. . . . CHANGES IN FECAL 
MICROBIOTA, SHORT CHAIN... 
(7*)[IJA, JSGE]

Sa1927. . . . A 24-WEEK, DOUBLE-
BLIND, RANDOMIZED TRIAL OF... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1929. . . . BACTERIAL UREASE MODULATES BOTH MICROBE-MICROBE AND... (2*)[6]
Sa1930. . . . THE EFFECT OF BILE ACIDS AS... [This research is financially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017R1A1B03034172)]
Sa1972. . . . POLYOLS ARE A KEY DRIVER OF... (3*)[Meat and Livestock Australia]
Sa1973. . . . ABSENCE OF NEUROTENSIN ATTENUATES INTESTINAL DYSBIOSIS... (2*)
Sa1974. . . . WHO USES PROBIOTICS AND WHY? A... (2*)
Sa1975. . . . INTERACTION OF SUGAR-SWEETENED BEVERAGE CONSUMPTION AND... (2*)
Sa1976. . . . POLYPHENOLS REVERSE THE PATHOLOGIC EFFECTS OF... (4*)[3][3][3][Intestoguard]
Sa1977. . . . HIGH MEAT INTAKE IS ASSOCIATED WITH... (2*)
Sa1978. . . . ZINC CARnosine Reduces Injury in an... (4*)[3][Xstro solutions]
Sa1979. . . . Stability of Dietary Patterns in Inflammatory... (2*)
Sa1980. . . . Food Intolerances Among Patients with inflammatory... (5*)
Sa1981. . . . Pilot Study to Determine Fermentability and... (4*)
Sa1982. . . . Levels of Compliance to Low Fodmaps... (5*)
Sa1983. . . . Self-reported Non-celiac Wheat Sensitivity in Patients... (2*)
Sa1984. . . . Chronic Vagal Nerve Stimulation using an... (2*)
Sa1985. . . . Prior Bariatric Surgery and Pregnancy Complications... (5*)
Sa1986. . . . Quality of Life, Mental Health and... (5*)
Sa1987. . . . Esophageal Physiologic Changes after Bariatric Surgery... (5*)
Sa1988. . . . Endoscopic Bariatric Therapies in Adults Over... (5*)
Sa1989. . . . Roux-en-Y Gastric Bypass is Associated With... (2*)
Sa1990. . . . Primary Obesity Surgery Endoluminal (Pose) for... (5*)
Sa1991. . . . Endoscopic Gastric Body Plication for the... (5*)
Sa1992. . . . Primary Obesity Surgery Endoluminal 1 and... (3*)[USG (San Clemente, CA)]
Su1000. . . . Sex, Insurance Status, and Race/Ethnicity Are... (5*)
Su1001. . . . Clinical Characteristics and Disease Features from... (2*)
Su1002. . . . Cholecystectomy Following Cholecdocholithiasis: The Effect of... (4*)
Su1003. . . . Racial Disparity in Chronic Hepatitis C... (5*)
Su1004. . . . Estimating the Impact of Asylum-seekers on... (4*)[2]
Su1005. . . . Variation in the Risk of Venuous... (5*)
Su1006. . . . The Effect of Using Interpreter Services... (5*)
Su1007. . . . Increasing incidence of Gastric Cancer In... (5*)
Su1008. . . . Clinical and Pathologic Characteristics of Early... (5*)
Su1009. . . . Treatment of H Pylori Is Not... (2*)
Su1010. . . . Prevalence of Extensive and Limited Gastric... (5*)
Su1011. . . . Heavy Alcohol Use Is Associated With... (5*)
Su1012. . . . Trends in Gastrointestinal Cancer Incidence: an... (5*)
Su1013. . . . Burden of Pancreatic Cancer: Four Decades... (2*)
Su1014. . . . Effect of FF Dietary Pattern on... (2*)
Su1015. . . . Increased Risk of Colorectal Cancer in... (5*)
Su1074. . . . Basophils Recruitment is One of the... (4*)
Su1075. . . . Probiotic-derived Polyphosphate Improves Damaged intestinal Epithelia... (4*)
Su1076. . . . In Rats with Superior Mesenteric Artery-occlusion... (4*)
Su1077. . . . antiulcer BPC 157 Effect in 96%... (4*)
Su1078. . . . Pentadecapeptide BPC 157 Therapy in Bile... (4*)
Su1079. . . . Pentadecapeptide BPC 157 Counteracts Intracranial Hypertension... (4*)
Su1080. . . . Pentadecapeptide BPC 157 Therapy in Rats... (4*)
Su1081. . . . In Rats with Superior Mesenteric Vein-occlusion... (4*)
Su1082. . . . Identification of Treatment Range and Apoptosis... (5*)
Su1083. . . . Antioxidant Effect of Uric Acid Ameliorates... (4*)
Su1084. . . . The Role of the IBD Risk... (2*)
Su1085. . . . IL25 Stimulates Movement of Type 2... (4*)
Su1086. . . . Inhibition of Vitamin D/VDR Pathway Downregulates... (2*)
Su1087. . . . A Gut-targeted Eicosapentaenoic Acid Derivative, Sefa-1024,... (4*)
Su1088. . . . Proprotein Convertase Furin Alleviates Colitis via... (4*)[2]
Su1089. . . . Differentiation of Human Induced Pluripotent Stem... (5*)
Su1090. . . . Anti-Inflammatory Effects of Atractylydalin Via Ppar-Alpha... (2*)
Su1091. . . . Detection and Genotyping of Helicobacter Pylori... (2*)
Su1092. . . . Causal Inference Analysis of the Transcriptome... (2*)[This work was supported by National Natural Science Foundation of China]
Su1093. ACTIVATION OF EPIDERMAL GROWTH FACTOR RECEPTOR... (2*)

Su1094. THE ER STRESS SENSOR IRE1p LINKS... (2*)

Su1095. DEGLYCOSYLATED AZITHROMYCIN ENHANCES INTESTINAL SMOOTH MUSCLE... (2*)

Su1096. ROLE OF P21-ACTIVATED KINASE, PAK4, IN... (2*)

Su1097. TL1A-MEDIATED BACTERIAL TRANSCYTOSIS BY A MLCK... (2*)

Su1098. FAILURE TO INDUCE OXPHOS IMPAIRS EPITHELIAL... (2*)

Su1099. INHIBITION OF JAG1/NOTCH1 SIGNALING EXACERBATES INTESTINAL... (2*)

Su1100. GLUCOSE-INDUCED MESENTERIC ARTERIAL RELAXATION VIA ENDOTHELIUM-DEPENDENT... (4*)

Su1101. DOWNREGULATION OF MITF MEDIATED AUTOPHAGIC FLUX... (4*)

Su1102. EXPLORING THE MOLECULAR SIGNALING PATHWAYS OF... (4*)

Su1103. VITAMIN D/VDR SIGNALING PATHWAY REGULATES COLONIC... (2*)

Su1104. ALPHA-TOCOPHYLQUINONE ACTIVATES ARYL HYDROCARBON RECEPTOR AND... (4*)

Su1105. TRIM 21 PROTECTS FROM ULCERATIVE COLITIS... (4*)

Su1106. KRÜPPEL-LIKE FACTOR 4 MODULATES GOBLET CELL... (2*)

Su1107. CYTOKINE-TRIGGERED STATS ACTION PROMOTES METASTASIS THROUGH... (7*)

Su1108. THE THYROID HORMONE NUCLEAR RECEPTOR Trα1... (2*)

Su1110. PS3-DREAM DIFFERENTIALLY CONTROLS TRANSCRIPTION OF... (2*)

Su1111. CLOCK GENE EXPRESSION LEVELS CAN... (5*)

Su1112. TRANSGENIC EXPRESSION OF MICRONOA-195 DISRUPTS TUFT... (2*)

Su1113. ESTABLISHING HUMAN COLONIC ORGANOIDS FROM TISSUE... (6*)

Su1114. CILIARY NEUROTROPHIC FACTOR DEFICIENCY IS A... (2*)

Su1115. SINGLE CELL RNA-SEQUENCING REVEALS AGE-ASSOCIATED ALTERATIONS... (4*)

Su1116. HIGH AUTOPHAGIC VESICLE CONTENT IDENTIFIES A... (2*)

Su1117. HUMAN COLONIC ORGANOIDS EXPRESS A SUBSET... (2*)

Su1118. THE ROLE OF BUTYRATE ON NHEB-DEFICIENT... (2*)

Su1119. SIRT6 PROTEIN CONTRIBUTES TO INTESTINAL CELL... (2*)

Su1120. CHALLENGING THE INTESTINAL BARRIER FUNCTION IN... (5*)

Su1121. THE EFFECT OF PSYCHOLOGICAL STRESS INDUCED... (5*)

Su1122. DEVELOPMENT OF BARRETT'S ESOPHAGUS (BE) AND... (2*)

Su1123. SLFN3 AFFECTS THE MORPHOLOGICAL RESPONSE TO... (2*)

Su1124. SMALL INTESTINE EPITHELIAL ORGANOIDS AS A... (4*)

Su1125. A MODEL TO STUDY ISCHEMIA-REPERFUSION INJURY ... (4*)

Su1126. THE ESTABLISHMENT OF GASTRIC FUNDIC AND... (2*)

Su1127. INTEGRATED MAPPING OF CHROMATIN ACCESSIBILITY AND... (2*)

Su1128. STROMAL STEM CELL NICHE COMPOSITION AND... (2*)

Su1129. A NEW PHENOMIC ANALYSIS PLATFORM HIGHLIGHTS... (4*)

Su1130. LRIG1-BASED LINEAGE TRACING HAS DISTINCT PATTERNS... (2*)

Su1132. ORAL MICROBIOME COMPONENTS MIGHT DETERIORATE BARRIER... (4*)

Su1133. AUTOIMMUNE ESOPHAGITIS PATIENT SAMPLES CONTAIN AUTOANTIBODIES... (4*)

Su1134. ESSENTIAL ROLE OF CALCIUM SIGNALING IN... (4*)

Su1135. SODIUM CAPRATE INCREASES BICARBONATE SECRETION VIA... (2*)

Su1136. THE GASTRIC CARDIA REVISTED: SURPRISING RESULTS... (4*)

Su1137. LYMPHOCYTIC ESOPHAGITIS: IS IT A MEMDICATION... (5*)

Su1138. ALLYL ISOThIOCYANATE, AN ACTIVATOR OF TRPA1... (2*)

Su1139. ELECTROACUPUNCTURE RESTORES INTESTINAL MUCOSAL BARRIER THROUGH... (2*)

Su1140. A RISK-BASED DIAGNOSTIC ALGORITHM OPTIMIZES THE... (5*)

Su1141. HEART RATE VARIABILITY IN PEOPLE WITH... (5*)

Su1142. ARSENIC AS A MEDIATOR OF PLEURAL EFFUSIONS: AN... (5*)

Su1143. EFFICACY AND SAFETY OF PEMBROLIZUMAB FOR... (5*)

Su1144. ENDOscopic ULTRASOUND GUIDED VERTEPORFIN PHOTODYNAMIC THERAPY... (2*)

Su1145. TUMOR SIZE, TUMOR STAGE, AND SURVIVAL... (2*)

Su1146. PANCO: AN OPEN-LABEL, SINGLE-ARM PILOT STUDY... (3*)

Su1147. PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PATIENT-DERIVED TUMOR... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1148. . . . DEPRESSION DIAGNOSIS PRECEDING AND FOLLOWING A... (5*)
Su1150. . . . OUTCOMES OF INITIAL PANCREATIC CANCER SURVEILLANCE... (4*)
Su1151. . . . DEEP LEARNING FOR HISTOLOGICAL ANALYSIS OF... (2*)
Su1152. . . . A SIMPLE MODEL TO SCREEN FOR... (5*)
Su1153. . . . NOVEL SMALL MOLECULE INHIBITOR OF ASPARTATE-β-HYDROXYLASE... (2*)
Su1154. . . . WHEN SHOULD WE OPERATE ON PANCREATIC... (2*) (6)
Su1155. . . . BISPHOSPHONATE USE DOES NOT IMPACT SURVIVAL... (5*)
Su1156. . . . RISK FACTORS AND INCIDENCE OF PANCREATIC... (5*)
Su1157. . . . EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE... (5*)
Su1158. . . . HIGH MORBIDITY AND MORTALITY ASSOCIATED WITH... (5*)
Su1159. . . . FACTORS ASSOCIATED WITH "MISSED CANCERS" IN... (5*)
Su1160. . . . GENETIC RISK OF PANCREATIC CANCER IN... (4*)
Su1161. . . . TRENDS IN 5-YEAR SURVIVAL RATES OF... (5*)
Su1162. . . . COMPOUNDS LN35663290 AND LN35690555 SUPPRESS GROWTH... (2*)
Su1163. . . . THE CLEARANCE OF TUMOR-DERIVED H2S BY... (5*)
Su1164. . . . EXPLOITING BIM DEPENDENCY OVERCOMES PD-L1-MEDIATED DRUG... (2*)
Su1165. . . . TARGETING NRF2 USING SPECIFIC INHIBITOR IN... (2*) (4)
Su1166. . . . IDO1 INHIBITION AUGMENTS THE ANTI-TUMOR EFFECTS... (2*)
Su1167. . . . EXPRESSION OF PD-L1 AND CTLA-4 IMMUNOHISTOCHEMICAL... (5*)
Su1168. . . . ENHANCED EXPRESSION OF ASPARAGINE SYNTHETASE UNDER... (5*)
Su1169. . . . RNA BINDING PROTEIN IMP1 MODULATES EXOSOME... (7*) (2)
Su1170. . . . GAIN-OF-FUNCTION OF ION CHANNEL TRPV1 REMODELS... (2*)
Su1171. . . . NADPH OXIDASES AND REACTIVE OXYGEN SPECIES... (2*)
Su1172. . . . HYDROGEN SULFIDE (H2S) INHIBITS DENDRITIC CELL... (2*)
Su1173. . . . DELETION OF THE MISMATCH REPAIR PROTEIN... (2*) (4)
Su1174. . . . CHARACTERIZATION OF IMMUNE MICROENVIRONMENT IN LYNCH... (2*)
Su1175. . . . CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-LIGAND 1... (5*)
Su1176. . . . CELL TYPE CONTRIBUTIONS OF THE INTERLEUKIN... (2*) (4)
Su1178. . . . LONG MYOSIN LIGHT CHAIN KINASE DOWNREGULATES... (2*)
Su1179. . . . PANETH CELL-DERIVED WNT3 SUPPORTS INTESTINAL TUMORIGENESIS... (2*) (4)
Su1180. . . . CXCR4 EXPRESSION ASSOCIATES WITH 5-HYDROXYMETHYLCYTOSINE MODIFICATION... (2*) (4)
Su1181. . . . THE ROLE OF INFLAMMATION IN REDOX... (2*) (European Union Funds, Innovative Economy Programme)
Su1182. . . . STOOL INTERLEUKIN-1β AS A POTENTIAL DIAGNOSTIC... (2*)
Su1183. . . . DIETARY FIBER INTAKE IS NOT ASSOCIATED... (2*)
Su1184. . . . EFFICACY AND SAFETY OF MONOCLONAL ANTIBODIES... (5*)
Su1185. . . . IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND... (6*) (3) (Celgene (Oxford-Celgene Postdoctoral Fellowship))
Su1186. . . . DEOXYCHOLIC ACID ENHANCES INTESTINAL LYMPHOCYTE MIGRATION... (5*)
Su1187. . . . ALMOST EVERYTHING CAUSES DIARRHEA: GASTROINTESTINAL MANIFESTATIONS... (6*)
Su1188. . . . ABDOMINAL CT SHOULD NOT BE USED... (5*)
Su1189. . . . SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN... (5*)
Su1190. . . . IS THERE AN ASSOCIATION BETWEEN SUBSTANCE... (5*)
Su1191. . . . ADULT-ONSET AUTOIMMUNE ENTEROPATHY: A SCOPING REVIEW... (5*)
Su1192. . . . CONCURRENT THERAPY WITH IMMUNE CHECKPOINT INHIBITORS... (2*) (7)
Su1193. . . . STING ACTIVATION INDUCES REG3γ EXPRESSION IN... (2*)
Su1194. . . . MODIFICATION OF THE INFLAMMATION-RELATED PHENOTYPE OF... (2*) (4)
Su1195. . . . DIFFERENTIAL ANTIBIOTIC AND ANTI-Fungal TREATMENT REQUIREMENTS... (2*)
Su1196. . . . THE ROLE OF THE SMALL INTESTINAL... (5*)
Su1197. . . . EXPLORING THE MOLECULAR BASIS OF FECAL-MICROBIAL... (4*) (6)
Su1198. . . . METAGENOMICS AND METABOLOMICS OF THE GASTROINTESTINAL... (2*) (7)
Su1199. . . . THE IMPACT OF BIOLOGICAL TREATMENT AND... (5*)
Su1200. . . . CLINICAL CHARACTERISTICS AND PRESENTATION OF PATIENTS... (5*)
Su1201. . . . DIFFERENCES IN SMALL INTESTINAL MICROBIOME PATTERNS... (6*)
Su1202. . . . QUANTITATIVE PCR AS A NOVEL APPROACH... (2*)
Su1203. . . . EFFECT OF FECAL MICROBIOTA TRANSPANTATION ON... (4*)
Su1204. . . . VARIATIONS OF THE MUCOSA ASSOCIATED MICROBIOTA... (2*)
Su1205. . . . GLYPHOSATE EXPOSURE ALTERS THE HOST MICROBIOME... (2*) (4)
Su1206. . . . ASSOCIATION OF GUT MICROBIOTA WITH GASTROINTESTINAL... (5*)
Su1207. . . . PREVALENCE AND RISK FACTORS OF HELICOBACTER... (2*)
Su1362. . . . A POPULATION-BASED STUDY COMPARING THE GASTRIC...

Su1363. . . . HELICOBACTER PYLORI ERADICATION THERAPY EFFECTIVELY IMPROVES...(5*)

Su1364. . . . ERADICATION OF HELICOBACTER PYLORI INFECTION DECREASES...(4*)

Su1365. . . . ASSOCIATIONS OF OLGA AND OLGIM STAGING...(2*)

Su1366. . . . CULTURE-GUIDED VS EMPirical HIGH-DOSE PROTON PUMP...

Su1367. . . . EXHALED 13C DURING A 13C-UREA BREATH...(4*)[(2)]

Su1368. . . . REAL TIME DETERMINATION OF H PYLORI...

Su1369. . . . INCREMENTAL YIELD OF RAPID URASE TEST...

Su1370. . . . THE OPTIMAL CUTOFF VALUE OF SEROLOGIC...

Su1371. . . . SEROLOGY AS A DIAGNOSTIC TOOL...

Su1372. . . . HELICOBACTER PYLORI ACTIVELY SUPPRESS INNATE IMMUNE...

Su1373. . . . REGULATION OF APOPTOTIC AND DNA...

Su1374. . . . COEVOLUTIVE ANALYSIS OF HELICOBACTER PYLORI ISOLATED...

Su1375. . . . HELICOBACTER PYLORI-INFECTED CANCER-ASSOCIATED FIBROBLASTS INHIBIT TGFβ-DEPENDENT...

Su1376. . . . EFFECTIVENESS OF MAASTRICHT V GUIDELINES APPLICATION...

Su1377. . . . LEVOFLOXACIN SEQUENTIAL THERAPY VERSUS BISMUTH QUADRUPLE...

Su1378. . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE OF RHB-105, A...

Su1379. . . . ANNUAL ERADICATION RATE OF BISMUTH-CONTAINING QUADRUPLE...

Su1382. . . . INEFFECTIVENESS OF 14-DAY VONOPRAZAN-BASED DUAL THERAPY...

Su1383. . . . CURRENT STATUS OF VONOPRAZAN-CONTAINING ERADICATION TREATMENT...

Su1384. . . . ANTIBIOTIC RESISTANCE AND ITS RELATED GENETIC ...

Su1385. . . . EFFICACY OF PROBIOTICS COMBINED WITH BISMUTH...

Su1386. . . . CULTURE-BASED TAILOR-MADE ANTIBIOTIC REGIMEN IS THE...

Su1387. . . . POLYPHENOLIC BIOFRATIONS EXTRACTED FROM AVOCADO...

Su1389. . . . GASTRIC INTESTINAL METAPLASIA BEFORE AND AFTER...

Su1390. . . . EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN...

Su1392. . . . TRIPLE THERAPY IS STILL AN EFFECTIVE...

Su1393. . . . EFFICACY OF RIFABUTIN FOR THE RESCUE...

Su1394. . . . SELECTION OF CLARITHROMYCIN IN FIRST-LINE HELICOBACTER...

Su1395. . . . EFFECTS OF HELICOBACTER PYLORI ERADICATION FOR...

Su1396. . . . A HIGH-THROUGHPUT METABOLIC ASSAY AND A...

Su1397. . . . FACTORS PREDICTIVE OF HELICOBACTER PYLORI INFECTION...

Su1398. . . . SEVEN-DAY VONOPRAZAN AND LOW-DOSE AMOXICILLIN DUAL...

Su1399. . . . PATIENTS WITH PEPTIC ULCER BLEEDING ADMITTED...

Su1400. . . . ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER...

Su1401. . . . ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER...

Su1402. . . . MISOPROSTOL EXPOSURE IS NOT ASSOCIATED WITH...

Su1403. . . . CLIPPING OVER-THE-SCOPE IS COST EFFECTIVE FOR...

Su1404. . . . COMPARISON OF THE AIMs65, GLASGOW-BLATCHFORD SCORE...

Su1405. . . . EXTERNAL VALIDATION OF THE CANUKA SCORING...

Su1406. . . . VASCULAR PROTECTIVE DRUGS AND THE OUTCOMES...

Su1407. . . . A NOVEL MORTALITY RISK SCORE THAT...

Su1408. . . . USE OF DOPPLER ENDOSCOPIC PROBE FOR...

Su1409. . . . DIFFERENCES IN THE CLINICAL COURSE OF...

Su1410. . . . TRANEXAMIC ACID FOR UPPER GASTROINTESTINAL BLEEDING:

Su1411. . . . PORTAL HYPERTENSION AND CKD Significantly INCREASE...

Su1412. . . . TIME TRENDS AND ENDOSEQIC CHARACTERISTICS OF...

Su1413. . . . ASSOCIATION OF GBS SCORE WITH ENDOSCOPIC...

Su1414. . . . ASSESSING THE RISK OF PEPTIC ULCER...

Su1415. . . . CRITICAL PEPTIC ULCER BLEEDING REQUIRING MASSIVE...

Su1416. . . . A POPULATION BASED STUDY TO IDENTIFY...

Su1417. . . . LESS IS MORE: AN EXAMINATION OF...

Su1418. . . . DIAGNOSTIC VALUE OF FOCAL ENHANCED GASTRITIS...

Su1419. . . . MALNUTRITION IS ASSOCIATED WITH INCREASED IN-HOSPITAL...

Su1421. . . . THE PROGNOSES DIFFERENCES IN ISCHEMIC HEART...

Su1458. . . . ASSESSING THE ROLE OF IRRIGATION OF...

Su1459. . . . PREDICTORS OF MORTALITY AND MORBIDITY IN...

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1460. . . . ASSOCIATION OF FREE FATTY ACID LEVELS... (5*)
Su1461. . . . ADVERSE HEALTHCARE RESOURCE OUTCOMES IN PATIENTS... (5*)
Su1462. . . . CHOLECYSTECTOMY VS NO SURGERY IN PATIENTS... (5*)
Su1463. . . . SARCOPENIA IS ASSOCIATED WITH WORSE OUTCOMES... (5*)
Su1464. . . . HIGH MORBIDITY AND MORTALITY BURDEN OF... (5*)
Su1465. . . . DRUG-INDUCED PANCREATITIS IS THE LEADING RISK... (2*)
Su1466. . . . IMPACT OF HIV STATUS ON OUTCOMES... (5*)
Su1467. . . . USE OF NSAIDS IS ASSOCIATED WITH... (5*)
Su1468. . . . A SIMPLE ALGORITHM TO IDENTIFY BILIARY... (5*)
Su1469. . . . STATIN USE IS ASSOCIATED WITH DECREASED... (5*)
Su1470. . . . INTRA-ABDOMINAL HYPERTENSION IS A STRONG PREDICTOR... (5*)
Su1471. . . . LONG TERM CONSEQUENCES OF ACUTE NECROTIZING... (5*)
Su1472. . . . SAFETY AND SUCCESS OF EARLY (<4... (5*)
Su1473. . . . PREDICTORS OF DIABETES MELLITUS FOLLOWING DISCHARGE... (5*)
Su1474. . . . INFLUENCE OF PRE-EXISTING DIABETES MELLITUS ON... (5*)
Su1475. . . . SEVERITY OF ACUTE PANCREATITIS HOSPITALIZATIONS IN... (5*)
Su1476. . . . IDENTIFICATION OF A RISK PROFILE FOR... (5*)
Su1477. . . . TRANSITION OF CLINICAL FEATURES OF ACUTE... (5*)
Su1478. . . . EARLY (<4 WEEKS) VERSUS STANDARD [≥... (5*)
Su1479. . . . TREND OF ACUTE PANCREATITIS IN JAPAN... (5*)
Su1480. . . . CONTROLLING GLYCEMIC HOMEOSTASIS ALLEVIATES ISLET B... (4*)
Su1481. . . . PANCREAS-DERIVED DOPAMINE INHIBITS INSULIN SECRETION IN... (2*)
Su1482. . . . THE DURABILITY OF ENDOSCOPIC ULTRASOUND-GUIDED ABLATION... (4*)
Su1483. . . . THE EFFECT OF ASPIRIN ON RATE... (5*)
Su1484. . . . VALIDATION OF BASELINE CHARLSON COMORBIDITY INDEX... (5*)
Su1485. . . . INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH... (5*)
Su1486. . . . LONG-TERM SURVEILLANCE OF LOW-RISK PRESUMED MUCINOUS... (5*)
Su1487. . . . MOLECULAR STABILITY, REGRESSION, AND PROGRESSION IN... (3*) (Interpace Diagnostics)
Su1488. . . . APPLICATION OF A RISK STRATIFICATION TOOL... (5*)
Su1489. . . . RISK OF NEOPLASTIC PROGRESSION IN PATIENTS... (5*)
Su1490. . . . CHARACTERIZATION OF PANCREATIC INTRADUCTAL PAPILLARY NEOPLASM-DERIVED... (5*)
Su1491. . . . THE EFFECT OF STATINS ON RATE... (5*)
Su1492. . . . EUS-GUIDED Pancreatic Cyst Chemoablation As A... (5*)
Su1493. . . . THE IMPACT OF ENDOSCOPIC ULTRASOUND-GUIDED CONFOCAL... (7*)
Su1494. . . . A 10-YEAR FOLLOW-UP DESCRIBING THE NATURAL... (5*)
Su1495. . . . A MULTIDISCIPLINARY Pancreatic Cyst Conference Reduces... (5*)
Su1496. . . . PREOPERATIVE ENDOSCOPIC ULTRASOUND (EUS) OR ENDOSCOPIC... (5*)
Su1497. . . . PREDICTORS OF ADVANCED NEOPLASIA AND LONG... (5*)
Su1498. . . . PERCENTAGE OF CYST GROWTH RATE AS... (5*)
Su1499. . . . PREVALENCE AND RISK FACTORS FOR INTRADUCTAL... (5*)
Su1500. . . . MOLECULAR ANALYSIS OF EUS-ACQUIRED PANCREATIC CYST... (5*)
Su1501. . . . THE ROLE OF ENDOSCOPIC ULTRASOUND-GUIDED THROUGH-THE-NEEDLE... (5*)
Su1502. . . . PREVALENCE OF AND FACTORS INFLUENCING PANCREATIC... (5*)
Su1503. . . . RANGE OF NORMAL LIVER STIFFNESS AND... (5*)
Su1504. . . . USE OF NOVEL CYTOPLEX ASSAY TO... (4*)(2)
Su1505. . . . HEALTH-RELATED QUALITY OF LIFE, EMOTIONAL, AND... (2*)
Su1506. . . . TRENDS AND VARIATIONS IN THE MANAGEMENT... (5*)
Su1507. . . . ESTABLISHING A PEDIATRIC TO ADULT (P2A)... (5*)(2)
Su1508. . . . IS ULTRASOUND ENOUGH? EVALUATING IMAGING FOR... (5*)
Su1672. . . . THE EMERGING ROLE OF FRAILTY AS... (5*)
Su1673. . . . SEPSIS IS THE LEADING CAUSE OF... (5*)
Su1674. . . . HANDGRIP STRENGTH DECLINE IN CHRONIC LIVER... (5*)
Su1675. . . . BARIATRIC SURGERY IN CANDIDATES FOR LIVER... (5*)
Su1676. . . . VALIDATION OF ENCEPHALAPP STROOP FOR MINIMAL... (2*)(1)
Su1677. . . . METHYLENE BLUE INFUSION FOR CRITICALLY ILL... (5*)
Su1678. . . . IMPACT OF RACE AND ETHNICITY ON... (2*)(3)([Investigator initiated grant from Grifols Pharmaceuticals])
Su1679. . . . RISK FACTORS FOR READMISSION WITH DECOMPENSATED... (5*)
Su1680. . . . THE HEPATORENAL SYNDROME PATIENT JOURNEY: PORTRAIT... (3*)([Mallinckrodt])
Su1681. . . . urgent Endoscopy is associated with lower... (5*)
Su1682. . . . urgent Endoscopy is associated with lower... (5*)
Su1683. . . . PREDICTORS OF 30 AND 90 DAY... (5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds    (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)    (3) = Industry or Commercial Entity    (4) = Institutional Funds
(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Title</th>
<th>Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Su1684...</td>
<td>Efficacy of Oral Thrombopoietin Receptor Agonist... (3*)</td>
<td>Shionogi Inc.</td>
</tr>
<tr>
<td>Su1685...</td>
<td>Small Intestine Varices at a High-Volume... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1686...</td>
<td>Comparing Overall GI and Non-GI Bleeding... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1687...</td>
<td>Utility of the Encephalapp Stroop Test... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1688...</td>
<td>Lower Gastrointestinal Bleeding in Patients with... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1689...</td>
<td>Multidrug Resistant Bacterial Infection Characteristics and... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1712...</td>
<td>Altered Mitochondrial Gene Expression in Duodenal... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1713...</td>
<td>Minimal Impact of Acute Injection and... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1714...</td>
<td>Lysophosphatidic Acid Receptor Expression is Reduced... (2*)</td>
<td>(4*)</td>
</tr>
<tr>
<td>Su1715...</td>
<td>Auricular Vagal Nerve Stimulation Improved Dysmotility... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1716...</td>
<td>Intravenous Immunglobulin in Refractory Gastropareisis Patients... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1717...</td>
<td>Chemokine Elevation in Patients with the... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1718...</td>
<td>Medium Energy Gastric Electrical Stimulation Can... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1719...</td>
<td>Improved Gastric Accommodation in Women with... (3*)</td>
<td>Cena Pharmaceuticals Inc, Wellesley, MA, USA</td>
</tr>
<tr>
<td>Su1720...</td>
<td>Can Temporary Gastric Electrical Stimulation Help... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1721...</td>
<td>The Frequency and Clinical Implications of... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1722...</td>
<td>Gastrointestinal Vascular Changes in Genetic and... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1723...</td>
<td>Cardiac Safety and Clinical Efficacy of... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1724...</td>
<td>Whole Genome Sequencing Analysis of Gastropareisis... (3*)</td>
<td></td>
</tr>
<tr>
<td>Su1725...</td>
<td>Trends and Socioeconomic Health Outcomes of... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1726...</td>
<td>Gastric Per-Oral Endoscopic Myotomy (G-POEM) For... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1727...</td>
<td>Supplementation of 17β-Estradiol Normalizes Rapid Gastric... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1728...</td>
<td>Gastrointestinal Symptoms During Gastric Emptying Scintigraphy... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1729...</td>
<td>Piloting a Prospective Pediatric Gastropareisis Symptom... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1730...</td>
<td>Sex and Body Mass Index Have... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1731...</td>
<td>The Relation Between Changes in Gastric... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1732...</td>
<td>Overabundance of Histamine Producing Enterobacteriaceae... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1733...</td>
<td>Trends and Outcomes of Idiopathic and... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1734...</td>
<td>Majority of Hospitalized Patients Labeled as... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1735...</td>
<td>Gastroduodenal Manometric and Gastric Emptying Scintigraphic... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1736...</td>
<td>Alteration of Intestinal Permeability and Effect... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1737...</td>
<td>Lessons Learned from 8 Years... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1738...</td>
<td>The Goldilocks Principle: 24 Hour Ambulatory... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1739...</td>
<td>Safety Pharmacology Evaluations of Tak-906, A... (3*) (This study was sponsored by Altos Therapeutics, LLC. Medical writing support was provided by Alex Kisbey of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.)</td>
<td></td>
</tr>
<tr>
<td>Su1740...</td>
<td>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of... (3*)</td>
<td>CinRx Pharma</td>
</tr>
<tr>
<td>Su1741...</td>
<td>Pathophysiological Evidence Provided by Pyloric Smooth... (5*)</td>
<td></td>
</tr>
</tbody>
</table>

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds

(5) = No Study Funding       (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)       (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Su1759. | TRANSCUTANEOUS ELECTRICAL STIMULATION JUMP-STARTS GASTRIC EMPTYING... (5*) |
| Su1760. | VISCERAL HYPOSensitivity AND HYPERsensitivity mask A... (4*) |
| Su1761. | Small Intestinal BACTERIAL OVERGrowth: IS IT... (5*) |
| Su1762. | relationship between symptoms during a GASTRIC... (2*) |
| Su1763. | Diagnostic Risk Stratification in POST-EGD Patients... (5*) |
| Su1764. | TAK-906, a NOVEL DOPAMINE D2/D3 RECEPTOR... (3*) |
| Su1765. | GASTROparesis Increases the Risk for Lung... (5*) |
| Su1766. | Differences in CLINICAL PRESENTATION BETWEEN Patients... (3*) |
| Su1767. | Factors Associated with Barrett's ESOPHiGAS in... (5*) |
| Su1768. | Prevalence of Gastroparesis and Functional Dyspepsia... (3*) |
| Su1769. | Real-World Evidence on Prevalence of Gastroparesis... (3*) |
| Su1770. | Measurement of the pyloric SpHincter using... (5*) |
| Su1771. | Impact of POLYP Features and Colonoscopy... (2*) |
| Su1772. | multi-Cancer Detection of Early-Stage cancers with... (3*) |
| Su1773. | More Fecal ImmunohistoCHEMICAL Tests are Needed... (3*) |
| Su1774. | Young Onset Colorectal ADENOMA: A Systematic... (2*) |
| Su1775. | Two Years Real World CLINical... (5*) |
| Su1776. | low Risk adenomas Versus no Adenomas... (5*) |
| Su1777. | A Multicentered Retrospective study of clinical... (5*) |
| Su1778. | Yield of and Risk Factors for... (4*) |
| Su1779. | A randomized controlled Trial of an... (4*) |
| Su1780. | THE "PREDICT, RESECT AND DISCARD" strategy... (5*) |
| Su1781. | improvement of Asia-Pacific colorectal Screening... (2*) |
| Su1782. | endorsement of Water Exchange (WE) Colonoscopy... (2*) |
| Su1783. | Test Characteristics of Fecal ImmunohistoCHEMICAL tests... (4*) |
| Su1784. | Characteristics and outcomes among individuals with... (2*) |
| Su1785. | ADR by Gender, Race and Ethnicity... (5*) |
| Su1786. | Higher Fecal HB Concentration predicts Risk... (5*) |
| Su1787. | Long-term Impact of a Physician... (5*) |
| Su1788. | Characteristics and outcomes of Patients with... (2*) |
| Su1789. | optimal Timing of Surveillance Colonoscopy After... (4*) |
| Su1790. | The Prevalence of Metachronous Advanced colorectal... (5*) |
| Su1791. | Mandated Boston Bowel Prep Scale Implementation... (5*) |
| Su1792. | Improving Fecal ImmunohistoCHEMICAL testing Rates for... (5*) |
| Su1793. | Proximal Versus Distal Colon ADR: A... (5*) |
| Su1794. | UPTake Rate of Colorectal Cancer screening... (2*) |
| Su1795. | Prevalence and Risk Factors for sessile... (6*) |
| Su1796. | Go Before you Go: Implementation of a Same Day... (5*) |
| Su1797. | Prevalence and Predictors of colorectal Neoplasms... (5*) |
| Su1798. | ColoreGaurd Positive screening: REAL World Positive... (5*) |
| Su1799. | PolySp Size Versus Number: What is... (5*) |
| Su1800. | Characterizing the Role of GAIN-OF-FUNCTION SYK... (2*) |
| Su1801. | Multi-Racial Risk Score Integration to Predict... (4*) |
| Su1802. | Molecular Prediction in Inflammatory bowel Disease... (2*) |
| Su1803. | The Clinical Phenotype of Collagenous Colitis... (5*) |
| Su1804. | Genetic Analysis of Ulcerative colitis in... (5*) |
| Su1805. | The Long-Term Corticosteroid sparing Effect of... (6*) |
| Su1806. | Risk of anal Cancer in Patients... (5*) |
| Su1807. | Quality of life, Fecal Calprotectin and... (5*) |
| Su1808. | Provider Relationships may be an important... (5*) |
| Su1809. | Evaluating Access to IBD Care across... (2*) |
| Su1810. | Outcomes of IBD Management based on... (5*) |
| Su1811. | Differences in Care and outcome among... (5*) |

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1867. . . . BIG DATA ANALYTICS DEMONSTRATE A NOVEL,... (2*)
Su1868. . . . EPIGENETIC PREDICTION OF CROHN'S DISEASE RECURRENCE:... (2*)
Su1869. . . . FAecal CALprotectin IS A USEFUL NON-INVASIVE... (4*)
Su1870. . . . WHEN LESS IS MORE AND MORE... (4*)
Su1871. . . . VALIDATION OF THE RED FLAGS INDEX... (3*)[7][Takeda]
Su1872. . . . TRENDS IN FAecal CALprotectin LEVELS... (5*)
Su1873. . . . HOSPITALIZATIONS FOR ACUTE HERPES AND VARICELLA... (5*)
Su1874. . . . USEFULNESS OF THE FAecal CALprotectin AS... (4*)
Su1875. . . . PROSPECTIVE VALIDATION OF FAecal CALprotectin AS... (5*)
Su1876. . . . 10 YEAR TRENDS OF RADIATION SPARING... (5*)
Su1877. . . . ENRICHMENT OF POST-TRANSLATIONAL MODIFICATIONS IN INFLAMMATORY... (4*)
Su1878. . . . ENHANCED MESENTERIC FAT VOLUME - A... (5*)
Su1879. . . . NOVEL APPROACH TO BIND AND SPECIFICALLY... (2*)
Su1880. . . . MACHINE LEARNING APPROACHES VALIDATE SEROLOGICAL MARKERS... (4*)
Su1881. . . . MULTIPLE ENDOPHENOTYPES OF ULCERATIVE COLITIS CORRELATE... (2*)
Su1882. . . . ENDOscopIC ASSESSMENT IN ACUTE SEVERE ULCERATIVE... (5*)
Su1883. . . . THROMbOCYTOSIS IN ACUTE INFLAMMATORY BOWEL DISEASE-... (5*)
Su1884. . . . A MUCOSAL MARKER PREDICTING TOFACTINIB INDUCED... [3*][Research Grant by Pfizer.]
Su1885. . . . SCREENING FOR STEATOHepatITIS AND FIBROSIS AMONG... (5*)
Su1886. . . . OXIDATIVE STRESS CORRELATES WITH DISEASE ACTIVITY... (2*)[European Union Funds, Innovative Economy Programme]
Su1887. . . . POINT-OF-CARE BOWEL ULTRASOUND FOR DETECTING ILEO-COLONIC... (5*)
Su1888. . . . INTESTINAL ULTRASOUND THROUGHOUT PREGNANCY IN INFLAMMATORY... (5*)
Su1889. . . . INTER-OBSERVER AGREEMENT OF AN EXPERT PANEL... (5*)
Su1890. . . . ULCERATIVE COLITIS PATIENTS WITH QUIESCENT OR... (4*)[6]
Su1891. . . . THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS... (5*)
Su1892. . . . A SINGLE CENTRE CROSS SECTIONAL COHORT... (1*)
Su1893. . . . ENHANCED MESENTERIC FAT VOLUME IS ASSOCIATED... (2*)[4]
Su1894. . . . ILEAL OR COLONIC HISTOLOGIC ACTIVITY DOES... (5*)
Su1895. . . . PREVALENCE AND CLINICAL SIGNIFICANCE OF ANASTOMOTIC... (5*)
Su1896. . . . VALIDATION OF DISEASE SEVERITY INDEX FOR... (2*)
Su1897. . . . TRANSMURAL HEALING WITH VEDOLIZUMAB IN PATIENTS... (3*)[Takeda]
Su1898. . . . ASSOCIATION BETWEEN SERUM AND TISSUE PROTEIN... (5*)
Su1899. . . . PATIENT-REPORTED OUTCOMES (PRO-2) AND INTESTINAL ULTRASOUND... (3*)
Su1900. . . . DIFферENCES IN EXTRA CELLULAR MATRIX REMODELING... (2*)
Su1901. . . . DIAGNOSTIC ACCURACY OF A SERUM-BASED BIOMARKER... (3*)[Research support from Prometheus Biosciences.]
Su1902. . . . CDEIS SCORE OF 2 IS OPTIMAL... (2*)
Su1903. . . . MAGNITUDE OF INCREMENTAL BENEFIT OF ACHIEVING... (2*)
Su1904. . . . CAN WE PREDICT THE PRESENCE OF... (5*)
Su1905. . . . CORRELATION BETWEEN MICROBIAL MARKERS AND FECAL... (5*)
Su1906. . . . A STOOL MARKER-BASED STRATEGY TIMELY AND... (5*)
Su1907. . . . GLUCOCORTICOID METABOLISM IS ASSOCIATED WITH DISEASE... (4*)
Su1908. . . . NEUTROPHIL-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH DISEASE... (4*)
Su1909. . . . PERIPHERAL BLOOD MONOCYTOSIS IS ASSOCIATED WITH... (5*)
Su1910. . . . EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL... (5*)
Su1911. . . . CORRELATION BETWEEN HISTOLOGIC AND ENDOSCOPIC SCORING... (5*)
Su1912. . . . CDEIS SCORE OF 2 IS OPTIMAL... (2*)
Su1913. . . . NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL... (5*)
Su1914. . . . CHANGES IN THE INTESTINAL MICROBIOTA OF... (2*)[This work was supported by a grant from the National Research Foundation (NRF) of Korea, funded by the Korea government (MSIP) (number: 2014R1A2A11052136, 2017R1A2B4006767, and 2019R1A2C2010404).]
Su1915. . . . RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH (HIGH... (3*)[This post-hoc analysis was entirely funded by Dr. Falk Pharma GmbH.]
Su1916. . . . FAecal MYELOPEROXIDASE - A POTENTIAL NON-INVASIVE... (1*)[New Zealand Society of Gastroenterology Research Fellowship Grant]
Su1917. . . . SCREENING FOR STEATOHepatITIS AND FIBROSIS AMONG... (5*)
Su1918. . . . CROHN'S DISEASE SMALL BOWEL STRICTURES: DEVELOPMENT... (4*)
Su1919. . . . EFFICACY OF HISTOLOGICAL SCORING... (5*)
Su1920. . . . DETECTION AND CHARACTERIZATION OF EXTRA-INTESTINAL MANIFESTATIONS... (3*)[Acknowledgements: This research was funded by a grant from Abbvie.]
Su1921. . . . EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL... (5*)
Su1922. . . . NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1923. . . . DIAGNOSTIC ACCURACY OF A HOME-PERFORMED FECAL... (5*)
Su1924. . . . CIRCULATING EXTRACELLULAR VESICLES CORRELATE WITH DISEASE... (4*)[2]
Su1925. . . . EARLY PREDICTION OF OUTCOME IN ACUTE... (5*)
Su1926. . . . FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS... (3*)[1](Arena Pharmaceuticals, Inc.)
Su1927. . . . GASTROINTESTINAL IMAGING IN CHRONIC GRANULOMATOUS DISEASE... (2*)
Su1928. . . . EVALUATING ASSOCIATION BETWEEN FECAL CALPROTECTIN AND... (3*)[Genentech, Inc.]
Su1929. . . . A HYBRID APPROACH OF HANDLING MISSING... (3*)[Takeda]
Su1930. . . . PCR CYCLE TIME AND CLOSTRIDIODES DIFFICILE... (5*)
Su1931. . . . PATIENT-REPORTED SYMPTOMS OVER A PERIOD OF... (5*)
Su1932. . . . COMPARISON OF PROSTAGLANDIN E–MAJOR URINARY METABOLITE... (1*)
Su1933. . . . FAECAL CALPROTECTIN AS THERAPEUTIC TARGET IN... (5*)
Su1934. . . . A DIRECT COMPARISON OF FECAL CALPROTECTIN... (5*)
Su1935. . . . PERIANAL EXAMINATION AT TIME OF COLONOSCOPY... (5*)
Su1936. . . . HISTOLOGIC INFLAMMATION DEFINED BY THE ROBARTS... (5*)
Su1937. . . . PREDICTORS OF PROGNOSIS AND OUTCOMES AFTER... (2*)
Su1938. . . . PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD... (5*)
Su1939. . . . DEMOGRAPHIC DATA AND THERAPY BEFORE PROCTOCOLECTOMY... (4*)
Su1940. . . . ACUTE SEVERE ULCERATIVE COLITIS IN PREGNANCY... (5*)
Su1941. . . . READMISSION RELATED HEALTH CARE UTILIZATION AND... (5*)
Su1942. . . . IMPACT OF EXTRA-INTESTINAL MANIFESTATION ON HEALTH... (5*)
Su1943. . . . THE ROLE OF ANTIMICROBIAL MARKERS IN... (3*)[Prometheus Laboratories covered the costs for the serological analyses.]
Su1944. . . . IMPACT OF CIRRHOSIS ON OUTCOMES IN... (5*)
Su1945. . . . IMPACT OF COLONOSCOPY ON OUTCOMES FOR... (5*)
Su1946. . . . IMMUNOGLOBULIN DEFICIENCIES IN PATIENTS WITH INFLAMMATORY... (2*)
Su1947. . . . ABDOMINAL PAIN IS INDEPENDENTLY ASSOCIATED WITH... (4*)
Su1948. . . . BURDEN OF DISEASE: SUBSTANCE ABUSE IN... (5*)
Su1949. . . . INCIDENCE OF OCCULT COLORECTAL CANCER IN... (4*)
Su1950. . . . PHENOTYPE AND NATURAL HISTORY OF INFLAMMATORY... (5*)
Su1951. . . . PRE-POUCH ILEITIS IS A RISK FACTOR... (5*)
Su1952. . . . SEROLOGICAL AND GENETIC MARKERS ARE ASSOCIATED... (5*)
Su1953. . . . THE NATURAL HISTORY OF COLECTOMY AMONG... (4*)
Su1954. . . . COLITIS DUE TO CYTOMEGALOVIRUS ASSOCIATED WITH... (5*)
Su1955. . . . EAST VERSUS WEST: INDICATIONS, POSTOPERATIVE MANAGEMENT... (5*)
Su1956. . . . PERIPHERAL BLOOD EOSINOPHILA IS-associated WITH... (5*)
Su1957. . . . ELDERLY-ONSET INFLAMMATORY BOWEL DISEASE IS ASSOCIATED... (5*)
Su1958. . . . CUMULATIVE RISK OF SURGERY IN PATIENTS... (2*)
Su1959. . . . NATURAL HISTORY OF ELDERLY-ONSET INFLAMMATORY BOWEL... (2*)
Su1960. . . . THIRTY DAY READMISSIONS AMONG PATIENTS WITH... (5*)
Su1961. . . . DECREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE... (5*)
Su1962. . . . DECREASING PREVALENCE OF CLOSTRIDIODES DIFFICILE INFECTION... (5*)
Su1963. . . . THE PREValence OF STROKE IS INCREASED... (5*)
Su1964. . . . IMPACT OF HAVING INFLAMMATORY BOWEL DISEASE... (5*)
Su1965. . . . INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOBIOLOGIC... (5*)
Su1966. . . . BIOLOGIC INITIATION WITHIN 12 MONTHS OF... (3*)[Eli Lilly and Company]
Su1967. . . . DISEASE BURDEN AND PATIENT-REPORTED OUTCOME MEASURES... (5*)
Su1968. . . . LOW BIOSIMILAR USE IN PATIENTS WITH... (5*)
Su1969. . . . TRENDS IN IMMUNOMODULATOR AND BIOLOGIC USE... (5*)
Su1970. . . . BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE... (5*)
Su1971. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB... (5*)
Su1972. . . . INCIDENCE OF POUCHITIS AND ANTIBIOTIC PRESCRIBING... (5*)
Su1973. . . . OUTCOMES OF FECAL DIVERSION FOR PERIANAL... (5*)
Su1974. . . . FATIGUE IS THE SELF-REPORTED SYMPTOM IN... (2*)
Su1975. . . . CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT... (6*)[3]
Su1976. . . . THE PREVALENCE OF INCIDENTAL TERMINAL ILEITIS... (5*)
Su1977. . . . HIGH VOLUMES OF SKELETAL MUSCLE AND... (5*)
Su1978. . . . PROTEIN ENERGY MALNUTRITION IS ASSOCIATED WITH... (5*)
Su1979. . . . NOVEL ASSOCIATIONS OF ADIPOSE TISSUE (AT)... (2*)
Su1980. . . . THE GEM PROJECT: IMPAIRED GUT BARRIER... (6*)[2]
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Su1981</td>
<td>TRENDS IN INFLAMMATORY BOWEL DISEASE (IBD) (3*) [Bristol-Myers Squibb]</td>
<td>(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>Su1982</td>
<td>AN UPDATE ON CLINICAL OUTCOME AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1983</td>
<td>HIGHER LEVELS OF FECAL CALPROTECTIN PREDICT... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1984</td>
<td>CLINICAL PRESENTATION AND OUTCOMES OF PRIMARY... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1985</td>
<td>CHARACTERISTICS OF ULCERATIVE COLITIS AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1986</td>
<td>THE MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1987</td>
<td>THE IMPACT OF SOCIAL DETERMINANTS OF... (2*) [NIDDK: 1K23DK117054-01A1]</td>
<td></td>
</tr>
<tr>
<td>Su1988</td>
<td>ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (2*)[6]</td>
<td></td>
</tr>
<tr>
<td>Su1989</td>
<td>AGE-SPECIFIC HEALTHCARE UTILIZATION TRENDS IN A... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1990</td>
<td>LCNRA ZFAS1 INTERACTS WITH POLYADENYLATE-BINDING PROTEIN... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1991</td>
<td>GENDER-SPECIFIC EFFECT OF DIETARY AND PHYSICAL... (2*)[4]</td>
<td></td>
</tr>
<tr>
<td>Su1992</td>
<td>THE FREQUENCY OF METABOLIC DISORDER IN... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1993</td>
<td>DIABETES AND PANCREATIC CANCER: A POPULATION-BASED... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su1994</td>
<td>ORAL IRON THERAPY PROMOTES A PROINFLAMMATORY... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1995</td>
<td>MICROBIOLOGICAL AND IMMUNOLOGICAL INFLAMMATORY IMMUNE RESPONSES... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su1997</td>
<td>DIVERGENT EFFECTS OF ANTIBIOTICS ON DEVELOPMENT... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su1998</td>
<td>FUSOBACTERIUM NUCLEATUM INFECTION IS FACILITATED IN... (2*)[4]</td>
<td></td>
</tr>
<tr>
<td>Su1999</td>
<td>PERIODONTAL DISEASE, TOOTH LOSS AND RISK... (2*)[7]</td>
<td></td>
</tr>
<tr>
<td>Su2000</td>
<td>ABNORMAL EATING PATTERN AND RISK OF... (2*)[4]</td>
<td></td>
</tr>
<tr>
<td>Su2001</td>
<td>EFFECTS OF BILE ACIDS ON METABOLIC... (2*)[This research is financialy supported by Basic Science]</td>
<td></td>
</tr>
<tr>
<td>Su2002</td>
<td>MAPPING OF THE BACTERIAL AND FUNGAL... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su2003</td>
<td>ILEAL MUCOSA-ASSOCIATED MICROBIOME SIGNATURE IN CHILDREN... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2004</td>
<td>VULNERABILITY TO INFLAMMATION... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2005</td>
<td>α-GLYCYRRHIZIC ACID, A COMPOUND EXTRACTED FROM... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su2006</td>
<td>MEGACYSTIS MICROCOLON INTESTINAL HYPERPERISTALIS SYNDROME: A... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2007</td>
<td>ABRAGLUTIDE, A NOVEL LONG-ACTING GLUCAGON-LIKE PEPTIDE-2... (3*) [Trial sponsored by Vectivia AG]</td>
<td></td>
</tr>
<tr>
<td>Su2008</td>
<td>A PHASE III STUDY OF TEGUGLUTIDE... (3*) [Funding: Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies]</td>
<td></td>
</tr>
<tr>
<td>Su2009</td>
<td>AN ANALYSIS OF THE BURDEN OF... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2010</td>
<td>SEX DIFFERENCES IN THE ASSOCIATION BETWEEN... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2011</td>
<td>THE EFFECT OF DIET COMPOSITION ON... (4*)</td>
<td></td>
</tr>
<tr>
<td>Su2012</td>
<td>OBESITY AND COLORECTAL NEOPLASM: IDENTIFYING OBESITY-ASSOCIATED... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2013</td>
<td>EFFECTIVENESS OF ONE-STOP COLORECTAL AND BREAST... (6*)</td>
<td></td>
</tr>
<tr>
<td>Su2014</td>
<td>THE ASSOCIATION OF SELF-REPORTED METABOLIC RISK... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su2015</td>
<td>THE ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2016</td>
<td>COMBINATION TARGETING OF SQUALENE MONOOXYGENASE AND... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su2017</td>
<td>GLYCINE PROTECTS FROM TLR4 AND NLRP3... (2*)</td>
<td></td>
</tr>
<tr>
<td>Su2018</td>
<td>ANTIOXIDANT CAPACITY RESPONSE DURING IBD EXACERBATION... (2*) [European Union Funds, Innovative Economy Programme]</td>
<td></td>
</tr>
<tr>
<td>Su2019</td>
<td>ADJUNCTIVE SUPPLEMENTATION WITH AN ORAL HEME... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2020</td>
<td>ENDOSCOPIC SLEEVE GASTROPLASTY AND POST-PROCEDURAL NUTRITIONAL... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2021</td>
<td>THE ROLE OF MALNUTRITION IN THE... (2*) [European Union Funds, Innovative Economy Programme]</td>
<td></td>
</tr>
<tr>
<td>Su2022</td>
<td>PROGNOSTIC ROLE OF ZINC DEFICIENCY ASSOCIATED... (5*)</td>
<td></td>
</tr>
<tr>
<td>Su2023</td>
<td>NUTRITIONAL IMPLICATIONS RELATED TO FOLLOWING A... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1000</td>
<td>ETIOLOGY AND OUTCOMES OF GASTROINTESTINAL BLEEDING... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1001</td>
<td>CAUSES OF UPPER GASTROINTESTINAL BLEEDING IN... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1002</td>
<td>CAUSES OF LOWER GASTROINTESTINAL BLEEDING IN... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1003</td>
<td>HOSPITAL PERFORMANCE FOR GASTROINTESTINAL BLEEDING MORTALITY,... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1004</td>
<td>INCREASING UTILIZATION OF ANGIOGRAPHY FOR LOWER... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1005</td>
<td>EARLY ENDOSCOPY IN CRITICALLY ILL PATIENTS... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1006</td>
<td>QUALITATIVE ANALYSIS OF BARRIERS TO THE... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1007</td>
<td>THE IMPACT OF NIGHT-TIME EMERGENCY DEPARTMENT... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1008</td>
<td>OBSERVED REDUCTION IN EXCESS DAYS FOR... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1009</td>
<td>COST-CONSCIOUSNESS AWARENESS TO PROMOTE HIGH VALUE-CARE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1010</td>
<td>SOMATOSTATIN AND ANALOGUES FOR ACUTE NON-VARICEAL... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1011</td>
<td>THALIDOMIDE AND BEVACIZUMAB FOR THE TREATMENT... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1012</td>
<td>HEMOGLOBIN MONITORING IN ACUTE GASTROINTESTINAL BLEEDING... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1013</td>
<td>INCREASING INCIDENCE OF ESOPHAGEAL ADENOCARCINOMA OCCURS... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1014</td>
<td>RISK STRATIFICATION OF GASTRIC CANCER AFTER... (4*) [This...</td>
<td></td>
</tr>
</tbody>
</table>
Mo1015. . . . GLOBAL Incidence AND Mortality of Esophageal... (5*)
Mo1016. . . . Epidemiology of Carcinoid Tumors of the... (5*)
Mo1017. . . . The Association of Modifiable Risk Factors... (2*)
Mo1018. . . . Tumor Location Is an Independent Predictor... (5*)
Mo1019. . . . Does Living Remotely Impact Access To... (5*)
Mo1020. . . . The global Reality of Gastric Cancer... (2*)
Mo1021. . . . Trends in Mortality From Young-Onset Gastric... (4*)
Mo1022. . . . Pancreatic Cancer in Hispanic Patients: A... (5*)
Mo1023. . . . Does Living Remotely Impact Stage of... (5*)
Mo1024. . . . Lower Income Level Is Associated With... (5*)
Mo1025. . . . Trends in Access to Testing/Treatment For... (5*)
Mo1026. . . . Yield of Outpatient Endoscopy for Dyspepsia... (5*)
Mo1027. . . . Global Incidence, Mortality and Temporal Trend... (5*)
Mo1028. . . . HPV16 Lineage B Is Associated With... (2*)
Mo1029. . . . New NASH Based Screening Criteria Enhances... (5*)
Mo1030. . . . Complications of Metabolic Syndrome May Distinguish... (5*)
Mo1031. . . . Protective Role of the Pro-Resolving Lipid... (4*)
Mo1032. . . . The CDC42/Rac Nucleotide Exchange Factor, βPAK-Interacting... (2*)
Mo1033. . . . Effect and Mechanisms of Constitutine TL1A... (4*)
Mo1034. . . . Intestinal Protection Induced by Treatment With... (4*)
Mo1035. . . . Effects of ASIV on Intestinal Epithelial... (1*)
Mo1036. . . . Sub-Mucosal Collagen Deposition Is Associated With... (5*)
Mo1037. . . . PDGFC Signaling Is a Potential Therapeutic... (2*)
Mo1038. . . . Actl6a Drives Gastric Cancer Progression Through... (2*)
Mo1039. . . . Early Detection of Esophageal Adenocarcinoma Progression... (4*)
Mo1040. . . . The Role of MKP-5-P38/Mapk Pathway In... (2*)
Mo1041. . . . Probiotic-Derived FERRICHROME Inhibits the Growth Of... (4*)
Mo1042. . . . Colorectal Cancer Associated-E. coli Induce the... (2*)
Mo1043. . . . Porphyrin Combined Use Accelerates Chemotherapeutic Effects... (5*)
Mo1044. . . . Verteroporfin Inhibits the Growth of Both... (4*)
Mo1045. . . . Effects of 17β-Estradiol On Colorectal Cancer... (2*)
Mo1046. . . . Platelet-Derived Growth Factor(PDGF) Regulates... (4*)
Mo1047. . . . Genotype-Linked MicroRNA-637 and EPHB3 Axis... (5*)
Mo1048. . . . Exosome-Delivered CIRCrna_1400 Regulates... (5*)
Mo1049. . . . CXCL1 and MASPIN Expression in Incomplete... (4*)
Mo1050. . . . Cabozantinib Treatment of Pancreatic Ductal... (5*)
Mo1051. . . . CD44 Variant Isoform 9 and Its... (4*)
Mo1052. . . . Fusobacterium Contributes to Colorectal Cancer Metastasis... (2*)
Mo1053. . . . Reduced Angiotensin II Type 2 Receptor... (2*)
Mo1054. . . . TGR5 Is Involved in bile Acids... (2*)
Mo1055. . . . Extremely Sensitive Next Generation Sequencing Mutation... (4*)
Mo1056. . . . Primary Sclerosing Cholangitis-Related Cholangiocarcinoma Proliferates Faster... (5*)
Mo1057. . . . Genetic Characterization of Molecular Targets In... (4*)
Mo1058. . . . Identification of a Novel Extracellular Matrix... (5*)
Mo1059. . . . New Fecal Bacterial Signature of Colorectal... (2*)
Mo1060. . . . The GALNT14 Genotype Predicts Postoperative Outcome... (4*)
Mo1061. . . . Identification of a Novel Extracellular Matrix... (5*)
Mo1062. . . . Matrix GLA Protein Promotes Colon Cancer... (4*)
Mo1063. . . . Genomewide Transcriptomic Profiling Identifies a Noninvasive... (5*)
Mo1064. . . . ETV1 Assessment Using EUS-FNA Sample Is... (5*)
Mo1065. . . . Clinicopathological Significance of CD44, CD44 Variants,... (5*)
Mo1066. . . . Granulocyte Colony-Stimulating Factor (G-CSF) Is Highly... (2*)
Mo1067. . . . Hsp70 As a Molecular Marker For... (2*)
Mo1068. . . . Screening Biomarkers Associated with Gastric Cancer... (2*)
Mo1069. . . . Gastrointestinal PIR-1245: A Promising Prognostic... (5*)
Mo1070. . . . The First Evidence for Slfn11 Expression... (2*)
Mo1071. . . . Cancer Nuclear Features Extracted From Pathology... (2*)
Mo1072. . . . Early Monitoring of Plasma Methylated Septin... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA AASLD, etc.)
Mo1073. . . . NOVEL FECAL PROTEIN BIOMARKER TEST FOR...
[6*][2](Sciences)
Mo1074. . . . THE ROLE OF USTERINUMAB IN COLORECTAL...
(5*)
Mo1075. . . . SYSTEMATIC CHARACTERIZATION OF PROGNOSTIC
VALUES OF... (2*)
Mo1076. . . . SPATIALLY RESOLVED ANALYSIS OF FAECAL METABOLITES...
(2*)[3](Waters Corporation)
Mo1077. . . . EPGENETIC AGE ACCELERATION AND COLORECTAL
SURGERY... (2*)
Mo1078. . . . ARSENIC INDUCES DOWNSRIGULATION ON TUMOR
SUPPRESSOR... (4*)
Mo1081. . . . LYMPH NODE INVOLVEMENT IN GASTRIC
ADENOCARCINOMA... (5*)
Mo1082. . . . KCNQ1OT1, THE LARGEST NON-CODING RNA OF...
(5*)
Mo1083. . . . MACHINE LEARNING-BASED PREDICTIVE MODELS ARE
MORE... (5*)
Mo1084. . . . GENOMIC PROFILING IDENTIFIES A NOVEL BIOMARKER...
(5*)
Mo1086. . . . MALIGNANT CONVERSION BASED ON NATURAL HISTORY...
(5*)
Mo1087. . . . THE EFFICACY OF PDT USING 5-AMINOLEVULINIC...
(4*)
Mo1088. . . . THE DIAGNOSTIC ROLE OF 18F-FLOURODEOXYGLUCOSE
POSITRON... (5*)
Mo1089. . . . HIGHER INCIDENCE OF ADVANCED GASTRIC NEOPLASMS...
(5*)
Mo1090. . . . TRENDS IN INCIDENCE AND STAGE AT... (2*)[This study was
supported by grants from the National Natural Science Foundation of China
(Grant No. 81660404 and No. 81560398) and the Natural Science Foundation of
Jiangxi Province (grant No. 20161AGG70014), Foundation of Jiangxi
Educational Committee (g)
Mo1091. . . . LOW GRADE GASTRIC MUCOSA-ASSOCIATED LYMPHOID
TISSUE... (5*)
Mo1092. . . . RISK PREDICTION MODEL FOR DETECTING GASTRIC...
(2*)
Mo1093. . . . ALPN-101, A FIRST-IN-CLASS DUAL ICS/CD28
ANTAGONIST,... (3*)[Alpine Immune Sciences]
Mo1094. . . . OPS-2071 HEALS T CELL MEDIATED COLITIS,... (5*)
Mo1095. . . . ATRIAL NATHRIURETIC PEPTIDE ATTENUATES INTESTINAL
INFLAMMATION... (2*)
Mo1096. . . . BTK DEFICIENCY LEADS TO NLRP3 INFLAMMASOME...
(2*)
Mo1097. . . . SYMPTOMATIC EFFECTS OF SHORT-CHAIN FATTY ACIDS SUPPLEMENTATION...
(4*)
Mo1098. . . . AN ESCHERICHIA COLI STRAIN WITH EXTRA... (2*)
Mo1099. . . . ESCHERICHIA COLI NISSLE 1917 EXPRESSING ELAFIN... (2*)
Mo1100. . . . PROPHYLACTIC ADMINISTRATION OF PHENOLIC
COMPOUND EXTRACTED... (4*)
Mo1101. . . . EFFECT OF WEICHANG’AN PILL ON TH17/TREG... (3*)
Mo1102. . . . MONONUCLEAR CELLS TARGETED HISTONE DEACETYLASE...
(4*)[3](GlaxoSmithKline - Stevenage - UK)
Mo1103. . . . DEFLIXIS, A NOVEL GUT-HOMOPHAGE ADMINISTRATION...
(4*)
Mo1104. . . . MULTICENTER STUDY OF THE EFFICACY OF... (3*)
Mo1105. . . . GB004, A NOVEL GUT-HOMOPHAGE ADMINISTRATION...
(4*)
Mo1106. . . . GB004, A NOVEL GUT-HOMOPHAGE ADMINISTRATION...
(3*)[Gossamer Bio, Inc.)
Mo1107. . . . THE GEM PROJECT: CROHN’S DISEASE POLYGENIC...
(6*)[2]
Mo1108. . . . AN INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSIS...
(5*)
Mo1109. . . . DEVIATION FROM ADDITIVE MODEL IN GENETICS...
(2*)[4]
Mo1110. . . . INTEGRATING EQTL EVIDENCE AND GWAS SUMMARY...
(2*)[4]
Mo1111. . . . RNASET2 RISK VARIANT AS A NOVEL... (4*)
Mo1112. . . . IDENTIFYING NOVEL HIGH-IMPACT RARE DISEASE-CAUSING
MUTATIONS,... (2*)
Mo1113. . . . GENOTYPING OF NUDT15 R139C PRIOR TO... (4*)
Mo1114. . . . ACCURATE PREDICTION OF THERAPEUTIC RESPONSE TO...
(6*)
Mo1115. . . . WHOLE-BLOOD EXPRESSION PROFILES IN...
INFLAMMATORY BOWEL... (2*)
Mo1116. . . . GENOME-WIDE DNA METHYLATION PROFILING IN...
DIFFERENTIATING... (2*)
Mo1117. . . . INCREASED ABDUANCE OF BACTERIAL BILE SALT...
(2*)[7]
Mo1118. . . . DEVELOPMENT OF AN EASY AND RAPID... (4*)
Mo1119. . . . NOVEL GENETIC VARIANTS ASSOCIATED WITH RISK...
(4*)
Mo1120. . . . PHENOME WIDE ASSOCIATION STUDY USING...
INFLAMMATORY... (5*)
Mo1121. . . . TARGETED MUCOSAL TRANSCRIPTOMICS ANALYSIS...
REVEALS DIFFERENTIAL... (2*)
Mo1122. . . . INTEGRATED NETWORK ANALYSIS USING PATIENT-SPECIFIC
SINGLE... (2*)
Mo1123. . . . META-ANALYSIS OF GENE EXPRESSION DISEASE SIGNATURES...
(5*)
Mo1124. . . . RNA-SEQ GENE EXPRESSION PROFILE REVEALS THAT...
(2*)[7]
Mo1125. . . . GENETIC ANALYSIS OF...
ULCERATIVE COLITIS RESPONSE... (5*)
Mo1126. . . . FAMILY-SPECIFIC HOST GENETIC AND GUT MICROBIAL...
(2*)
Mo1127. . . . REPERTOIRE ANALYSIS OF...
MEMORY T—CELL RECEPTORS... (1*)
Mo1128. . . . INFLUENCE OF NUDT15 AND TPMT ON...
(5*)
Mo1129. . . . THE IMPACT OF A SNP-DOSE-RESPONSE-EFFECT ON...
(2*)
Mo1130. . . . SGK2 KNOCKDOWN BY GENE EDITING PROMOTES...
(2*)
Mo1131. . . . QUANTITATIVE PROTEOMIC ANALYSIS OF...
MACROPHAGES FROM... (5*)
Mo1132. . . . TLR4 SIGNALING PROTECTS THE INTESTINAL...
EPITHELIUM... (2*)
Mo1133. . . . ACTIVATION OF ARYL HYDROCARBON RECEPTOR...
ATTENUATES... (2*)
Mo1134. . . . THE REGULATION OF ARYL HYDROCARBON RECEPTOR... (4*)
Mo1135. . . . ENDOPLASMIC RETICULUM STRESS ACTIVATES REGULATORY T... (2)
Mo1136. . . . INTESTINAL ALKALINE PHOSPHATASE EXERTS ANTI-INFLAMMATORY EFFECTS... (4*)
Mo1137. . . . HDAC3 MEDIATES THE INFLAMMATORY RESPONSE AND... (2*)
Mo1138. . . . STRESS-INDUCED VISCERAL PAIN: ROLE OF MICROGLIA... (4*)
Mo1139. . . . PHYSIOLOGIC IN VIVO HOMEOSTASIS OF INTESTINAL... (5*)
Mo1140. . . . SACRAL NERVE STIMULATION IMPROVES RECTAL DISTENTION-INDUCED... (2*)
Mo1141. . . . SQUALAMINE, AN AMINOSTEROL POTENTIALLY USEFUL IN... (2*)
Mo1142. . . . INTESTINAL ELECTRICAL STIMULATION ENHANCES RELEASE OF... (2*)
Mo1143. . . . ALTERATION OF ANTERIOR CINGULATE FUNCTIONAL CONNECTIVITY... (2*)
Mo1144. . . . EARLY ADVERSE LIFE EVENTS MODULATE FUNCTIONAL... (2*)
Mo1145. . . . THE STRUCTURE OF VAGAL NOCICEPTIVE AFFERENT... (2*)
Mo1146. . . . CHRONIC INTRA-COLONIC LINACLOTIDE ADMINISTRATION ALTERS GLIAL... (3*)[(2)][Supported by Ironwood Pharmaceuticals Inc, Allergan and NHMRC Australia.)
Mo1147. . . . INTESTINAL HYPERPERMEABILITY IN A DUAL EXPERIMENTAL... (5*)
Mo1148. . . . IMPACT OF ADVERSE CHILDHOOD EXPERIENCES ON... (2*)[(4)
Mo1149. . . . A NOVEL R-SPONDIN 1/POMC NEUROCIRCUIT IN... (2*)
Mo1150. . . . CENTRAL MECHANISM OF INTESTINAL ELECTRICAL STIMULATION... (2*)
Mo1151. . . . ACCELERATED GASTRIC EMPTYING IN A SUBSET... (5*)
Mo1152. . . . SPECTRAL ANALYSIS OF FREQUENCY OF COLON... (2*)
Mo1153. . . . PREDICTING TREATMENT RESPONSE TO THE LOW... (5*)
Mo1154. . . . RQ-00433412, A NOVEL ORALLY ACTIVE GHRELIN... [RaQualia Pharma Inc.]
Mo1155. . . . PERIPHERAL GHRELIN MEDIATES THE OREXGENIC EFFECTS... (1*)
Mo1156. . . . LOW COMPLICATION RATES IN THE OUTPATIENT... (5*)
Mo1157. . . . DIFFERENCES IN BRAIN SIGNATURES IN ULCERATIVE... (2*)
Mo1158. . . . A MULTICENTER, PROSPECTIVE TRIAL EVALUATING THE... (3*)[(Medtronic - research support)
Mo1159. . . . BIOMARKERS OF EXTRACELLULAR MATRIX REMODELLING ARE... (5*)
Mo1160. . . . SEROLOGICAL BIOMARKERS OF INTERSTITIAL MATRIX AND... (5*)
Mo1161. . . . THE SIMPLIFIED MARIA SCORE IS STRONGLY... (4*)
Mo1162. . . . INITIAL CLINICAL EXPERIENCE OF USING TETHERED... (2*)
Mo1163. . . . ENDOSCOPY-DRIVEN ALGORITHM IDENTIFIES BARRETT NEOPLASIA WITH... (5*)
Mo1164. . . . VOLUMETRIC LASER ENDOMICROSCOPY FOR IDENTIFICATION OF... (2*)
Mo1165. . . . WIRELESS ELECTRODE PATCHES SHOW INTRAPATIENT REPRODUCIBILITY... (6*)
Mo1166. . . . THE NEW SIMPLIFIED MARIA SCORE APPLIES... (5*)
Mo1167. . . . DEVELOPMENT OF A SOFTWARE (ASSESS UC)... (5*)
Mo1168. . . . ACCURACY OF CLINICAL STAGING FOR T2N0... (4*)
Mo1169. . . . X-RAY PHASE CONTRAST IMAGING FOR STAGING... (4*)
Mo1170. . . . OPTIMIZING VOLUMETRIC LASER ENDOMICROSCOPY SCORING SYSTEMS... (5*)
Mo1171. . . . ARTIFICIAL INTELLIGENCE (AI) BASED ANALYSIS OF... (3*)[(CDX Diagnostics)
Mo1172. . . . A RADIOMICS MACHINE LEARNING PREDICTOR CAN... (2*)
Mo1173. . . . TRANSNASAL ENDOMICROSCOPY FOR UNSEDATED OCT IMAGING... (6*)
Mo1174. . . . DEVELOPMENT OF A SELF-GUIDED TRAINING MODULE... (5*)
Mo1175. . . . USE OF MACHINE LEARNING AND COMPUTER... (2*)
Mo1176. . . . DEVELOPMENT OF A MACHINE LEARNING [ML]... (7*)(4)
Mo1177. . . . RESPONSE AND PROGRESSION OF SMALL BOWEL... (3*)
Mo1179. . . . OUTCOMES OF THE SIX FOOD ELIMINATION... (5*)
Mo1180. . . . PATTERNS OF ALLERGIC SENSITIZATION BASED ON... (5*)
Mo1181. . . . G-EOE-RD: EXTENT OF EOSINOPHILIC ESOPHAGITIS PREDICTS... (5*)
Mo1182. . . . AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF... (3*)[(Adare Pharmaceuticals)
Mo1183. . . . PREDICTORS OF RESPONSE TO CORTICOSTEROID THERAPY... (3*)[(This study was funded by Shire ViroPharma, Inc., a member of the Takeda group of companies. Medical writing support was provided by Luci Witcomb PhD, of Pharmagenesis London, London, UK, and funded by Shire Human Genetic Therapies Inc., a member of the Ta]
Mo1184. . . . AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF... (3*)[(Adare Pharmaceuticals Inc]
Mo1185. . . . ENDOSCOPY DETECTS HISTOLOGIC REMISSION WITH VERY... (2*)
Mo1186. . . . STRONG ASSOCIATION WITH... (2*)[(T32 DK007634, R01DK101856)
Mo1187. . . . DILATION REDUCES POSITIVE CORRELATION BETWEEN SYMPTOMS... (2*)
Mo1188. . . . DETERMINATION OF AN ENDOSCOPIC RESPONSE THRESHOLD... (2*)[(3)][T32 DK007634, R01DK101856)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1189. DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS IMPROVES WITH... [2*][R01DK101856, T32DK007634]

Mo1190. ESOPHAGEAL DISTENSION Dysfunction during Swallow-INDUCED PERISTALSIS... [2*]

Mo1191. ANTI-TUMOR NECROSIS FACTOR THERAPY AND EOSINOPHILIC... [5*]

Mo1192. ACID SUPPRESSANT MEDICATIONS AND EOSINOPHILIC ESOPHAGITIS... [5*]

Mo1193. PREDICTORS OF RESPONSE TO DIETARY THERAPY... [6*][The Belletete Foundation]

Mo1194. GENDER-STRATIFIED CLINICAL COURSE AND TREATMENT RESPONSE... [2*][4]

Mo1195. POOR ENVIRONMENTAL QUALITY OF LIFE AND... [2*]

Mo1196. PREVALENCE AND COMORBID OCCURRENCE OF ESOPHAGIAL... [5*]

Mo1197. THE COMORBID OCCURRENCE OF EOSINOPHILIC ESOPHAGITIS... [5*]

Mo1198. RETROSPECTIVE REVIEW OF MILD ESOPHAGIAL EOSINOPHILIA... [5*]

Mo1199. PERIPHERAL EOSINOPHILIA AND HYPOALBUMINEMIA ARE ASSOCIATED... [2*]

Mo1200. INDIVIDUALS WITH EOSINOPHILIC ESOPHAGITIS ARE AT... [2*]

Mo1201. LONG-TERM TREATMENT WITH PROTON PUMP INHIBITORS... [5*]

Mo1202. EOSINOPHILIC ESOPHAGITIS - VISUAL SCORE: A... [5*]

Mo1203. EOSINOPHILIC ESOPHAGITIS QUALITY OF LIFE QUESTIONNAIRE... [5*]

Mo1204. EOSINOPHILIC ESOPHAGITIS QUALITY OF LIFE QUESTIONNAIRE... [5*]

Mo1205. INCIDENCE OF BIOPSY-VERIFIED EOSINOPHILIC ESOPHAGITIS: NATIONWIDE... [5*]

Mo1206. FACTORS RELATED TO SUBJECTIVE SYMPTOMS IN... [5*]

Mo1207. HIGH HEALTH CARE UTILIZATION OF ENDOSCOPY... [2*]

Mo1208. COMPONDED FLUTICASONE SLURRY IS AN EFFECTIVE... [5*]

Mo1209. TREATMENT OF LYMPHOCYTIC ESOPHAGITIS IN A... [5*]

Mo1210. CONTRIBUTING FACTORS TO DELAY IN DIAGNOSIS... [5*]

Mo1212. PATIENT CHARACTERISTICS AND DISEASE SEVERITY IN... [5*]

Mo1213. LAMINA PROPRIA YIELD USING PERPENDICULAR PLACEMENT... [4*]

Mo1214. PROVOCATIVE TESTS DURING HIGH-RESOLUTION MANOMETRY MAY... [5*]

Mo1215. LYMPHOCYTIC ESOPHAGITIS HAS BETTER OUTCOMES COMPARED... [5*]

Mo1216. PREVALENCE OF NONADHERENCE IN MAINTENANCE THERAPY... [5*]

Mo1217. QUALITATIVE PATIENT INTERVIEWS TO ASSESS CONTENT... [3*][Sanofi and Regeneron Pharmaceuticals, Inc.]

Mo1218. EFFICACY OF BENRALIZUMAB, A MONOCLONAL ANTIBODY... [5*]

Mo1219. IMPACT OF EOSINOPHILIC ESOPHAGITIS DISEASE ACTIVITY... [2*]

Mo1220. FREQUENCY AND PREDICTORS OF LOSS TO... [2*]

Mo1221. MORTALITY IN EOSINOPHILIC ESOPHAGITIS - NATIONWIDE,... [2*]

Mo1222. EOSINOPHILIC ESOPHAGITIS AND ASYMPTOMATIC ESOPHAGEAL EOSINOPHILIA... [5*]

Mo1223. DEMOGRAPHIC AND CLINICAL CORRELATES OF THE... [5*]

Mo1224. SEASONAL AND REGIONAL VARIATIONS OF HOSPITAL... [5*]

Mo1225. EPIDEMIOLOGY AND SEASONAL PATTERNS OF HOSPITALIZATIONS... [5*]

Mo1226. CORRELATION OF TREATMENT OPTIONS AND... [5*]

Mo1227. IN HUMAN ESOPHAGEAL SMOOTH MUSCLE CELLS,... [4*]

Mo1228. DUPILUMAB NORMALIZES THE EOSINOPHILIC ESOPHAGITIS DISEASE... [3*][Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.]

Mo1229. TH2-CYTOKINES SUPPRESS CD73-POSITIVE CELL-MEDIATED EPITHELIAL REGENERATION... [2*]

Mo1230. DIFFERENTIALLY CORRELATED GENE MODULES SUGGEST DIFFERENTIALLY... [5*]

Mo1231. RNA SEQUENCING REVEALS ALTERED SELENO PROTEIN EXPRESSION... [2*][4]

Mo1232. CHARACTERIZATION OF SALIVARY, GaSTRIC AND ESOPHAGEAL... [5*]

Mo1233. OSEOPHAGEAL MUCOSA INNERVATION IN PAEDIATRIC EOSINOPHILIC,... [4*]

Mo1234. UTILITY OF MAJOR BASIC PROTEIN, EOTAXIN-3,... [2*]

Mo1235. ESOEOPHAGEAL MUCOSA INNERVATION IN PAEDIATRIC EOSINOPHILIC,... [4*][Educational Grant provided by Allakos.]

Mo1236. MAST CELL LEVEL AND CLINICAL CORRELATES... [3*][Education grant from Allakos.]

Mo1237. ESTABLISHMENT OF NORMAL TISSUE MAST CELL,... [4*][Educational Grant provided by Allakos.]

Mo1238. TIME DEPENDENT ESOPHAGEAL CLEARANCE OF GLADIN... [4*]

Mo1239. SMOKING PROMOTES CHEMO-RESISTANCE THROUGH INDUCING WEE1... [2*][4]

Mo1239. QUANTIFICATION OF LYMPHOVASCULAR INVASION IS USEFUL... [5*]

Mo1240. GTR STIMULATION ENHANCES THE ANTI-TUMOR IMMUNE... [4*]

Mo1241. INDIVIDUAL RISK CALCULATOR TO PREDICT LYMPH... [5*]

Mo1242. I K R K REGULATES CXCL9 AND IMMUNE CELL... [2*]

Mo1243. THE ALCOHOL USE DISORDERS IDENTIFICATION TEST... [5*]

Mo1244. GLUTATHIONE S-TRANSFERASE OMEGA 2 (GSTO2)... [5*]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds   
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mo1304</td>
<td>CLINICOPATHOLOGICAL CHARACTERISTICS AND LYMPH NODE METASTASIS... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1306</td>
<td>HIGH GRADE DYSPLASIA (HGD) AND ESOPHAGEAL... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1307</td>
<td>CLINICAL AND GENOMIC CHARACTERISTICS OF SUPERFICIAL... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1308</td>
<td>CLINICAL SIGNIFICANCE OF EARLY EVALUATION DURING... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1309</td>
<td>IS THERE A NON-BARRETT'S PATHWAY TO... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1310</td>
<td>ESOPHAGEAL ADENOCARCINOMA AFTER BARIATRIC SURGERY: A... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1311</td>
<td>DOES CONTROLLING ESOPHAGEAL PH &gt; 4... (3*)[(Tsumura &amp; Co.)</td>
<td></td>
</tr>
<tr>
<td>Mo1312</td>
<td>ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1313</td>
<td>STUDY ON EXPANSION OF INDICATION OF... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1314</td>
<td>RISK OF GENERALIZATION IN PATIENTS WITH... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1315</td>
<td>DIETARY TRIGGERS IN IRREVERSIBLE BOWEL SYNDROME... (2*)[(Companies Winclove, Ingredia, Ingredion, Nexira, Naturex, Bioiberica, Wecare, Roquette and Darling Ingredients)</td>
<td></td>
</tr>
<tr>
<td>Mo1316</td>
<td>FREQUENCY AND INTENSITY OF GASTROINTESTINAL SYMPTOMS... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1317</td>
<td>ASSOCIATION BETWEEN INTESTINAL LACTASE AND SYMPTOMS... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1318</td>
<td>PREVALENCE OF SELF-REPORTED FOOD INTOLERANCES AMONG... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1319</td>
<td>USEFULNESS OF FECAL CALPROTECTIN IN PRIMARY... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1320</td>
<td>IMPACT OF HUMAN MILK OLIGOSACCHARIDES ON... (3*)[(Glycom A/S sponsored the trial)</td>
<td></td>
</tr>
<tr>
<td>Mo1321</td>
<td>THE UTILITY OF GLUCOSE HYDROGEN BREATH... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1322</td>
<td>HUMAN MILK OLIGOSACCHARIDES IMPROVE BOWEL HABITS,... (3*)[(Glycom, Inc.)</td>
<td></td>
</tr>
<tr>
<td>Mo1323</td>
<td>SEX-BASED DIFFERENCES IN FECAL SHORT-CHAIN FATTY... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1324</td>
<td>36 MONTH SURVEILLANCE DATA CONFIRMS SAFETY... (3*)[(IM HealthScience, LLC)</td>
<td></td>
</tr>
<tr>
<td>Mo1325</td>
<td>INFLAMMATORY STATUS OF POST-INFECTIONG IRREVERSIBLE BOWEL... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1326</td>
<td>IRREVERSIBLE BOWEL SYNDROME (IBS) SYMPTOMS AND... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1327</td>
<td>ANALYSIS OF A RANGE OF ABDOMINAL... (3*)[(This study was funded by Allergan plc. Writing assistance by Complete HealthVizion, funded by Allergan plc.)</td>
<td></td>
</tr>
<tr>
<td>Mo1328</td>
<td>EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN IRREVERSIBLE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1329</td>
<td>RIFAXIMIN IS EFFICACIOUS FOR THE Treatment... (3*)[(Salix Pharmaceuticals)</td>
<td></td>
</tr>
<tr>
<td>Mo1330</td>
<td>EFFECT OF MOBXIBUSTION ON SYMPTOMS AND... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1331</td>
<td>LONG-TERM NATURAL HISTORY OF SYMPTOMS AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1332</td>
<td>ASSOCIATIONS OF FOOD INTOLERANCES WITH IRREVERSIBLE... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1333</td>
<td>PHASE 1 RESULTS OF ORP-101, A... (4*)[(The studies discussed in this abstract were funded by OrphoMed, Inc.)</td>
<td></td>
</tr>
<tr>
<td>Mo1334</td>
<td>SEXUAL DYSFUNCTION (SXD) WORSENS QUALITY OF... (5*)</td>
<td></td>
</tr>
<tr>
<td>Mo1335</td>
<td>HUMAN MILK OLIGOSACCHARIDES IMPROVE SYMPTOMS... (3*)[(Glycom Inc)</td>
<td></td>
</tr>
<tr>
<td>Mo1336</td>
<td>HIGHLY SENSITIVE DIAGNOSIS OF IRREVERSIBLE BOWEL... (6*)</td>
<td></td>
</tr>
<tr>
<td>Mo1338</td>
<td>A POOLED ANALYSIS OF TWO PHASE... (3*)[(Salix Pharmaceuticals)</td>
<td></td>
</tr>
<tr>
<td>Mo1339</td>
<td>RELATIVE ABUNDANCES OF MICROBIAL GENES INVOLVED... (2*)</td>
<td></td>
</tr>
<tr>
<td>Mo1340</td>
<td>MILD TRAUMATIC BRAIN INJURY CAUSED BY... (4*)</td>
<td></td>
</tr>
<tr>
<td>Mo1341</td>
<td>STRESS-INDUCED ACTIVATION OF CORTICOTROPIN-RELEASING HORMONE, VASOPRESSIN... (2*)</td>
<td></td>
</tr>
</tbody>
</table>

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1361. . . . ANTI-TUMOR NECROSIS FACTOR THERAPY IS EQUIVALENT...
(5*)
Mo1362. . . . IDENTIFYING KEY FACTORS FOR THE EFFECTIVENESS...
(5*)
Mo1363. . . . BARIATRIC SURGERY DECREASES PREVALENCE OF PANCREATIC...
(5*)
Mo1364. . . . THE LONG-TERM RESEARCH OF THERAPEUTIC EFFECT...
(5*)
Mo1365. . . . RISE IN OBESITY PREVALENCE EXPLAINS THE...
(5*)
Mo1366. . . . EFFICACY OF GEMCITABINE/NAB-PACLITAXEL INDUCTION CHEMOTHERAPY FOLLOWED...
(5*)
Mo1367. . . . CLINICAL PROFILE AND OUTCOMES OF EARLY-ONSET...
(5*)
Mo1368. . . . TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY IN...
(5*)
Mo1369. . . . IDENTIFICATION OF LIPOCALIN-2 EXPRESSION BY DIGITAL...
(4*)
Mo1370. . . . PROPENSITY SCORE MATCHED ANALYSIS OF NEOADJUVANT...
(5*)
Mo1371. . . . INFLAMMATORY RESPONSE IN EXPERIMENTAL PANCREATITIS INDUCED...
(2*)
Mo1372. . . . LONG-TERM MANAGEMENT OF TYPE 1 AUTOIMMUNE...
(4*)
Mo1373. . . . HUMAN PANCREAS-ON-A-CHIP TO STUDY PRESSURE-INDUCED PANCREATITIS...
(2*)
Mo1374. . . . PIRFENIDONE IMPROVES SEQUELAE OF WELL-ESTABLISHED CHRONIC...
(2*)
Mo1375. . . . IMPAIRED LONG-CHAIN FATTY ACID METABOLISM IN...
(2*)
Mo1376. . . . ASSESSMENT OF GENE EXPRESSION PROFILE IN...
(5*)
Mo1377. . . . AMINO ACID DEPRIVATION ON PANCREATIC HEALTH...
(4*)
Mo1378. . . . INHIBITION OF PROTEIN KINASE D ATTENUATES...
(2*)
Mo1379. . . . IMPORTANCE OF DRUGS TARGETING TO AUTOPHAGY...
(5*)
Mo1380. . . . PIRFENIDONE TREATMENT AMELIORATES THE SEVERITY OF...
(2*)
Mo1381. . . . ROLE OF IL-17A IN THE PATHOGENESIS...
(2*)
Mo1382. . . . MECHANISMS UNDERLYING THE PATHOGENESIS OF HYPOCALCEMIA...
(2*)(4)
Mo1383. . . . IGG4-NEGATIVE SCLEROSING PANCREATITIS: A THIRD SUBTYPE...
(5*)
Mo1384. . . . PREVALENCE OF ACUTE AND CHRONIC PANCREATITIS...
(5*)
Mo1385. . . . SL99A2 ATTENUATES ACUTE PANCREATITIS THROUGH INHIBITING...
(5*)
Mo1386. . . . IS HYPERTHYROIDISM ASSOCIATED WITH INCIDENCE OF...
(5*)
Mo1387. . . . TARGETING NUCLEAR RECEPTOR NR5A2 IMPROVES EXOCRINE...
(4*)
Mo1388. . . . CLINICAL CHARACTERISTICS OF PATIENTS WITH ATEZOLIZUMAB...
(5*)
Mo1389. . . . ACUTE KIDNEY INJURY IS AN INDEPENDENT...
(5*)
Mo1390. . . . ELECTIVE ENDOTRACHEAL INTUBATION PRIOR TO EGD...
(5*)
Mo1391. . . . ROLE OF ENDOSCOPIC EVALUATION PRIOR TO...
(5*)
Mo1427. . . . NOVEL METABOLIC PREDICTORS OF INCIDENT SYMPTOMATIC...
(2*)
Mo1428. . . . THE NEUTROPHIL PROPORTION AMONG WHITE BLOOD...
(5*)
Mo1429. . . . CLINICAL EPIDEMIOLOGY OF CHOLEDOCOLITHIASIS: EXAMINING THE...
(5*)
Mo1430. . . . SINGLE AND REPEITIVE PERCUTANEOUS GALLBLADDER ASPIRATION...
(5*)
Mo1431. . . . URINASTATIN VERSUS NAFAMOSTAT MESYLATE IN THE...
(5*)
Mo1432. . . . PROTON PUMP INHIBITOR (PPI) USE IS...
(5*)
Mo1433. . . . IS REPEAT ERCP REQUIRED AFTER INITIAL...
(5*)
Mo1434. . . . WHICH IS THE DETERMINING FACTOR...
(5*)
Mo1435. . . . LITHOLYTIC AGENTS AS AN ALTERNATIVE TREATMENT...
(5*)
Mo1436. . . . GALLSTONE DISEASE IN PATIENTS WITH NON-ALCOHOLIC...
(5*)
Mo1437. . . . EFFECT OF BILE ACID COMPOSITION ON...
(2*)(This research is financially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant no. NRF-2017R1A1B03034172))
Mo1438. . . . URINE AND SERUM METABOLICOMICS DISCRIMINATE...
(4*)
Mo1439. . . . IMPAIRED BILE SECRETION PROMOTES SICKLE CELL...
(6*)
Mo1440. . . . ASSOCIATION BETWEEN ATAZANAVIR-INDUCED HYPERBILIRUBINEMIA AND CARDIOVASCULAR...
(5*)
Mo1441. . . . COMPARISON OF OUTCOMES OF TREATMENT WITH...
(5*)
Mo1442. . . . HEPATITIS C PREVALENCE IN CABELL COUNTY...
(5*)
Mo1443. . . . MOBILE FOOD TRUCK LICENSES AS A...
(5*)
Mo1444. . . . CHARACTERIZATION OF PATIENTS WITH CHRONIC HEPATITIS...
(5*)
Mo1519. . . . PREVALENCE OF AND RISK FACTORS FOR...
(5*)
Mo1521. . . . DIARY FOR IRRITABLE BOWEL SYMPTOMS—CONSTIPATION...
(3*)(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc. Editorial assistance by Complete HealthVizion, funded by Allergan plc and Ironwood Pharmaceuticals, Inc)
Mo1522. . . . THE EFFICACY OF ELOBIXIBAT AS AN...
(5*)
Mo1523. . . . PREDICTORS OF NAUSEA SEVERITY IN CHILDREN...
(5*)
Mo1524. . . . PAIN TREATMENT EFFICACY IN PATIENTS WITH...
(5*)
Mo1525. . . . LONG TERM FOLLOW UP OF CYCLIC...
(5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds      (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)      (3) = Industry or Commercial Entity      (4) = Institutional Funds      (5) = No Study Funding      (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)      (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1526. . . . PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE... (5*)
Mo1527. . . . ASSESSMENT OF REONSE TO THERAPY IN... (4*)
Mo1528. . . . HIGH RATE OF CONCORDANCE BETWEEN PHYSICIANS... (5*)
Mo1529. . . . MALABSORBITIVE BARIATRIC SURGERY AND IBS, LOW... (5*)
Mo1530. . . . GENDER DIFFERENCES IN PATIENTS WITH SYSTEMIC... (5*)
Mo1532. . . . FUNCTIONAL GASTROINTESTINAL SYMPTOMS COMMON AND FREQUENTLY... (5*)
Mo1533. . . . VOLATOMICS IN INFLAMMATORY BOWEL DISEASE AND... (2*)[(4)
Mo1534. . . . PREVALENCE OF METHANE POSITIVE SMALL INTESTINAL... (5*)
Mo1535. . . . INTERNET SURVEY ON LAXATIVE USE BY... (3*)[(EA Pharma Co. Ltd)
Mo1536. . . . FUNCTIONAL DYSPESIA, PEPTIC ULCER AND HELICOBACTER... (2*)[(6)
Mo1537. . . . MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE DUODENAL... (4*)
Mo1538. . . . EQUATING SCORES OF THE FUNCTIONAL DIGESTIVE... (2*)
Mo1539. . . . THIRTY DAY UNPLANNED READMISSIONS FOR CYCLICAL... (5*)
Mo1540. . . . THE EFFICACY AND SAFETY OF GCWB104... (4*)
Mo1541. . . . INTEGRATING PSYCHOLOGICAL SCREENING INTO MEDICAL CARE... (5*)
Mo1542. . . . DUODENAL EOSINOPHILS ACTIVITY IN DYSPESIA: ONLY... (5*)
Mo1543. . . . A DOUBLE-EDGED SWORD? #NAME? PERIPHERAL MECHANISM... (5*)
Mo1544. . . . IS SMALL INTESTINAL DYBSOSIS (SIBO) RELATED... (5*)
Mo1545. . . . DISTINCT TREATMENT CHOICES BETWEEN PRIMARY CARE... (3*)[(Xian jansen Pharmaceutical Ltd)
Mo1546. . . . DYSPESIA SYMPTOMS IN FUNCTIONAL DYSPESIA (FD)... (4*)
Mo1547. . . . LHMBT POSITIVE IBS-D PATIENTS PRESENTED A... (2*)
Mo1548. . . . REEVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE... (3*)[(Alfasigma USA)
Mo1549. . . . CHARACTERISTICS AND PREDICTIVE MODELING OF POST-INFECTION... (2*)[(Supported by NIH K23 DK 103911 and R03 120745.)
Mo1550. . . . A NOVEL SCORE TO EVALUATE ABDOMINAL... (3*)[(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)
Mo1551. . . . PSYLLIUM REDUCES COLONIC HYDROGEN PRODUCTION FOLLOWING... (2*)
Mo1552. . . . AN ANALYSIS OF PLACEBO RATE AND... (6*)
Mo1553. . . . EVALUATION OF SENSORY SENSITIVITY AND SOMATIC... (5*)
Mo1555. . . . BILE ACID MALABSORPTION: AN OVERLOOKED DIAGNOSIS... (5*)
Mo1556. . . . PREVALENCE OF EXOCRINE Pancreatic INSUFFICIENCY IN... (3*)[(Abbott Laboratories)
Mo1557. . . . FACTORS AFFECTING CENTRAL NEUROMODULATOR USE BY... (4*)
Mo1558. . . . PREVALENCE OF FIRST-EVER DIAGNOSIS OF IRRITABLE... (5*)
Mo1559. . . . QUANTITATIVE ASSESSMENT OF THE BIDIRECTIONAL RELATIONSHIP... (5*)
Mo1559. . . . FACTORS ASSOCIATED BETWEEN IMPROVEMENT... (5*)
Mo1560. . . . CANNABIS USE IS ASSOCIATED WITH REDUCED... (5*)
Mo1561. . . . THE EFFECT OF LONG-ACTING MESALAMINE OF... (3*)[(Supported in part by grants from Shire Pharmaceuticals and the Department of Defense)
Mo1562. . . . ECONOMIC AND SOCIAL BURDEN OF IRRITABLE... (5*)
Mo1563. . . . DISCRIMINATING BETWEEN PATIENTS WITH IRRITABLE BOWEL... (2*)[(4)
Mo1564. . . . THE CLINICAL OUTCOMES OF CLOSTRIDIUM DIFFICILE... (5*)
Mo1565. . . . MUCOSAL SEROTONIN REUPTAKE TRANSPORTER (SERT) EXPRESSION... (2*)
Mo1566. . . . ANTI-VINCLULIN AND ANTI-CYTOLETAL DISTENDING TOXIN B... (6*)
Mo1567. . . . DIFFERENCES IN BRAIN STRUCTURE PREDICT SYMPTOM... (2*)
Mo1569. . . . IDENTIFICATION OF COLONIC MUCOSAL MICRONAS ALTERED... (4*)[(2)
Mo1570. . . . THE INTESTINAL MICROBIOTA FROM A PATIENT... (4*)
Mo1571. . . . INTRARECTAL ADMINISTRATION OF A TRPV4 ANTAGONIST... (4*)
Mo1572. . . . MUCOSA-ASSOCIATED INTESTINAL MUCOBIOTA AND SERUM CYTOKINES... (2*)
Mo1573. . . . IRIRRABLE BOWEL SYNDROME WITH DIARRHEA IS... (5*)
Mo1574. . . . DIFFERENTIAL MRNA EXPRESSION IN ILEAL MUCOSAL... (2*)
Mo1575. . . . RELATIONSHIPS OF SHORT CHAIN FATTY ACIDS... (2*)
Mo1576. . . . DETERMINANTS OF RENTENTION IN CARE AFTER... (5*)
Mo1577. . . . BRIEF BEHAVIORAL THERAPY FOR INSOMNIA IN... (6*)
Mo1578. . . . INDIVIDUALS WITH IBS REPORT HIGH RATES... (5*)
Mo1579. . . . I JUST FEEL LIKE AN OUTCAST: STIGMA EXPERIENCES OF PATIENTS LIVING... (4*)
Mo1580. . . . GASTROENTEROLOGISTS’ PRESCRIBING PATTERNS AND COMFORT-LEVEL VARY... (5*)
Mo1581. . . . CHARACTERIZATION OF COGNITIVE FLEXIBILITY IN ESOPHAGEAL... (2*)
Mo1582. . . . IS THERE AN ASSOCIATION BETWEEN IMPROVEMENT... (2*)
Mo1583. . . . HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: THE... (5*)
Mo1584. . . . DO I REALLY HAVE TO DO... (2*)
Mo1585. . . . FACTORS ASSOCIATED WITH Efficacy OF COGNITIVE... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1586. . . . TREATMENT EXPECTANCY FOR GI SYMPTOM IMPROVEMENT...
(2*)
Mo1587. . . . PSYCHOPHYSIOLOGICAL CORRELATES OF ESOPHAGEAL HYPERSONILLAGE: BUILDING...
(2*)
Mo1588. . . . POST-TRAUMATIC STRESS DISORDER IS PREVALENT AND...
(5*)
Mo1589. . . . HYPERACTIVITY AND AGGRESSION ARE ASSOCIATED WITH...
(2*)
Mo1590. . . . TRANSIENT EXPOSURE TO ENVIRONMENTAL ENRICHMENT PRODUCES...
(2*)
Mo1591. . . . GUT-FOCUSED HYPNOTHERAPY FOR CHILDREN AND ADOLESCENTS...
(5*)
Mo1592. . . . GREATER RISK FOR ADVERSE HOSPITALIZATION OUTCOMES...
(5*)
Mo1593. . . . KNOWLEDGE AND ATTITUDES OF DISCONTINUING COLON...
(4*)
Mo1594. . . . WHICH GUIDELINE TO FOLLOW? A NATIONAL...
(4*)
Mo1595. . . . COLONRECTAL CANCER SCREENING AMONG AMERICAN ADULTS...
(5*)
Mo1596. . . . BASELINE FECAL HEMOGLOBIN CONCENTRATION IS AN...
(5*)
Mo1597. . . . COLONRECTAL CANCER SCREENING AND YIELD IN...
(2*)
Mo1598. . . . ESTIMATING THE IMPACT OF IMPERFECT ADHERENCE...
(3*)|(Exact Sciences)
Mo1599. . . . HIGH-RISK SERRATED LESION DETECTION AT CRC...
(5*)
Mo1600. . . . HOSPITAL LEVEL POLYPECTOMY RATE WITHIN THE...
(2*)
Mo1601. . . . TRENDS IN COLONRECTAL CANCER SCREENING COMPLETION...
(3*)|(2*).(2*).(Exact Sciences Corporation, Madison, WI)
Mo1602. . . . INTERNATIONAL SURVEY OF INTERVAL CANCER AUDIT...
(5*)
Mo1603. . . . ADENOMA AND ADVANCED ADENOMA DETECTION RATE...
(2*)|(7)
Mo1604. . . . COLONOSCOPY FINDINGS FOLLOWING A FECAL IMMUNOCHEMICAL...
(5*)
Mo1605. . . . OLDER ADULTS TOLERANCE OF COLONOSCOPY AND...
(4*)
Mo1606. . . . EXERCISE IS ASSOCIATED WITH LOWER RISK...
(5*)
Mo1607. . . . INFLUENCE OF MASCULINITY ON COLORECTAL CANCER...
(4*)
Mo1608. . . . PERCEPTIONS AND BARRIERS TO COLORECTAL CANCER...
(4*)
Mo1609. . . . HIV PATIENTS WITH LOW CD4 COUNTS...
(5*)
Mo1610. . . . THE ASSOCIATION OF PATIENTS’ PERCEPTION OF...
(5*)
Mo1611. . . . PATIENT NAVIGATION AFTER POSITIVE FECAL IMMUNOCHEMICAL...
(5*)
Mo1612. . . . COLORECTAL CANCER SCREENING OUTREACH PROGRAMS USING...
(2*)
Mo1613. . . . IDENTIFYING BARRIERS TO ADHERENCE TO SURVEILANCE...
(5*)
Mo1614. . . . POST-OPERATIVE HOSPITAL OUTCOMES OF ELECTIVE SURGERY...
(5*)
Mo1615. . . . POTENTIAL CLINICAL UTILITY OF SNP-BASED POLYGENIC...
(5*)
Mo1616. . . . OPTIMAL SMALL POLYP (6-9 MM) RESECTION...
(5*)
Mo1617. . . . WHERE ARE WE TODAY? EFFORTS TO...
(5*)
Mo1618. . . . THE USE OF A QUICK AND...
(5*)
Mo1619. . . . THE SAFETY AND POLYP DETECTION RATE...
(5*)
Mo1620. . . . AGE, NOT GENDER, AFFECTS PATIENT COMPLIANCE...
(5*)
Mo1621. . . . INCREASED FECAL BILE ACID EXCRETION IN...
(2*)
Mo1798. . . . THE SAFETY AND POLYP DETECTION RATE...
(5*)
Mo1788. . . . THE DIAGNOSIS OF CARBOHYDRATE MALABSORPTION BY...
(5*)
Mo1789. . . . A COMPARISON OF LACTULOSE BREATH TESTS...
(5*)
Mo1790. . . . CLINICAL UTILITY AND DIAGNOSTIC YIELD OF...
(5*)
Mo1791. . . . APPLICATION OF NORTH AMERICAN CONSENSUS CRITERIA...
(1*)
Mo1792. . . . EFFECTS OF SHORT-TERM PPI INTAKE ON...
(5*)
Mo1793. . . . ROBUSTNESS OF IBD DISABILITY INDEX (IBDDI)...
(5*)
Mo1794. . . . FECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE...
(5*)
Mo1795. . . . FRAILTY IS ASSOCIATED WITH NATIONWIDE READMISSION...
(5*)
Mo1796. . . . TUMOR NECROSIS FACTOR ANTAGONISTS ARE SUPERIOR...
(5*)
Mo1797. . . . LOSS OF SATB2 EXPRESSION IN COLORECTAL...
(4*)
Mo1798. . . . ACTIVE INFLAMMATORY BOWEL DISEASE, PARTICULARLY FISTULIZING...
(5*)
Mo1799. . . . THE ROLE OF ACOUSTIC RADIATION FORCE...
(5*)
Mo1900. . . . INFLAMMATORY BOWEL DISEASE AND LUNG CANCER...
(5*)
Mo1901. . . . DISEASE BURDEN AND OUTCOMES OF INFLAMMATORY...
(5*)
Mo1902. . . . HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH...
(5*)
Mo1903. . . . CLOSTRIDIODES DIFFICILE INFECTION IS NOT ASSOCIATED...
(5*)
Mo1904. . . . PRE-ADMISSION CANNABIS USE IS POSITIVELY CORRELATED...
(5*)
Mo1905. . . . CROHN’S DISEASE PHENOTYPE AND ACTIVITY ARE...
(5*)
Mo1906. . . . CIRCULATING LEVELS OF VITAMIN D BINDING...
(3*)|(Immundiagnostik AG)
Mo1907. . . . EVALUATION AND COMPARISON OF SAFETY CHARACTERISTICS...
(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1868. EFFICACY AND SAFETY OF SIMULTANEOUS TREATMENT... (5*)
Mo1869. EFFICACY OF DOSE INTENSIFICATION OF USTEKINUMAB... (5*)
Mo1870. ASSESSMENT OF BODY WEIGHT CHANGES IN... (4*)
Mo1871. VEDOLIZUMAB TREATMENT IN PATIENTS WITH REFRACTORY... (5*)
Mo1872. SAFETY AND CLINICAL EFFICACY OF DOUBLE... (5*)
Mo1873. WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE... (5*)
Mo1874. BLOOD T CELL FREQUENCIES PREDICT AND... (4*)
Mo1875. EVALUATION OF BIOLOGIC TREATMENT PATTERNS AMONG... (3*)[(Janssen Scientific Affairs, LLC)
Mo1876. TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR... [Study sponsored by: Janssen Scientific Affairs, LLC, Horsham, PA, USA]
Mo1877. DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE (IBD)... (5*)
Mo1880. USTEKINUMAB DOSE ESCALATION EFFECTIVE IN REAL-WORLD... (5*)
Mo1881. USTEKINUMAB TROUGH LEVEL PREDICTS REMISSION AND... (1*)[(6)
Mo1882. EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN... (5*)
Mo1883. REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS... (3*)[(Takeda)
Mo1884. PREDICTORS OF VEDOLIZUMAB TREATMENT PERSISTENCE IN... (5*)
Mo1885. VEDOLIZUMAB - PERIOPERATIVE INFECTION RATES IN... (5*)
Mo1886. REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB IN CROHN'S... (3*)[The study was financially supported by Takeda.)
Mo1887. IMPACT OF TUMOR NECROSIS FACTOR ALPHA... (2*)[(4)
Mo1888. DECODING DELAYS IN BIOLOGIC AND SMALL... (6*)
Mo1889. CORRELATION OF EARLY INFlixIMAB LEVELS WITH... (3*)[(Janssen Scientific Affairs, LLC)
Mo1890. VEDOLIZUMAB DOSE ESCALATION IMPROVES DISEASE ACTIVITY... (5*)
Mo1891. QUALITY OF TRANSITION CARE IN PEDIATRIC... (5*)
Mo1892. PREDICTING SUB-OPTIMAL TRANSITIONS IN ADOLESCENTS WITH... (5*)
Mo1893. PHENOTYPE AND OUTCOME OF INFLAMMATORY BOWEL... (4*)
Mo1894. APPROACH TO TRANSGENDER AND GENDER NON-CONFORMING... (5*)
Mo1895. POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB... (2*)[(4)
Mo1896. INFliximab SERUM LEVELS DURING INDUCTION PREDICT... (5*)[Kvh has received a research grant from Mundipharma Comm. VA and Celltrion Healthcare Co.)
Mo1897. TOTAL ABDOMINAL COLECTOMIES WITH PROCTECTOMY ARE... (4*)
Mo1898. LOW RISK OF LYMPHOMA IN PEDIATRIC... (2*)
Mo1899. SEX DIFFERENCES IN STATORAL GROWTH IMPAIRMENT... (2*)[(6)
Mo1900. THE INCIDENCE AND CHARACTERISTICS OF VENOUS... (2*)
Mo1901. CHILDREN WITH INFLAMMATORY BOWEL DISEASE EXPERIENCE... (4*)
Mo1902. NON-MONOCYGENIC VERY EARLY ONSET INFLAMMATORY BOWEL... (5*)
Mo1903. HIGH RATES OF SURGERY PERSIST FOR... (5*)
Mo1904. INSURANCE TYPE INFLUENCES INFlixIMAB INITIATION TIME... (5*)
Mo1905. THE ASSOCIATION BETWEEN HIRSCHSPRUNG'S DISEASE AND... (5*)
Mo1906. FEASIBILITY OF THE FIRST PAEDIATRIC RANDOMIZED... (4*)[(3)[Rebiotix Inc. supplied the fecal transplant product for this study.]
Mo1907. REAL WORLD EXPERIENCE WITH USTEKINUMAB IN... (5*)
Mo1908. INFlixIMAB TREATMENT FAILURE IN CHILDREN WITH... (5*)
Mo1909. EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
Mo1910. SAFETY AND EFFICACY OF SUPRATHERAPEUTIC SERUM... (5*)
Mo1911. NORMALISATION OF STOOL CALPROTECTIN- IS IT... (5*)
Mo1912. RISK OF CANCERS IN PEDIATRIC INFLAMMATORY... (5*)
Mo1913. MICROBIOTA-MODIFYING DRUG CSA13-DEPENDENT FECAL METABOLITES EXERT... (2*)[(3)[Merck]
Mo1914. SUPERIOR EFFICACY OF HIGHER VOLUME FRESH... (5*)
Mo1915. IT IS NOT COST EFFECTIVE TO... (5*)
Mo1916. RISING TEMPORAL TRENDS IN THE PREVALENCE... (5*)
Mo1917. CLINICAL BURDEN OF RECURRENT CLOSTRIDIODES DIFFICILE... (3*)[(Ferring Pharmaceuticals Inc.)
Mo1918. VALIDATION OF A PREDICTIVE SCORING TOOL... (5*)
Mo1919. BOWEL ANASTOMOSIS IS ASSOCIATED WITH... (5*)
Mo1920. EPIDEMIOLOGY AND TREND ANALYSIS OF CLOSTRIDIODES... (5*)
Mo1921. COMPARATIVE RISK OF CLOSTRIDIUM DIFFICILE INFECTION... (5*)
Mo1922. ROLE OF SERUM PROCALCITONIN IN PREDICTING... (5*)
Mo1923. RELATIONSHIP BETWEEN ILEOCecal RESECTION AND POSTOPERATIVE... (5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Mo1924. | DIFFERENCES IN THE FECAL MICROBIOME AND... (4*) |
| Mo1925. | THE IMPACT OF APPENDECTOMY IN... (5*) |
| Mo1926. | PROBIOTICS FOR THE PREVENTION OF CLOSTRIDIUM... (5*) |
| Mo1927. | CLOSTRIDIODES DIFFICILE RIBOTYPE AS A PREDICTOR... (5*) |
| Mo1928. | ARE PATIENTS WITH DIFFICILE RIBOTYPE AS A FAILURE IS NOT FINAL: CLINICAL RESPONSE... (5*) |
| Mo1929. | ORALLY ADMINISTERED LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION... (4*) |
| Mo1930. | THE DONOR DOES NOT MATTER IN... (3*) [(This analysis was funded by Rebiotix Inc. (Roseville, MN, USA))]
| Mo1931. | FAILURE IS NOT FINAL: CLINICAL RESPONSE... (3*) [(This analysis was funded by Rebiotix Inc. (Roseville, MN).)] |
| Mo1932. | CRITICAL ROLE FOR TOXIN ACTIVATING CLOSTRIDIUM... (4*) |
| Mo1933. | USE OF PROTON PUMP INHIBITORS DOES... (5*) |
| Mo1934. | IS CELIAC DISEASE ASSOCIATED WITH WORSE... (5*) |
| Mo1935. | IDENTIFYING BARRIERS AMONG PRIMARY CARE PHYSICIANS... (5*) |
| Mo1936. | CLOSTRIDIODES DIFFICILE INFECTION IN PATIENTS WITH... (5*) |
| Mo1937. | ACID-SUPPRESSIVE THERAPY AS A RISK FACTOR... (5*) |
| Mo1938. | SEQUENTIAL FECAL MICROBIOTA TRANSPANTATION FOR FULMINANT... (5*) |
| Mo1939. | TEMPORAL MODULATION OF TCR REPertoire FOLLOWING... (4*) [(2)] |
| Mo1940. | TRENDS IN CLOSTRIDIUM DIFFICILE INFECTION INCIDENCE... (5*) |
| Mo1941. | CLOSTRIDIUM DIFFICILE INFECTION AS A CAUSE... (5*) |
| Mo1942. | OUTCOMES OF CLOSTRIDIODES DIFFICILE INFECTION IN... (5*) |
| Mo1943. | SEQUENTIAL FECAL MICROBIOTA TRANSPLANT BY ENEMA... (2*) [(4)] [(MERCK Pharmaceuticals provided the fidaxomicin for this research for free. No other contributions were made.)] |
| Mo1944. | COMPARING TREATMENT OUTCOMES BETWEEN OPENBIOME FROZEN... (4*) |
| Mo1945. | EFFICACY AND SAFETY OF FECAL MICROBIOTA... (5*) |
| Mo1946. | ASSOCIATION OF FECAL CALPROTECTIN AND RECURRENCE... (4*) |
| Mo1947. | DETECTION OF NON-TOXIGENIC CLOSTRIDIODES... (5*) |
| Mo1948. | OUTCOMES OF INPATIENT FECAL TRANSPLANT ADMINISTRATION... (2*) |
| Mo1949. | ONE AND DONE? EVALUATION OF EFFICACY... (3*) [(Rebiotix Inc.)] |
| Mo1950. | HETEROGENEITY OF RANDOMIZED CONTROLLED TRIALS OF... (3*) [(Ferring Pharmaceuticals)] |
| Mo1951. | REPORTING OF RANDOMIZED CONTROLLED TRIAL METHODOLOGICAL... (3*) [(Ferring Pharmaceuticals)] |
| Mo1952. | PATIENT SEX DOES NOT IMPACT EFFICACY... (5*) |
| Mo1953. | METAGENOMIC ANALYSIS OF HUMAN FECAL VIROME... (2*) |
| Mo1954. | ANAEROBIC FECAL MICROBIOTA TRANSPLANTATION PREPARATIONS ARE... (5*) |
| Mo1955. | HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (6*) [(2)] |
| Mo1956. | ASSOCIATION OF FECAL MICROBIOME WITH RESILIENCE... (2*) |
| Mo1957. | LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN EARLY... (2*) |
| Mo1958. | UTILITY OF A CONSUMER-FRIENDLY PORTABLE HYDROGEN... (3*) [(GOS-based prebiotic provided for free from manufacturer (FrieslandCampina).)] |
| Mo1959. | COMPARISON OF TWO READY-TO-USESUPPLEMENTARY FOODS (RUSF)... (6*) [(3)] [(Arla Foods and the Danish Dairy Research Foundation)] |
| Mo1960. | EFFECT OF FIBER, OSMOLARITY, AND PROTEIN... (2*) |
| Mo1961. | CLINICAL EXPERIENCE OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY... (5*) |
| Mo1962. | COMBINATION OF PUREED DIET CONTAINING GELLING... (5*) |
| Mo1963. | SEX DIFFERENCES IN DIETARY COPPER-FRUCTOSE INTERACTION-INDUCED... (2*) |
| Mo1964. | EFFECTS OF ESTROGEN ON THE EXPRESSION... (2*) [(National Natural Science Foundation of China (NSFC)] |
| Mo1966. | COMMD10 REGULATES ADIPOSE TISSUE MACrophage CONTROL... (6*) |
| Mo1967. | CRANBERRY PROANTHOCYANIDINS ATTENUATE METABOLIC DISORDERS, INCLUDING... (2*) [(4)] |
| Mo1968. | MECHANISM UNDERLYING STIMULATION OF APICAL BoA1... (2*) |
| Mo1969. | OBESITY-INDUCED STIMULATION OF INTESTINAL VILLUS CELL... (2*) |
| Mo1970. | UNIQUE MECHANISM OF STIMULATION OF GLUCOSE... (2*) |
| Mo1971. | PHARMACOTHERAPY FOR OBESITY - TRENDS USING... (5*) |
| Mo1972. | CLASS II+III OBESITY IS AN INDEPENDANT... (5*) |
| Mo1973. | ECTOPIC FAT ACCUMULATION IN THE LIVER... (2*) |
| Mo1974. | WEIGHT REGAIN FOLLOWING BARIATRIC SURGERY: A... (5*) |
| Mo1975. | IMPACT OF BARIATRIC SURGERY ON ESOPHAGEAL... (5*) |
| Mo1976. | UPPER GI SYMPTOMS IN PATIENTS POST-BARIATRIC... (5*) |
| Mo1977. | THE RELATIONSHIP BETWEEN VISUAL PROCESSING IMPAIRMENTS... (5*) |
| Mo1978. | EFFECT OF WEIGHT LOSS ON RETINOCHEMORIAL... (5*) |
| Tu1000. | APPROPRIATENESS OF PROTON PUMP INHIBITORS AFTER... (5*) |

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1001. . . . OUTCOMES OF A PROTON PUMP INHIBITOR... (5*)
Tu1002. . . . PROTON PUMP INHIBITOR (PPI) PRESCRIBING PATTERNS... (5*)
Tu1003. . . . LONG TERM USE OF PPI’S DOES... (5*)
Tu1004. . . . PROVINCIAL PRESCRIBING DATA OF PROTON PUMP... (2*)
Tu1005. . . . USE OF PROTON-PUMP INHIBITORS DURING ANTI-
COAGULATION... (3*)[Daiichi Sankyo Co., Ltd.)
Tu1006. . . . THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE... (5*)
Tu1007. . . . WORLDWIDE INCIDENCE AND PREVALENCE OF METABOLIC... (4*)
Tu1008. . . . A META-ANALYSIS OF THE VALUE OF... (5*)
Tu1009. . . . CONTAMINATION RATE OF REUSABLE PATIENT-READY DUODENOSCOPES... (5*)
Tu1010. . . . HIGHER ADULT-ATTAINED HEIGHT IS AN INDEPENDENT... (4*)
Tu1011. . . . MYTHS ABOUT OBSTRUCTIVE SLEEP APNEA DEBUNKED... (5*)
Tu1012. . . . INSURANCE STATUS AND LEVEL OF EDUCATION... (5*)
Tu1013. . . . YOUNGER PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA HAVE... (5*)
Tu1014. . . . MODULATION OF THE POSITIVE ASSOCIATION BETWEEN... (4*)
Tu1015. . . . GASTRIC ADENOMA INCREASES THE RISK FOR... (5*)
Tu1016. . . . OCCURRENCE OF ESOPHAGEAL ADENOCARCINOMA IN... (3*)
Tu1017. . . . RISK FACTORS IN THE DEVELOPMENT OF... (2*)
Tu1018. . . . INCIDENCE AND MORTALITY RATES OF APPENDICEAL... (5*)
Tu1183. . . . CHARACTERISTICS OF 30-DAY ALL CAUSE READMISSIONS... (5*)
Tu1184. . . . GASTROENTEROLOGISTS AND INFECTIOUS DISEASE PHYSICIANS ARE... (5*)
Tu1185. . . . OLDER AGE AND PRESENCE OF ADVANCED... (3*)[(Research grant from Gilead Sciences)
Tu1186. . . . ECONOMIC BURDEN OF INPATIENT CARE IN... (5*)
Tu1187. . . . IF YOU HAVE TO ASK, YOU... (5*)
Tu1188. . . . MALE GENDER, INSURANCE STATUS, AND RACE/ETHNICITY... (5*)
Tu1189. . . . GASTRIC ELECTRICAL STIMULATOR FOR GASTROPAEsis, A... (5*)
Tu1190. . . . IMPAIRED ACTIVATION OF SYMPATHETIC NERVOUS SYSTEM... (3*)[Tsumura & Co.)
Tu1191. . . . DISTRIBUTION OF DUODENAL TUFT CELLS IS... (2*)
Tu1192. . . . ACTIVATION OF AKT-PI3K SIGNALLING AND miRNA-MEDIATED... (2*)
Tu1193. . . . COQ10 PROTECTS GASTRIC ENDOThelial CELLS AGAINST... (2*)
Tu1194. . . . EFFECT OF AMINO ACID-BASED ORAL REHYDRATION ON THE... (2*)
Tu1195. . . . ELUCIDATION OF THE MECHANISMS BY WHICH... (2*)
Tu1196. . . . EFFECT OF HELICOBACTER PYLORI ON THE... (2*)
Tu1197. . . . EFFECT OF AMINO ACID-BASED ORAL REHYDRATION... (4*)[(3)][Entrinsic Health Solutions Inc. (fund based on a research agreement with the University of Florida)]
Tu1198. . . . PROPRIETARY BLEND OF AMINO ACIDS DECREASED... (4*)
Tu1199. . . . INTEGRATIVE ANALYSIS OF DIFFERENTIAL lncRNA/MRNA EXPRESSION... (2*)
Tu1200. . . . BILE REFLUX PROMOTES GASTRIC INTESTINAL METAPLASIA... (2*)[(4)
Tu1201. . . . EPITHELIAL TO MESENCHYMAL TRANSITION IN RESPONSE... (2*)[(6)]
Tu1202. . . . MITOCHONDRIAL DYSFUNCTION ALTERS METABOLISM OF HEPATIC... (2*)[(4)
Tu1203. . . . M6A MODIFICATION CONTROLS THE AUTOPHAGIC RESPONSE... (5*)
Tu1204. . . . BETTER UNDERSTANDING OF MENETRIER’S DISEASE AND... (4*)[(7)
Tu1205. . . . OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING... (2*)
Tu1206. . . . EFFECT OF BACILLUS SUBTILIS AND ENTEROCOCCUS... (2*)
Tu1207. . . . APPLICATION OF A WHOLE BLOOD PHARMACODYNAMIC... (3*)[Gilead Sciences, Inc.)
Tu1208. . . . NEUROPEPTIDE W ALLEVIATES HEPATORENAL OXIDATIVE DAMAGE... (4*)
Tu1209. . . . CHIRALLY-MODIFIED LARAZOTIDE COMPOUND ANALOG #6 FACILITATES... (3*)[Funding from Innovate Biopharmaceuticals, Inc. 8480 Honeycutt Rd #120, Raleigh, NC 27615]
Tu1210. . . . GENOME-WIDE TRANSCRIPTONAL RESPONSES TO ASPIRIN WITH... (2*)[(4)
Tu1211. . . . AN ANTISENSE OLIGONUCLEOTIDE FOR MICRORNA-24-3P EXHIBITS... (2*)[(6]
Tu1212. . . . RELEVANT HETEROGENEITY IN MISMATCH REPAIR DEFICIENT... (2*)[(6]
Tu1213. . . . USE OF BIOLOGICS AND IMMUNOMODULATORS DO... (5*)
Tu1214. . . . THE SAFETY, EFFICACY, AND OUTCOMES FOR... (5*)
Tu1215. . . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)
Tu1216. . . . CLINICAL, ENDOSCOPIC AND HISTOLOGICAL OUTCOMES AMONG... (5*)
Tu1217. . . . THE EFFICACY OF LOWER ENDOSCOPIC SURVEILLANCE... (5*)
Tu1218. . . . RELATIONSHIP BETWEEN GERMLINE MUTATION, PHENOTYPE AND... (2*)
Tu1219. . . . THE EFFICACY OF UPPER ENDOSCOPIC SURVEILLANCE... (5*)
Tu1220. . . . IMPLEMENTATION AND OUTCOMES OF A NURSE-
ADMINISTERED... (4*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1221. . . . CLINICOPATHOLOGICAL ANALYSIS OF SIX FAMILIES WITH... (5*)
Tu1222. . . . MALIGNANCY RISK IN FAMILIAL ADENOMATOUS POLYPS... (5*)
Tu1223. . . . FACTORS THAT AFFECT PENETRANCE OF COLORECTAL... (5*)
Tu1224. . . . ADVANCED COLORECTAL POLYPS AS A WAY... (5*)
Tu1225. . . . MUTYH ASSOCIATED POLyps AS A WAY... (5*)
Tu1226. . . . SMALL INTESTINAL INVOLVEMENT IN FAMILIAL ADENOMATOUS... (5*)
Tu1227. . . . CCL11 EXACERBATES COLITIS VIA MODULATION OF... (2*)
Tu1228. . . . INTERLEUKIN-38 IS ELEVATED IN INFLAMMATORY BOWEL... (2*)
Tu1229. . . . AUTOTAXIN STIMULATES LPA2 RECEPTOR IN MACROPHAGES... (2*)
Tu1230. . . . EXAMINATION OF NEW PREDICTIVE FACTORS USING... (1*)
Tu1232. . . . NEW INSIGHTS INTO THE ROLE OF... (2*)
Tu1233. . . . REPAIR RECEPTOR CD74 IS NECESSARY FOR... (2*)
Tu1234. . . . SACRAL NERVE STIMULATION INHIBITS THE MAPK/NF-kB... (2*)
Tu1235. . . . TNF RECEPTOR 1 PROMOTES EARLY-LIFE IMMUNITY... (2*)
Tu1236. . . . DANGEROUS LIAISONS: CO-HOUSING WITH Mlf-/- MICE... (4*)
Tu1237. . . . ADENOSINE A3 RECEPTOR REGULATES INTESTINAL EPITHELIAL... (2*) (National Natural Science Foundation of Guangdong Province, China (no. 2018A030313772) and Science and Technology Innovation Commission of Shenzhen Municipality, China (no. JCY201703071548519)).
Tu1238. . . . SERUM PCSK9 AS NOVEL BIOMARKER FOR... (5*)
Tu1239. . . . CIAP INHIBITION WITH SMAC MIMETICS IN... (2*) (4)
Tu1240. . . . SALIDROSIDE AMELIORATES EXPERIMENTAL COLITIS BY ATTENUATING... (5*)
Tu1241. . . . SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING... (5*)
Tu1242. . . . INTERLEUKIN-34 DEFICIENCY EXACERBATED EXPERIMENTAL DSS-INDUCED COLITIS... (2*)
Tu1243. . . . METALLOPROTEINASE 8 (MMP-8) DEFICIENCY RENDERS... (4*)
Tu1244. . . . PN-943, AN ORAL α4β7 INTEGRIN ANTAGONIST... (3*)(Protagonist Therapeutics)
Tu1245. . . . TL1A EXCERBATED CHRONIC EXPERIMENTAL COLITIS THROUGH... (2*) (National Natural Science Foundation of China)
Tu1246. . . . COLONIC MUCOSAL KINASE ACTIVITY, CYTOKINE AND... (3*) (The research presented in this abstract was funded by an unrestricted investigator initiated research grant of Pfizer (ASPIRE 2017). The funding party did not have any role in the design, conduct, analyses or reporting of the study.)
Tu1247. . . . DELTA OPIOID RECEPTOR SIGNALING IN ENDOSONES... (6*)
Tu1248. . . . THE ROLE OF PAI-1 IN THE... (2*) (European Union Funds, Innovative Economy Programme)
Tu1249. . . . THE ROLE OF INFLAMMATION AND MALNUTRITION... (2*) (European Union Funds, Innovative Economy Programme)
Tu1250. . . . INTESTINAL HELMINTHS PROMOTE ALLOTOLEANCE AND REGULATE... (2*)
Tu1251. . . . MAST CELLS ARE SIGNIFICANTLY ACTIVATED IN... (3*) (Allakos, Inc.,)
Tu1252. . . . DAMP MOLECULES NMI AND IFP35 MAY... (2*)
Tu1253. . . . RANDOMIZED CONTROLLED TRIAL OF COGNITIVE BEHAVIORAL... (6*)
Tu1254. . . . GLYCANS ARE DUAL REGULATORY ELEMENTS IN... (2*) (4)
Tu1255. . . . MICROBIOTA AND VIRUENCE FACTORS ASSOCIATED WITH... (6*)
Tu1256. . . . CHROMOGRAVANIN A REGULATES THE GUT MICROBIOTA COMPOSITION... (2*)

Abstract Funding Source Key

* = Primary Source
1) = Clinical Practice Funds 2) = Government (e.g. NIH, CDC, Health Ministry, etc.) 3) = Industry or Commercial Entity 4) = Institutional Funds 5) = No Study Funding 6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) 7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1277. PERIPHERAL GASTROINTESTINAL CIRCADIAN DISRUPTION ASSOCIATED WITH (3*)(Funded by Pfizer 2019 Inflammatory Bowel Disease Competitive Grant Program)

Tu1297. ENDOPLASMIC RETICULUM STRESS-MEDIATED MACROPHAGE-TO-MYOFIBROBLAST TRANSITION CONTRIBUTES. (2*)

Tu1279. FLAGELLIN-INDUCED CASPASE-1 ACTIVATION OF HUMAN INTESTINAL (2*)

Tu1280. SUCCESSFUL ESTABLISHMENT OF DECELLULARIZED INTESTINAL (2*)

Tu1281. PROTEINS CITRULLINATION AND CROHN'S DISEASE: PAD4. (5*)

Tu1283. PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL... (3*)(Morphic Therapeutic)

Tu1284. PROTECTIVE EFFECT OF SAFFRON IN MOUSE... (2*)

Tu1285. CROHN'S DISEASE ILEAL B3 WITH STENOSIS... (7*)

Tu1286. HYDROGEN PEROXIDE-MEDIATED CROSSTALK OF EPITHELIAL DUOX2... (2*) (4)

Tu1287. MUCUS FROM HUMAN STEM CELLDERIVED COLONOIDS... (5*)

Tu1288. NEUTROPHILS REGULATE PROGRESSION OF COLON CANCER... (6*) (7)

Tu1289. MACROPHAGE CYSTATHIONINE GAMMA-LYASE CONTRIBUTES TO EXPERIMENTAL... (2*) (6)

Tu1290. PANETH CELL DEFECST IN CROHN'S DISEASE... (2*) (6)

Tu1291. DYSBIOSIS AND GOBLET CELLS DEPLETION TRIGGERS... (2*) (4)

Tu1292. EFFICACY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE... (4*)

Tu1293. EPITHELIAL LONG NON-CODING RNA REGULATE IN-CIS... (2*)

Tu1294. EXOGENOUS L-FUCOSE PROTECTS THE INTESTINAL MUCOSAL... (2*)

Tu1295. GRAPHENE OXIDE AGGRAVATED DEXTRAN SULFATE SODIUM-INDUCED... (2*)

Tu1296. BILE ACIDS DELAY THE WOUND HEALING... (5*)

Tu1297. GUT MICROBIAL META-ANALYSIS OF INFLAMMATORY AND... (2*)

Tu1298. LOW ABUNDANCE OF LACTOCOCCUS LACTIS IN... (5*)

Tu1299. HELICOBACTER_BILIS MAY PLAY A ROLE IN... (5*)

Tu1300. SULFATE-REDUCING BACTERIA INCREASE EXPRESSION OF PRO-INFLAMMATORY... (4*)

Tu1301. ANTI-INFLAMMATORY EFFECT OF FAECALIBACTERIUM PRAUSNITZII ON... (2*)

Tu1302. INVESTIGATING THE ROLE OF BIOACTIVES PRODUCED... (4*)

Tu1303. INTESTINAL MICROBIOTA CHANGES ACCORDING TO DISEASE... (5*)

Tu1304. STREPTOCOCCUS MOBILIS-LIKE BACTERIAL GASTROPATHY: IS THE... (5*)

Tu1305. FECAL BACTERIOPHAGES INCREASED THE GROWTH OF... (6*)

Tu1306. CARBON MONOXIDE IS AN IMPORTANT FACTOR... (2*)

Tu1307. MICROBIOTA-TLR2 MEDIATED NESTIN-DERIVED ENTERIC NEUROGENESIS IN... (2*)

Tu1308. NEURAL NETWORK ENHANCEMENT AND GLIAL HYPERPLASIA... (5*)

Tu1310. ALTERATIONS IN EPICEPITHELIAL MODIFIERS IN GASTRIC... (4*) (6)

Tu1311. THE EFFECT OF ACUTE STRESS DISORDER... (5*)

Tu1312. NERVE GROWTH FACTOR PRODUCED BY ENTERIC... (5*)

Tu1313. ESTIMATING THE GLOBAL PREVALENCE OF BARRETT'S... (5*)

Tu1314. REFLUX ESOPHAGITIS IS ASSOCIATED WITH WORSE... (5*)

Tu1315. ADHERENCE TO QUALITY INDICATORS IN THE... (5*)

Tu1316. ONLY 65% OF INDIVIDUALS MEETING THE... (2*)

Tu1317. HEALTHCARE UTILIZATION BURDEN FOR GASTROESOPHAGEAL REFLUX... (3*)(IBM Truven Commercial Claims & Encounter (patient de-identified) database access using Ethicon data license)

Tu1318. EFFICACY OF VONOPRAZAN IN PATIENTS WITH... (1*)

Tu1319. THE EPIDEMIOLOGY OF BARRETT'S ESOPHAGUS IN... (5*)

Tu1320. ASSOCIATION BETWEEN OBSTRUCTIVE SLEEP APNEA AND... (5*)

Tu1321. VONOPRAZAN 10 OR 20 MG DEMONSTRATED... (3*)(Funded by Takeda Development Center Asia Pte Ltd, Singapore.)

Tu1322. EFFICACY OF UPPER ESOPHAGEAL SPHINTER ASSIST... (7*)

Tu1323. HIGH QUALITY OF LIFE IMPAIRMENT IN... (5*)

Tu1324. COMBINED HYPOPHYRANGEL-ESOPHAGEAL IMPEDANCE-PH MONITORING: A PILOT... (5*)

Tu1325. ESOPHAGEAL FUNCTION AND REFLUX EVALUATIONS IN... (5*)

Tu1326. GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF... (5*)

Tu1327. OBJECTIVE MEASURES OF GASTROESOPHAGEAL REFLUX ARE... (5*)

Tu1328. A SUBJECTIVE DIAGNOSIS OF GERD IS... (5*)

Tu1329. PRE-TRANSPLANT REFLUX TESTING DEMONSTRATES HIGH PREVALENCE... (5*)

Tu1330. THE PREDICTIVE VALUE OF FULL COLUMN... (5*)

Tu1331. PRE-TRANSPLANT GERD INCREASES POST-LUNG TRANSPLANT MORTALITY... (5*)

Tu1332. EFFICACY OF A HIGH-DOSE PROTON PUMP... (5*)

Tu1333. CORRELATION OF GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1334. ... A STUDY ON THE EFFECT OF... (5*)

Tu1335. ... SLEEP DISORDERS ARE VERY COMMON IN... (5*)

Tu1336. ... REFLUX MONITORING WITH IMPEDANCE-PHMETRY: NEW SET... (4*)

Tu1337. ... ESOPHAGEAL CONTRACTILE SEGMENT IMPEDANCE (CSI) FROM... (5*)

Tu1338. ... NOVEL ESOPHAGEAL BASELINE IMPEDANCE METRICS CORRELATE... (5*)

Tu1339. ... PATIENTS WITH BORDERLINE ACID EXPOSURE TIME... (5*)

Tu1340. ... MUCOSAL INTEGRITY TESTING OR PH MONITORING:... (5*)

Tu1341. ... SALIVARY PEPsin AS A BIOMARKER OF... (5*)

Tu1342. ... ABNORMAL BOLUS REFLUX WITH NORMAL ACID... (5*)

Tu1343. ... REFLUX PROFILES IN POST-BARIATRIC SURGERY PATIENTS... (5*)

Tu1345. ... THE DIAGNOSTIC USEFULNESS OF E-CADHERIN AND... (1*)

Tu1346. ... DISTAL MEAN NOCTURNAL BASAL IMPEDANCE AS... (5*)

Tu1347. ... ESTABLISHING AN OPTIMAL CUT-OFF FOR DISTAL... (5*)

Tu1348. ... PEPsin AND BILE ACIDS DETECTION IN... (5*)

Tu1349. ... CLINICAL UTILITY OF BASELINE IMPEDANCE MEASURED... (5*)

Tu1350. ... USEFULNESS OF MEAN NOCTURNAL BASELINE IMPEDANCE... (5*)

Tu1351. ... DIAGNOSTIC ACCURACY OF THE ESOPHAGO-GASTRIC JUNCTION... (5*)

Tu1352. ... MUCOSAL IMPEDANCE ENABLES ACCURATE DETECTION OF... (7*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1394. . . . LOWER ESOPHAGEAL SPHINCTER AND PERISTALTIC PRESSURES... (5*)
Tu1395. . . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS... (5*)
Tu1396. . . . BOLUS TRANSIT IN ESOPHAGOGASTRIC JUNCTION OUTFLOW... (5*)
Tu1397. . . . CLINICAL, PSYCHOLOGICAL AND MANOMETRIC CHARACTERISTICS OF... (5*)
Tu1398. . . . DELAYED ESOPHAGOGASTRIC JUNCTION RELAXATION AND ELEVATED... (5*)
Tu1399. . . . HIGH PROPORTIONS OF OBSTRUCTIVE PHENOTYPES WITHIN... (5*)
Tu1400. . . . ABSENCE OF CONTRACTION RESERVE IN SEVERE... (5*)
Tu1401. . . . EFFECT OF PERORAL ENDOSCOPIC MYOTOMY FOR... (5*)
Tu1402. . . . UNINTENDED MYOTOMY OF THE CRURAL DIAPHRAGM... (5*)
Tu1403. . . . ACHALASIA, HYPERCONTRACTILE AND SPASTIC ESOPHAGEAL MOTILITY... (1*)
Tu1404. . . . CIRCADIAN ALTERATIONS OF ESOPHAGEAL CONTRACTILITY IN... (1*)
Tu1405. . . . ESOPHAGEAL AND GASTRIC MOTILITY ARE RELATED... (1*)
Tu1406. . . . VISCOS BOLUS AND TRENDELENBURG POSITION ALLOW... (2*)
Tu1407. . . . EFFECTS OF EXTERNAL NEURAL STIMULATION ON... (2*)
Tu1408. . . . IMPEDANCE SIGNALS RECORDED DURING ESOPHAGEAL MANOMETRY... (2*)
Tu1409. . . . IDENTIFYING CLINICAL PHENOTYPES OF HYPERCONTRACTILE ESOPHAGEAL... (2*)
Tu1410. . . . INFLUENCE OF PRUCALOPRIDE ON SILDENAFIL-INDUCED INHIBITION... (4*)
Tu1411. . . . LEG ELEVATION MANEUVER IMPROVES MEASURING CONTRACTILE... (4*)
Tu1412. . . . IMPACT OF INEFFECTIVE ESOPHAGEAL MOTILITY ON... (4*)
Tu1413. . . . ESOPHAGEAL ACID REFLUX BURDEN IN GERD... (4*)
Tu1414. . . . ARRHYTHMIC ESOPHAGEAL DEGLUTITION: OVEREXPRESSION AND... (2*)
Tu1415. . . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)
Tu1416. . . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)
Tu1417. . . . ESOPHAGOGASTRIC JUNCTION-CONTRACTILE INTEGRAL FOR CLINICAL ASSESSMENT... (2*)
Tu1418. . . . THE INFLUENCE OF CRURAL DIAPHRAGM ON... (5*)
Tu1419. . . . UTILITY OF A NEW AUTOMATED ANALYSIS... (5*)
Tu1420. . . . ESOPHAGOGASTRIC JUNCTION MORPHOLOGY AND CONTRACTILE INTEGRAL... (5*)
Tu1421. . . . INCREASED INCIDENCE OF ALTERED COUPING OF... (2*)
Tu1422. . . . ABNORMALITIES OF DEGLUTITIVE PHARYNGEAL BIOMECHANICS NEGATIVELY... (2*)
Tu1423. . . . EVALUATION OF DYSPHAGIA SYMPTOM ASSOCIATION WITH... (2*)
Tu1424. . . . HIGH-RESOLUTION IMPEDANCE MANOMETRY PARAMETERS MAY IMPROVE... (2*)
Tu1425. . . . HIGH RESOLUTION MANOMETRY IN UPRIGHT POSITION... (5*)
Tu1426. . . . CHARACTERIZING THE PROXIMAL ESOPHAGEAL SEGMENT IN... (5*)
Tu1427. . . . ACHALASIA PHENOTYPE IS ASSOCIATED WITH PREDICTABLE... (5*)
Tu1428. . . . EVALUATION OF INCREASED INCIDENCE OF DYSFUNCTION... (5*)
Tu1429. . . . THE CONVOLUTIONAL NEURAL NETWORK ACCURATELY IDENTIFIES... (5*)
Tu1430. . . . ESOPHAGEAL OUTFLOW RESISTANCE IN PARKINSON'S DISEASE... (5*)
Tu1431. . . . RAPID DRINKING CHALLENGE EVALUATED BY HIGH-RESOLUTION... (5*)
Tu1432. . . . THE VALUE OF REPEAT MANOMETRIC TESTING... (5*)
Tu1433. . . . REGIONAL PHARYNGEAL CONTRACTILE INTEGRALS (PHCI)... (5*)
Tu1434. . . . SUPRAGASTRIC BELCHING INDUCE RE-REFLUX DURING REFLUX... (4*)
Tu1435. . . . IMPLEMENTATION AND ANALYSIS OF A 2-YEAR... (5*)
Tu1436. . . . PERISTALTIC FUNCTION BUT NOT INTEGRATED SPHINCTER... (5*)
Tu1437. . . . DEMOGRAPHIC AND GASTROINTESTINAL SYMPTOM CHARACTERISTICS OF... (4*)
Tu1438. . . . ESOPHAGEAL DYSFUNCTION IS PREVALENT FOLLOWING LUNG... (5*)
Tu1439. . . . EVALUATING THE IMPACT OF POSITION, VOLUME... (5*)
Tu1440. . . . THE CLINICAL SYMPTOMS AND MANOMETRIC CHARACTERISTICS... (1*)
Tu1441. . . . PREVALENCE AND CLINICAL SIGNIFICANCE OF ESOPHAGEOGASTRIC... (5*)
Tu1442. . . . THE EFFECTS OF A NOVEL VISCOS... (6*)
Tu1443. . . . FACTORS ASSOCIATED WITH HIATAL HERNIA IN... (5*)
Tu1444. . . . THE ROLE OF ABDOMINAL CT SCAN... (5*)
Tu1445. . . . ROLE OF BROAD-SPECTRUM ANTIBIOTICS IN THE... (5*)
Tu1446. . . . CHARACTERIZATION OF PATIENTS WHO SHOULD RECEIVE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Tu1449. . . . GASTROINTESTINAL INFECTIONS IN CANCER PATIENTS WITH... (5*)</th>
<th>Tu1466. . . . PREVALENCE OF INADEQUATE SEROLOGICAL CELIAC DISEASE... (5*)</th>
<th>Tu1587. . . . CELIAC DISEASE ASSOCIATED WITH HIGHER RISK... (5*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tu1450. . . . COMBINATION IMMUNOSUPPRESSIVE THERAPY POST-SOLID ORGAN TRANSPLANTATION... (5*)</td>
<td>Tu1467. . . . INCREASED ENERGY EXPENDITURE AND REDUCED EXERCISE... (5*)</td>
<td>Tu1588. . . . PROSPECTIVE STUDY OF RENAL ULTRASOUND AND... (4*)</td>
</tr>
<tr>
<td>Tu1451. . . . THE DIAGNOSTIC VALUE OF FECAL CALPROTECTIN... (4*)</td>
<td>Tu1468. . . . EXOCRINE PANCREATIC INSUFFICIENCY IS COMMON IN... (5*)</td>
<td>Tu1589. . . . PREDICTIVE FACTORS OF INTRA ABDOMINAL HYPERTENSION... (5*)</td>
</tr>
<tr>
<td>Tu1452. . . . ATYPICAL ENTEROPATHOGENIC E. COLI (EPEC) ISOLATES... (2*)</td>
<td>Tu1469. . . . CHARACTERISTICS AND MATERNAL-FETAL OUTCOMES OF PREGNANT... (5*)</td>
<td>Tu1590. . . . TRENDS IN THE MANAGEMENT OF ACUTE... (5*)</td>
</tr>
<tr>
<td>Tu1453. . . . COMPARISON OF ENDOSCOPIC FEATURES, CLINICAL OUTCOME... (5*)</td>
<td>Tu1470. . . . INCREASED RISK OF CELIAC DISEASE IN... (5*)</td>
<td>Tu1591. . . . RED CELL DISTRIBUTION WIDTH (RDW) TO... (5*)</td>
</tr>
<tr>
<td>Tu1454. . . . MULTIPLEX GASTROINTESTINAL PATHOGEN PANELS ARE ASSOCIATED... (5*)</td>
<td>Tu1471. . . . CELIAC-ASSOCIATED LIVER DYSFUNCTIONS: PREVALENCE AND CLINICOPATHOLOGIC... (5*)</td>
<td>Tu1592. . . . OBESITY AND NECROTIZING PANCREATITIS: INCIDENCE... (5*)</td>
</tr>
<tr>
<td>Tu1455. . . . WHEAT AMYLASE TRYPsin INHIBITORS (ATIS): ANALYSES... (4*)</td>
<td>Tu1472. . . . FACING THE UNKNOWN: NAVIGATING CELIAC DISEASE... (5*)</td>
<td>Tu1593. . . . TRANSGASTRIC DEBRIDEMENT IN NECROTIZING PANCREATITIS: ENDOSCOPIC... (5*)</td>
</tr>
<tr>
<td>Tu1456. . . . MAST CELL-NERVE INTERACTIONS CORRELATE WITH BLOATING... (4*)</td>
<td>Tu1473. . . . NON-CELIAC GLUTEN SENSITIVITY CAN BE DIFFERENTIATED... (4*)</td>
<td>Tu1594. . . . OVER 50% OF PATIENTS WITH ABDOMINAL... (5*)</td>
</tr>
<tr>
<td>Tu1457. . . . POTENTIAL ROLE OF TCRγδ+ INTRAEPITHELIAL LYMPHOCYTES... (4*)[(6)]</td>
<td>Tu1474. . . . CAN HUMAN LEUKOCYTE ANTIGEN TYPING DIFFERENTIATE... (5*)</td>
<td>Tu1595. . . . THE PANCREATITIS ACTIVITY SCORING SYSTEM PREDICTS... (5*)</td>
</tr>
<tr>
<td>Tu1458. . . . IMPACT OF GERMINATION ON GLUTEN, AMYLASE... (4*)</td>
<td>Tu1475. . . . SMALL BOWEL MUCOSA ATROPHY IN A... (4*)</td>
<td>Tu1596. . . . PRESENCE OF NECROSIS INCREASES THE ODDS... (5*)</td>
</tr>
<tr>
<td>Tu1459. . . . SYMPTOMATIC AND ASYMPTOMATIC CELIAC DISEASE PATIENTS... (5*)</td>
<td>Tu1476. . . . THE SIGNIFICANCE AND CLINICAL OUTCOME OF... (5*)</td>
<td>Tu1597. . . . PRIOR NSAID USE IS ASSOCIATED WITH... (5*)</td>
</tr>
<tr>
<td>Tu1460. . . . BIFIDOBACTERIUM INFANTIS NLS-SS SHIFTS FECAL MICROBIOTA... (5*)</td>
<td>Tu1477. . . . LOW QUALITY DIET AND FOOD PATTERNS... (4*)[(2)]</td>
<td>Tu1598. . . . INCIDENCE AND PREVALENCE OF ACUTE AND... (5*)</td>
</tr>
<tr>
<td>Tu1461. . . . INCREASED ERYTHROCYTE-BOUND IMMUNOGLOBULIN COMPLEXES IN CELIAC... (4*)</td>
<td>Tu1579. . . . THIRTY-DAY READMISSION AMONG PATIENTS WITH ALCOHOLIC... (5*)</td>
<td>Tu1599. . . . NATIONWIDE TRENDS IN CHOLECYSTECTOMY RATES AMONG... (5*)</td>
</tr>
<tr>
<td>Tu1462. . . . INTERLEUKIN(IL) 1-IL-6, TUMOR NECROSIS FACTOR #NAME?... (4*)</td>
<td>Tu1580. . . . ACUTE PANCREATITIS IN HISPANICS: SEVERITY, LENGTH... (5*)</td>
<td>Tu1600. . . . QUALITY GAPS IN MANAGEMENT OF ACUTE... (5*)</td>
</tr>
<tr>
<td>Tu1463. . . . IN-VIVO ASSESSMENT OF CELIAC CLINICAL FORMULATION... (3*)[(Innovate Biopharmaceuticals)]</td>
<td>Tu1581. . . . BEYOND THE INDEX HOSPITALIZATION: CAN THE... (4*)</td>
<td>Tu1601. . . . OUTCOMES OF 126 HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS... (5*)</td>
</tr>
<tr>
<td>Tu1464. . . . NEO-EPITOPE TISSUE TRANSGlutaminase IS THE BEST... (3*)</td>
<td>Tu1582. . . . ACUTE PANCREATITIS IN PATIENTS WITH END... (5*)</td>
<td>Tu1602. . . . ACUTE PANCREATITIS WITH COMORBID ANXIETY AND... (5*)</td>
</tr>
<tr>
<td>Tu1465. . . . SEROREACTIVITY TO FIRMICUTES FLAGELLIN PRECEDES THE... (4*)</td>
<td>Tu1583. . . . EPIDEMIOLOGY AND RISK OF PANCREATITIS IN... (5*)</td>
<td>Tu1603. . . . ASSOCIATION BETWEEN FASTING BREATH HYDROGEN LEVELS... (5*)</td>
</tr>
<tr>
<td></td>
<td>Tu1584. . . . OUTCOMES OF OPEN VS. LAPAROSCOPIC VS... (5*)</td>
<td>Tu1604. . . . DEVELOPMENT OF AN EUS CONVOLUTIONAL NEURAL... (5*)</td>
</tr>
<tr>
<td></td>
<td>Tu1585. . . . NATIONWIDE TRENDS, PREVALENCE, DISPARITIES, AND OUTCOMES... (5*)</td>
<td>Tu1605. . . . ROLE OF ENDOSCOPY IN PATIENTS WITH... (5*)</td>
</tr>
<tr>
<td></td>
<td>Tu1586. . . . PROPHYLACTIC CYSTGASTROSTOMY PREVENTS LATE PERIPANCREATIC FLUID... (5*)</td>
<td>Tu1606. . . . QUANTITATIVE EVALUATION OF TREATMENT EFFECT USING... (5*)</td>
</tr>
</tbody>
</table>

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1607. . . . CLINICAL USEFULNESS OF FDG-PET/CT FOR DIFFERENTIATION... [5*]
Tu1608. . . . THE COMBINATION OF INTRAVENOUS FLUID AND... (5*)
Tu1609. . . . METHODOLOGY OF PANCREATIC JUICE COLLECTION FROM... (5*)
Tu1610. . . . ENDOSCOPIC ULTRASOUND (EUS)-GUIDED DRAINAGE OF PANCREATIC... (5*)
Tu1611. . . . PREVALENCE TREND, HOSPITAL UTILIZATION, AND PREDICTORS... (5*)
Tu1612. . . . FOXA2 EXPRESSION IS SIGNIFICANTLY ASSOCIATED WITH... (4*)
Tu1613. . . . GERMLINE RET AND MAPT (TAU) MUTATIONS... (5*)
Tu1614. . . . GENE CO-EXPRESSION NETWORK ANALYSIS OF PRECURSOR... (4*)[1]6 (5*)
Tu1615. . . . RISK FACTORS ASSOCIATED WITH FATTY PANCREAS... (5*)
Tu1616. . . . FAMILIAL PANCREATIC NEUROENDOCRINE TUMORS – ROLE... (5*)
Tu1617. . . . RNASEQ ANALYSIS OF SEVENTEEN PANCREATITIS TPIAT... (2*)
Tu1618. . . . VITAMIN D/VITAMIN D RECEPTOR AXIS DYSFUNCTION... (2*)
Tu1619. . . . WATER AVOIDANCE STRESS PROMOTES MOUSE PANCREATIC... (4*)
Tu1621. . . . ALTERED COMPOSITION OF GUT MICROBIOTA IN... (2*)[4]
Tu1634. . . . THE COMPLICATION RATE AND DOWNSTREAM PROCEDURE... (5*)[3 of the authors are Medtronic employees. This was a Medicare database analysis. Medtronic employees assisted in converting clinical procedures instructed by physicians to the appropriate CPT and ICD-10 codes and in completing the SAS programming to extra]
Tu1635. . . . YIELD OF RADIOLOGIST RECOMMENDATION FOR HEPATOLOGY... (5*)
Tu1636. . . . HYPOXIC HEPATITIS IS UNDERRECOGNIZED AND UNDERDIAGNOSED... (5*)
Tu1637. . . . LONGITUDINAL HCV CARE OF PREGNANT PATIENTS... (5*)
Tu1638. . . . USEFULNESS OF ANTI-LKM-1 ANTIBODY TESTING IN... (5*)
Tu1639. . . . EPIDEMIOLOGY AND RISK FACTORS OF CHOLANGIOCARCINOMA... (5*)
Tu1640. . . . OVEREXPRESSION OF FOXM1 PREDICTS POORER SORAFENIB... (4*)[2][3](Ministry of Science and Technology, Taiwan Kaohsiung Medical University, Taiwan)
Tu1641. . . . OUTCOMES OF PATIENTS WITH HILAR CHOLANGIOCARCINOMA... (5*)
Tu1642. . . . QUANTITATIVE HEPATIC FUNCTION PREDICTS TIME TO... (5*)
Tu1643. . . . SEX, RACIAL AND ETHNIC DISPARITIES IN... (5*)
Tu1644. . . . REVEALING THE MOLECULAR DRIVERS OF HEPATOBLASTOMA... (2*)
Tu1645. . . . MIR-125B-5P CONFLICTS RESISTANCE TO SORAFENIB BY... (5*)
Tu1646. . . . INCIDENCE AND MORTALITY TRENDS OF INTRAHEPATIC... (5*)
Tu1647. . . . LONG-TERM OUTCOMES OF SELF-EXPANDABLE METAL... (5*)
Tu1648. . . . PROGNOSTIC IMPACT OF TYROSINE KINASE INHIBITOR... (1*)
Tu1649. . . . MECHANISTIC STUDY OF COPPER-STIMULATED PROGRESSION OF... (5*)
Tu1650. . . . EPIDEMIOLOGY AND PREVALENCE OF GALLBLADDER CANCER... (5*)
Tu1651. . . . OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA... (5*)
Tu1652. . . . PREVALENCE AND MANAGEMENT OF GALLBLADDER CANCER... (5*)
Tu1653. . . . THERAPEUTIC EFFICACY AND SAFETY OF LENVATINIB... (1*)
Tu1753. . . . ASSOCIATIONS BETWEEN MOOD DISORDERS AND GASTRIC... (5*)
Tu1754. . . . IMPAIRED DUODENAL MUCOSAL BARRIER FUNCTION CAUSES... (5*)
Tu1755. . . . NATIONAL TRENDS IN READMISSION FOR CANNABINOIDS... (5*)
Tu1756. . . . SMALL BOWEL TRANSIT ABNORMALITIES IN PATIENTS... (5*)
Tu1757. . . . EFFECTS OF 4-WEEK CURCUMINOID ON CLINICAL... (2*)
Tu1758. . . . EFFICACY OF TOPIRAMATE AS PROPHYLAXIS IN... (5*)
Tu1759. . . . EFFECT OF PROTON PUMP INHIBITOR ON... (5*)
Tu1760. . . . DUODENAL BILE SALTS AND MUCOSAL CHANGES... (4*)
Tu1761. . . . DEVELOPMENT OF A MOTILITY FAIRLY INDEX... (4*)
Tu1762. . . . IMPACT OF SLEEP IMPROVEMENT ON GASTROINTESTINAL... (5*)
Tu1763. . . . A RECURRING COST OF CARE: EMERGENCY... (5*)
Tu1764. . . . NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)
Tu1765. . . . FUNCTIONAL DYSPEPSIA AND NON-CELIAC WHEAT SENSITIVITY... (4*)[2]
Tu1766. . . . DISCRIMINATION OF PATIENTS WITH CHRONIC NAUSEA... (5*)
Tu1768. . . . EFFICACY OF SUMATRIPTAN AS ABORTIVE TREATMENT... (5*)
Tu1769. . . . HALOPERIDOL USE IN THE EMERGENCY DEPARTMENT... (5*)
Tu1770. . . . RUMINATION SYNDROME: ASSESSMENT OF VAGAL TONE... (4*)
Tu1771. . . . FACTORS IN ESTABLISHMENT OF ENTERAL AUTONOMY... (5*)
Tu1772. . . . NAUSEA AND VOMITING SEVERITY IS ASSOCIATED... (5*)
Tu1773. . . . ANTRAL EXPRESSION OF PROSTAGLANDIN E SYNTHASE... (1*)
Tu1774. . . . EVALUATION OF GASTRIC MOTOR FUNCTION IN... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1775. . . . SLEEP PARASOMNIAS ARE ASSOCIATED WITH AUTONOMIC... (2*)

Tu1776. . . . MAGNETIC RESONANCE DEFECOGRAPHY IN CHILDREN AND... (5*)

Tu1777. . . . PROSPECTIVE EVALUATION OF ANAL SPHINCTER BOTULINUM... (5*)

Tu1778. . . . ROLE OF GLUCOSE BREATH TEST FOR... (5*)

Tu1779. . . . IMPROVED FUNCTIONING PRECEDES IMPROVEMENT OF ABDOMINAL... (5*)

Tu1780. . . . VASOACTIVE INTESTINAL PEPTIDE PLASMA CONCENTRATIONS IN... (5*)

Tu1781. . . . AKKERMANSIA MUCINIPHILA AND BIFIDOBACTERIUM BIFIDUM G9-1:... (5*)

Tu1782. . . . YIELD AND PREDICTORS OF POSITIVE COLONIC... (5*)

Tu1783. . . . EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE... (5*)

Tu1784. . . . TYROSINE KINASE INHIBITORS THAT TARGET ERBB... [2*]

Tu1785. . . . EOSINOPHILIC COLITS IN CANCER PATIENTS ... (5*)

Tu1786. . . . IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED DIARRHEA AND COLITIS... (5*)

Tu1787. . . . THE STATUS AND RELATED FACTORS OF... (1*),(4)

Tu1788. . . . CLINICAL CHARACTERISTICS AND TREATMENT DIFFERENCES BETWEEN... (5*)

Tu1789. . . . INTESTINAL PERMEABILITY IN PATIENTS WITH FUNCTIONAL... (4*)

Tu1790. . . . BIFIDOBACTERIUM LONGUM RELIEVES VISCERAL HYPERSENSITIVITY AND... (2*)

Tu1791. . . . BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN... (5*)

Tu1792. . . . BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED... (5*)

Tu1793. . . . BILE ACID MALABSORPTION AND OUTCOMES AFTER... (4*)

Tu1794. . . . DIARRHEA IN THE LUNG TRANSPLANT RECIPIENT:... (5*)

Tu1795. . . . A CLINIC-PATHOLOGICAL COMPARISON BETWEEN CROHNS' DISEASE... (4*)

Tu1796. . . . ALTERNATION OF GUT MICROBIOTA IN PATIENT... (5*)

Tu1797. . . . MANAGEMENT OF PATIENTS WITH HISTOLOGICALLY PROVEN... (5*)

Tu1798. . . . EARLY-ONSET COLORECTAL ADENOCARCINOMA INCIDENCE RATES ARE... (5*)

Tu1799. . . . RISK FACTORS FOR EARLY ONSET SPORADIC... (2*)

Tu1800. . . . RISK FACTORS FOR EARLY ONSET SPORADIC... (2*)

Tu1801. . . . METABOLIC SYNDROME: ARE CURRENT COLON CANCER... (2*)

Tu1802. . . . VARIATION IN ESTIMATED COLORECTAL CANCER RISK... (5*)

Tu1803. . . . PREVALENCE OF COLORECTAL NEOPLASIA IN PATIENTS... (5*)

Tu1804. . . . THE MEAN AGE AT COLORECTAL CANCER... (5*)

Tu1805. . . . THE RISK OF SECOND PRIMARY MALIGNANCY... (5*)

Tu1806. . . . YOUNG ONSET COLORECTAL CANCER RISK AMONG... (2*)

Tu1807. . . . THE RISK OF EARLY-ONSET COLORECTAL CANCER... (5*)

Tu1808. . . . EFFECT OF COMORBIDITIES ON RISK OF... (5*)

Tu1809. . . . IS ORAL ANTICOAGULATION ASSOCIATED WITH IMPROVED... (5*)

Tu1810. . . . COLORECTAL CANCER INCIDENCE AND MORTALITY... (2*) (4)

Tu1811. . . . DOES PROXIMITY TO TERTIARY REFERRAL CENTER... (5*)

Tu1812. . . . DEVELOPMENT AND VALIDATION OF RISK PREDICTION... (2*) (7)

Tu1813. . . . LONG-TERM INCIDENCE AND MORTALITY OF COLORECTAL... (2*) (7)

Tu1814. . . . MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR... (2*) (5)

Tu1815. . . . THE IMPACT OF DIVERTICULAR DISEASE ON... (5*)

Tu1816. . . . THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (5*)

Tu1817. . . . THE LONG-TERM RISKS OF LOW-RISK ADENOMA,... (2*)

Tu1818. . . . CAREFUL SELECTION OF BOTH POSITIVITY THRESHOLD... (3*) (4) (Eiken Chemical Company.)

Tu1819. . . . COMPLEMENTARY HYPERMETHYLATED CTDNA BIOMARKERS FOR EARLY... (2*) (3) (Clinical Genomics Pty Ltd)

Tu1820. . . . PATIENT CHARACTERISTICS AND MORTALITY ASSOCIATED WITH... (5*)

Tu1821. . . . COLORECTAL CANCER (CRC) IN THE YOUNG:... (5*)

Tu1822. . . . HIGHER IMPACT ON CLINICAL OUTCOMES FROM... (3*) (Exact Sciences)

Tu1823. . . . MOBILE MESSENGERS-INITIATED REMINDERS IMPROVES COMPLIANCE IN... (6*)

Tu1824. . . . THE RISK OF EARLY-ONSET SPORADIC... (2*)

Tu1825. . . . MEDIA COVERAGE OF THE AMERICAN CANCER... (5*)

Tu1826. . . . EVALUATION OF EFFECTIVENESS AND COST- EFFECTIVENESS OF... (4*)

Tu1827. . . . THE ASSOCIATION OF PATIENTS' PERCEPTION OF... (5*)

Tu1828. . . . OFFERING A BLOOD TEST INCREASES COLORECTAL... (3*) (7) (Epigenomics)

Tu1829. . . . EFFECT OF ANTITHROMBOTIC THERAPY ON DIAGNOSIS... (5*)

Tu1830. . . . IS THE COLORECTAL CANCER SCREENING GUIDELINE... (5*)

Tu1831. . . . BARRIERS TO COLONOSCOPIC FOLLOW UP AFTER... (4*)

Tu1832. . . . GROWING SURVIVAL DISPARITIES AMONGST ASIAN ETHNICITIES... (5*)

Tu1833. . . . CDH1 GENE MUTATIONS PREDISPOSE PATIENTS TO... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1834. . . . INCIDENCE AND ANATOMICAL DISTRIBUTION OF COLORECTAL... (5*)

Tu1835. . . . UTILITY OF FECAL IMMUNOCHEMICAL TEST (FIT)...(5*)

Tu1836. . . . TUMOR AREA AND MICROSCOPIC EXTENT OF... (3*)|(GRAIL Inc)

Tu1837. . . . HIGH SEDATION REQUIREMENTS FOR PATIENTS AGES... (5*)

Tu1838. . . . COLORECTAL CANCER SCREENING: ADDING RISK PROFILING... (5*)|(NIL)

Tu1839. . . . CLINICOPATHOLOGICAL CHARACTERIZATION AND SURVIVAL OUTCOME OF... (5*)

Tu1840. . . . THE EFFECT OF DIRECT-ACTING ORAL ANTICOAGULANTS... (5*)

Tu1841. . . . FREQUENCY OF SIGNS AND SYMPTOMS PRECEDING... (5*)

Tu1842. . . . GEOGRAPHIC DISPARITIES OF YOUNG ONSET COLORECTAL... (5*)

Tu1843. . . . INCREASED RISK OF ADVANCED COLONIC ADENOMAS... (5*)

Tu1844. . . . CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER RELATED... (5*)

Tu1845. . . . COMPARATIVE EFFECTIVENESS OF SURVEILLANCE COLONOSCOPY TIMING... (2*)

Tu1846. . . . PHASE 2A PROOF OF CONCEPT PLACEBO... (3*)|(ABIVAX)

Tu1847. . . . THE IMPACT OF COGNITIVE BEHAVIORAL MINDFULNESS... (6*)

Tu1848. . . . EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1849. . . . HISTOLOGIC REMISSION AND MUCOSAL HEALING IN... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1850. . . . DOSE ESCALATION OF UPADACITINIB IN CROHN’S... (3*)|(Abivie, Inc.)

Tu1851. . . . CORTICOSTEROID SPARING EFFECTS OF USTEKINUMAB THERAPY... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1852. . . . PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A... (3*)|(Oppilian Pharma)

Tu1853. . . . SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1854. . . . MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF... (3*)|(The study was funded by Eli Lilly and Company)

Tu1855. . . . EFFICACY AND SAFETY OF ESCALATION TO... (3*)|(Pfizer Inc)

Tu1856. . . . THE EFFECT OF TOFACITINIB ON SERUM... (3*)|(Pfizer Inc)

Tu1857. . . . TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS... (3*)|(Pfizer Inc)

Tu1858. . . . ASSESSMENT OF AGE AS A RISK... (3*)|(Pfizer Inc)

Tu1859. . . . CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1860. . . . ASSOCIATION OF HISTOLOGIC-Endoscopic MUCOSAL HEALING AFTER... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1861. . . . A RANDOMIZED, OBSERVER-BLIND PHASE IB MULTIPLE,... (3*)|(Sponsored by Genentech, Inc.)

Tu1862. . . . BI 695501 DEMONSTRATES SIMILAR EFFICACY AND... (3*)|(Boehringer Ingelheim)

Tu1863. . . . TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE... (3*)|(Pfizer Inc)

Tu1864. . . . ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB... (3*)|(This study was supported by Janssen)

Tu1865. . . . VEDOLIZUMAB TREATMENT PERSISTENCE AND SAFETY IN... (3*)|(Takeda)

Tu1866. . . . EFFICACY AND SAFETY OF AN ADDITIONAL... (3*)|(Pfizer Inc)

Tu1867. . . . EFFICACY OF TOFACITINIB DOSE ESCALATION TO... (3*)|(Pfizer Inc)

Tu1868. . . . THE EFFECT OF TOFACITINIB ON EXTRAINTESTINAL... (3*)|(Pfizer Inc)

Tu1869. . . . TIME TO LOSS OF EFFICACY AMONG... (3*)|(Pfizer Inc)

Tu1870. . . . C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO... (3*)|(Pfizer Inc)

Tu1871. . . . THE CONCORDANCE OF SHORT FORM-36 HEALTH... (3*)|(Pfizer Inc)

Tu1872. . . . IDENTIFICATION OF BIOMARKERS AND MECHANISTIC INSIGHT... (3*)|(AbbVie, Inc.,)

Tu1873. . . . LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB... (3*)|(AbbVie Inc)

Tu1874. . . . MAINTENANCE OF REMISSION WITH TOFACITINIB IN... (3*)|(Pfizer Inc)

Tu1875. . . . IMPACT OF DISEASE DURATION ON TOFACITINIB... (3*)|(Pfizer Inc)

Tu1876. . . . A PILOT DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL... (2*)|(6)|(Supported by grants from the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD), the Canadian Association of Gastroenterology (CAG), AbhVie Canada and Crohn’s and Colitis Canada (CCC). Vitamin D was provided in kind by Euro-Pharm International)

Tu1877. . . . EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL... (3*)|(Celltrion, Inc.)

Tu1878. . . . FILGOTINIB DECREASES MOLECULAR MARKERS OF JAK1... (3*)|(Gilead Sciences, Inc.)

Tu1879. . . . EFFICACY AND SAFETY OF LONG-TERM TREATMENT... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1880. . . . EFFECTS OF THE JANUS KINASE (JAK1)-SELECTIVE... (3*)|(Sponsored by Gilead Sciences, Inc.)

Tu1881. . . . SAFETY, PHARMACOKINETICS AND IMMUNE MODULATORY PROPERTIES... (3*)

Tu1882. . . . GB004, A NOVEL PROLYL HYDROXYLASE... (3*)|(Gossamer Bio, Inc)

Tu1883. . . . HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED... (3*)|(GOAL-ARC is

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
supported as an investigator initiated study by MSD and Thermo Fisher Scientific)

Tu1884. . . . DIAGNOSTIC ACCURACY OF RECTAL BLEEDING AND... (3*)|(Pfizer Inc)

Tu1885. . . . EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1886. . . . DOSE ADJUSTMENT IN PATIENTS WITH MODERE... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1887. . . . IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED... (3*)|(Abbvie, Inc.)

Tu1888. . . . EARLY AND SUSTAINED IMPROVEMENT IN STOOL... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1889. . . . UPADACITINIB WAS NOT ASSOCIATED WITH ANAEMIA... (3*)|(Abbvie, Inc.)

Tu1890. . . . THE EFFICACY AND SAFETY OF ADALIMUMAB... (3*)|(Abbvie)

Tu1891. . . . RISK OF LATE POST-OPERATIVE RECURRENCE OF... (5*)

Tu1892. . . . TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF... (1*)

Tu1893. . . . REAL WORLD EFFECTIVENESS OF TOFACITINIB FOR... (5*)

Tu1894. . . . IMPACT OF DISCONTINUING THIOPURINES AT ANTI-TNF... (4*)|(2)

Tu1895. . . . TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION... (5*)

Tu1896. . . . TOFACITINIB IS SAFE AND EFFECTIVE AS... (5*)

Tu1897. . . . PORTAL VEIN THROMBOSIS IS A RISK... (5*)

Tu1898. . . . EXCLUSIVE ENTERAL NUTRITION WITH A POLYMERIC... (5*)

Tu1899. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB... (4*)|(7)

Tu1900. . . . A PHARMACOKINETIC (PK) AND SAFETY STUDY... (3*)|(Enterome)

Tu1901. . . . NON-ADHERENCE TO MAINTENANCE MEDICATIONS IN PREGNANT... (2*)

Tu1902. . . . COMPREHENSIVE REGISTERED DIETICIAN ASSESSMENT IN THE... (4*)

Tu1903. . . . EVALUATION OF POTENTIAL MECHANISMS UNDERLYING THE... (3*)|(Gilead Sciences, Inc.)

Tu1904. . . . USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY... (5*)

Tu1905. . . . CANNABIS EFFECT ON INPATIENT DISEASE OUTCOMES... (4*)

Tu1906. . . . PREVALENCE AND ASSOCIATION OF CANNABIS USE... (5*)

Tu1907. . . . EFFICACY INCLUDING RAPID RESPONSE AND... (4*)

Tu1908. . . . EFFECT OF FIBER-BASED ENTERAL FEEDS ON... (2*)|(4)

Tu1909. . . . IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON... (3*)|(4)|(This study was primarily funded as an investigator initiated study by Finch Therapeutics)

Tu1910. . . . SUBJECTS ON A GLUTEN-FREE DIET HAVE... (6*)

Tu1911. . . . THE EFFECT OF A PLANT-BASED DIET... (2*)

Tu1912. . . . NUTRIENT-DEPENDENT PHYSIOLOGICAL AND PROTEOMIC ANALYSIS OF... (2*)

Tu1913. . . . ROLE OF DIETARY AND NON-DIGESTIBLE CARBOHYDRATES... (2*)

Tu1914. . . . THE SMALL INTESTINAL MICROBIOME IN OBESITY... (6*)

Tu1915. . . . MICROBIOTA-MEDIATED EFFECTS OF DIETARY FIBER ON... (2*)|(4)

Tu1916. . . . CURDLAN FEEDING IN MICE IMPROVES DSS... (2*)

Tu1917. . . . PRANDIAL DIETARY ZINC INTAKE AFFECT DEVELOPMENT... (2*)

Tu1918. . . . THE INFLUENCE OF WALNUT CONSUMPTION ON... (6*)

Tu1919. . . . A NOVEL INTEGRATED IN VIVO/EX... (2*)|(3)|(Lantmännen Research Foundation)

Tu1920. . . . ASSOCIATION BETWEEN DIETARY FAT INTAKE AND... (6*)|(2)

Tu1921. . . . THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (5*)

Tu1922. . . . DIET SIGNIFICANTLY ALTERS ENTEROHEPATIC RECIRCULATION OF... (4*)|(2)

Tu1923. . . . SPIRULINA PLATENSIS ALLEVIATE CHRONIC LOW-GRADE INFLAMMATORY... (5*)

Tu1924. . . . CHANGES IN THE GUT MICROBIOTA AND... (4*)

Tu1925. . . . SEX- AND COLORECTAL CANCER-ASSOCIATED CHANGES IN... (4*)

Tu1926. . . . MICROBIAL DIGESTION OF XANTHIN GUM IN... (2*)

Tu1927. . . . THE EFFECTS OF CAROTENOID INGESTION ON... (2*)

Tu1928. . . . STREPTOCOCCUS SP. VT_162 MRNAS TARGETS CONTRIBUTES... (2*)

Tu1929. . . . ANTIMICROBIAL RESISTANCE GENE BURDEN DECREASES OVER... (2*)

Tu1930. . . . FECAL LIPIDOMICS ANALYSIS OF THE NEONATAL... (2*)

Tu1931. . . . LACTOBACILLUS-CONTAINING PROBIOTICS ARE ASSOCIATED WITH CHANGES... (6*)

Tu1932. . . . THE DOSE-RESPONSE RELATION BETWEEN A FIBER... (5*)|(Tsumura & Co.)

Tu1933. . . . THE CHALLENGES IN DEVELOPING A FAECAL... (4*)

Tu1934. . . . SALIVARY AND STOOL MICROBIOTA DIFFERENCES ARE... (2*)

Tu1935. . . . DOES THE USE OF ANGIOTENSIN RECEPTOR... (5*)

Tu1936. . . . PATIENT PERSPECTIVES ON THE LONG-TERM MANAGEMENT... (2*)

Tu1937. . . . PATIENT WILLINGNESS TO PARTICIPATE IN CELIAC... (5*)

Tu1938. . . . PROBIOTICS FOR CELIAC DISEASE: A SYSTEMATIC... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>1939</td>
<td>IS A MULTIVITAMIN SUFFICIENT TO MEET... (5*)</td>
<td>(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>1940</td>
<td>PREVALENCE OF OBESITY IN PATIENTS WITH... (5*)</td>
<td></td>
</tr>
<tr>
<td>1941</td>
<td>SELF-REPORTED NON-CELIAC GLUTEN SENSITIVITY IN KOREAN... (5*)</td>
<td></td>
</tr>
<tr>
<td>1942</td>
<td>COMPARISON OF PARENTAL GLUTEN-FREE DIET KNOWLEDGE... (6*)</td>
<td></td>
</tr>
<tr>
<td>1943</td>
<td>REFERRAL FOR DIETARY INTERVENTION FOR CELIAC... (5*)</td>
<td></td>
</tr>
<tr>
<td>1944</td>
<td>A GASTROENTEROLOGIST SUPERVISED BEHAVIORAL WEIGHT MANAGEMENT... (5*)</td>
<td></td>
</tr>
<tr>
<td>1945</td>
<td>FREQUENCY OF OBESITY COUNSELING BY PHYSICIANS... (5*)</td>
<td></td>
</tr>
<tr>
<td>1946</td>
<td>USE OF A NOVEL VIRTUAL HEALTH... (5*)</td>
<td></td>
</tr>
<tr>
<td>1947</td>
<td>IMPACT OF A CHILDRENCENTER-BASED OBESITY... (2*)</td>
<td></td>
</tr>
<tr>
<td>1948</td>
<td>TRENDS IN OBESITY SELF-AWARENESS AMONG OBESE... (5*)</td>
<td></td>
</tr>
<tr>
<td>1949</td>
<td>GLOBAL, REGIONAL AND TIME-TREND PREVALENCE OF... (4*)</td>
<td></td>
</tr>
<tr>
<td>1950</td>
<td>OBESE MINORITIES HAVE HIGHER HOSPITALIZATION RATES... (5*)</td>
<td></td>
</tr>
<tr>
<td>1951</td>
<td>AUTOPHAGY DYSFUNCTION THROUGH HEPATIC BCL-2 OVEREXPRESSION... (3*) (Tsumura &amp; Co.)</td>
<td>(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>1952</td>
<td>DEFINING THE ROLE OF INTESTINE-SPECIFIC FFA2... (4*)</td>
<td></td>
</tr>
<tr>
<td>1954</td>
<td>IMMEDIATE POSTOPERATIVE COMPLICATION REASON FOR READMISSION... (5*)</td>
<td></td>
</tr>
<tr>
<td>1955</td>
<td>CALCIUM-SENSING RECEPTOR REGULATES INTESTINAL DIPEPTIDE ABSORPTION... (2*) (National Natural Science Foundation of China (NSFC))</td>
<td>(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>1957</td>
<td>ANOREXIA NERVOSA CARE PATHWAY. THE ROAD... (5*)</td>
<td></td>
</tr>
<tr>
<td>1958</td>
<td>CONTINUOUS DECREASE OF THE MYOBLAST DETERMINATION... (3*)</td>
<td></td>
</tr>
<tr>
<td>1959</td>
<td>INTESTINAL ELECTRICAL STIMULATION FOR TREATING DIABETES... (2*)</td>
<td></td>
</tr>
<tr>
<td>1960</td>
<td>COST EFFECTIVENESS OF OFFERING UNSEDATED COLONOSCOPY... (5*)</td>
<td></td>
</tr>
<tr>
<td>1961</td>
<td>WHEN TO FORGO ENDOSCOPY IN FAVOR... (5*)</td>
<td></td>
</tr>
<tr>
<td>1962</td>
<td>VISITATION WITH A GASTROENTEROLOGIST AND PATIENT... (4*)</td>
<td></td>
</tr>
<tr>
<td>1963</td>
<td>SINGLE-USE DUODENOSCOPES FOR ERCP: A COST-EFFECTIVE... (5*) [(Boston Scientific reimbursed funds to purchase a 1-year license for the Treeage Decision analysis software used to build and analyze the economic model. The presenting author, Ananya Das, MD is a teaching and research consultant with Boston Scientific.)</td>
<td>(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)</td>
</tr>
<tr>
<td>1964</td>
<td>USABILITY OF A NOVEL DISPOSABLE ENDOSCOPE... (2*)</td>
<td></td>
</tr>
<tr>
<td>1965</td>
<td>GASTROINTESTINAL ENDOSCOPY CAPACITY IN EAST AFRICA... (5*)</td>
<td></td>
</tr>
<tr>
<td>1966</td>
<td>ANAESTHETIC SUPPORT TO PERFORM COLONOSCOPY:WHEN IS... (5*)</td>
<td></td>
</tr>
<tr>
<td>1967</td>
<td>RATE OF GASTROINTESTINAL ENDOSCOPY USE AND... (2*)</td>
<td></td>
</tr>
<tr>
<td>1968</td>
<td>TO SCOPE OR NOT TO SCOPE?... (4*)</td>
<td></td>
</tr>
<tr>
<td>1969</td>
<td>IMPROVING QUALITY OF UPPER ENDOSCOPY AMONG... (4*)</td>
<td></td>
</tr>
<tr>
<td>1970</td>
<td>MACHINE LEARNING CAN IMPROVE ESTIMATION OF... (5*)</td>
<td></td>
</tr>
<tr>
<td>1971</td>
<td>A NOVEL AND EFFICIENT METHOD USING... (5*)</td>
<td></td>
</tr>
<tr>
<td>1972</td>
<td>POSITIVE MULTI-TARGET STOOL DNA TEST AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>1973</td>
<td>AUTOMATED DIGITAL PATIENT NAVIGATION PROGRAM IMPROVES... (5*)</td>
<td></td>
</tr>
<tr>
<td>1974</td>
<td>EVALUATING THE NUMBER NEEDED TO SCREEN... (3*) [(Guardant Health)]</td>
<td></td>
</tr>
<tr>
<td>1975</td>
<td>INCIDENCE OF INADEQUATE ENDOSCOPIC ASSESSMENT AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>1976</td>
<td>MISINFORMING THE PUBLIC: PREDICTORS OF FACTUAL... (5*)</td>
<td></td>
</tr>
<tr>
<td>1977</td>
<td>CHARACTERIZATION OF UNPLANNED HOSPITAL VISITS AFTER... (5*)</td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td>WHERE DO WE GO FROM HERE?... (5*)</td>
<td></td>
</tr>
<tr>
<td>1979</td>
<td>FACTORS ASSOCIATED WITH DELAYS IN INPATIENT... (5*)</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>SHORT TERM CARDIOVASCULAR COMPLICATIONS RELATED TO... (5*)</td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>ASSOCIATION MODELING BETWEEN PATIENTS' AGE AND... (5*)</td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>COMPARISON BETWEEN SPLIT-DOSE AND SINGLE-DOSE POLYETHYLENE... (5*)</td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>COMPARING THE IMPACT OF MORTALITY DATA... (5*)</td>
<td></td>
</tr>
<tr>
<td>1984</td>
<td>COMPARING THE REAL-WORLD EFFECTIVENESS OF 4L... (1*)</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>A PATIENT-DRIVEN APPROACH TO IMPROVING THE... (4*)</td>
<td></td>
</tr>
<tr>
<td>1986</td>
<td>OPEN ACCESS COLONOSCOPY: AN UNDERUTILIZED PROGRAM... (5*)</td>
<td></td>
</tr>
<tr>
<td>1987</td>
<td>THE IMPACT OF A 2 LITER... (5*)</td>
<td></td>
</tr>
<tr>
<td>1988</td>
<td>TELEPHONE TRIAGE TO 'STRAIGHT TO TEST'(TSTT)... (5*)</td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>PRE-COLONOSCOPY BOSTON BOWEL PREPARATION SCORE ASSESSMENT... (5*)</td>
<td></td>
</tr>
<tr>
<td>1990</td>
<td>MACHINE LEARNING MODELS FOR PREDICTING NAFLD... (5*)</td>
<td></td>
</tr>
<tr>
<td>1991</td>
<td>ANALYSIS OF ERCP IMAGE USING ARTIFICAL-INTELLIGENCE... (5*)</td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td>NEEDLE-BASED CONFOCAL LASER ENDOMICROSCOPY (NCLE) FOR... (5*)</td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>PERCUITANEOUS TRANSHEPATIC GALLBLADDER DRAINAGE FACILITATES... (5*)</td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>FACTORS RELATED TO THE IMAGE CLEANLINESS... (1*)</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>PILOT STUDY TO IDENTIFY PREDICTORS OF... (1*)</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>NON-INVASIVE BREATH TEST SCREENING TO ASSESS... (2*)</td>
<td></td>
</tr>
</tbody>
</table>
Tu1997. . . UPPER GI TRACT BIOPSY USING AN... (6*)
Tu1998. . . PREDICTORS OF LOCATION, SIZE AND NUMBER... (5*)
Tu1999. . . WIZARDY OF CHROMATIC HANDS- SAVING THE... (5*)
Tu2000. . . RISK OF METACHRONOUS ADVANCED NEOPLASTIC LESIONS... (5*)
Tu2001. . . A NOVEL PANEL OF 92 BLOOD-BASED... (4*)(6)
Tu2002. . . DOES THE 330° VIEWING ANGLE COLONOSCOPE... (5*)
Tu2003. . . ESTABLISHING NEED FOR SERRATED POLYP DETECTION... (0*)
Tu2004. . . APPLICATION OF COMPUTATIONAL FLUID DYNAMICS TO... (4*)
Tu2005. . . DUODENAL UNDERWATER ENDOSCOPIC MUCOSAL RESECTION IS... (5*)
Tu2006. . . EVALUATION OF PERFORMANCE IN COLON CAPSULE... (5*)
Tu2007. . . OUTCOMES OF PHARMA COLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS... (5*)
Tu2008. . . SYSTEMATIC REVIEW AND META-ANALYSIS OF DECOMPRESSION... (5*)
Tu2009. . . IMMUNOHISTOCHEMISTRY EXPRESSION OF CYTOKINES FOR DIAGNOSING... (4*)
Tu2010. . . HEALTH RELATED QUALITY OF LIFE AND... (5*)
Tu2011. . . GASTRIC VERSUS ESOPHAGEAL BUTTON BATTERY INGESTIONS... (4*)
Tu2012. . . CAREGIVERS KNOWLEDGE ATTITUDE AND PRACTICES ON... (5*)
Tu2013. . . EOSINOPHILIC ESOPHAGITIS IN NON-CAUCASIANS: A UNIQUE... (5*)
Tu2014. . . LYMPHANGIOGRAPHY AS A DIAGNOSTIC AND THERAPEUTIC... (5*)
Tu2015. . . GASTROINTESTINAL AND HEPATIC MANIFESTATIONS OF PTEN... (5*)
Tu2016. . . HIRSCHSPRUNG'S DISEASE IN PATIENTS WITH CONGENITAL... (5*)
Tu2017. . . LONG-TERM SAFETY OF THE SEQUENTIAL USE... (5*)